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Recently, vaccines based on messenger RNA were validated in (pre)clinical studies as 
prophylactic vaccines against infectious diseases as well as immunotherapeutics to treat cancer. 
The great potential of mRNA vaccines is based on the capacity to elicit strong cytotoxic CD8+ T 
lymphocyte (CTL) responses against infected cells or cancer cells. The successful developments 
of new techniques to formulate mRNA into nanoparticles as well as the favourable safety profile 
of mRNA, contributed to the current great medical interest in mRNA vaccines. 
Our research group used to study mRNA DOTAP/DOPE-based vaccines to elicit T cell responses 
against the HIV-1 antigen. During this work, vaccine-evoked type I interferons (IFNs) were 
addressed to have a negative impact on the mRNA vaccine efficacy. In a first section of this 
thesis we assessed whether type I IFNs influenced the anti-tumoral activity of the vaccine in B16 
tumor model. We showed that upon prophylactic and therapeutic immunization, the induction 
of type I IFNs hampered vaccine-evoked tumor protection. Therefore, the primary aim of this 
dissertation was to address the mechanism of the inhibiting type I IFN effects and how vaccine-
induced type I IFN responses could be evaded or eliminated. To this end, different strategies 
were tested at the level of mRNA encoding antigens as well as at the level of the vaccine carrier. 
In a first endeavour, we evaluated whether type I IFN induction, due to innate immune 
activation, could be evaded using chemically modified mRNA. Modified mRNA is originally 
designed for gene therapy approaches as they are considered to bind less effective to cellular 
RNA sensors. However, no significant weaker IFNβ induction was measured upon the injection 
of modified mRNA DOTAP/DOPE lipoplexes compared to unmodified mRNA lipoplexes. In line 
with these results, no positive impact on the capacity of mRNA lipoplexes to elicit cytotoxic CD8+ 
T cell responses was observed. 
In a following part of this thesis, we validated a new peptide-mediated formulation of mRNA, 
based on the interaction between cell penetrating peptides (CPPs) and mRNA antigens. In this 
study we complexed mRNA to the amphipathic peptide RALA in order to form RALA mRNA 
nanocomplexes. RALA has a pH-dependent lytic activity, allowing to translocate the mRNA from 
the endosomal compartments into the cytosol. This translocation process is considered to be 
crucial for the processing and presentation of antigens by MHC-I molecules to CD8+ T cells. 
Injecting RALA mRNA nanocomplexes resulted in far stronger CTL responses compared with the 
standard DOTAP/DOPE formulation. Furthermore, we addressed that the immunogenicity of 
modified mRNA RALA nanocomplexes is completely independent of type I IFNs. Further 
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mechanistic research proved that the immunogenic character of the modified mRNA RALA 
nanocomplexes is associated with the pH-dependent amphipathic character of RALA. 
In a last section of this dissertation, we aimed to evaluate whether RNA can function as a Th1-
skewing adjuvant for protein vaccines. To this end, we formulated non-coding RNA into 
PEGylated polymer-based nanoparticles. This polymer-based formulation resulted in improved 
RNA protection and enhanced RNA targeting to lymph node dendritic cells when compared to 
unformulated RNA or RNA complexed to cationic liposomes. Most importantly, we presented 
the RNA polymer-based nanoparticles as a potent novel adjuvant for the eliciting of effective 
cytotoxic CD8+ T cells responses against co-delivered protein antigens.  
We hope that the new realizations obtained by this doctoral research concerning the use of RNA 
as antigen-encoding device or as an adjuvants component opened new opportunities for future 
medical approaches in the field of vaccinology. 
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Recent werden vaccins gebaseerd op boodschapper RNA (mRNA) gevalideerd in (pre)klinische 
studies enerzijds voor hun toepassing als profylactische vaccins gericht tegen infectieziekten en 
anderzijds als immunotherapeutische behandeling van kanker. Het potentieel van mRNA 
vaccinatie binnen deze twee onderzoeksgebieden berust op zijn capaciteit om sterke 
cytotoxische CD8+ T lymfocyt (CTL) antwoorden te induceren, gericht tegen geïnfecteerde cellen 
of kankercellen. Het succesvol onderzoek naar nieuwe strategieën voor het formuleren van 
mRNA-gecodeerde antigenen in nanopartikels alsook het hoog veiligheidsprofiel van mRNA 
hebben bijgedragen tot de huidige medische interesse in mRNA-gebaseerde vaccins. 
Binnen de onderzoeksgroep werd DOTAP/DOPE-gemedieerde mRNA vaccinatie bestudeerd voor 
het opwekken van T-cel immuniteit tegen HIV-1 antigenen. Daarbij werd aangetoond dat het 
subcutaan toedienen van mRNA DOTAP/DOPE lipoplexen een antiviraal type I interferon (IFN)-
antwoord opwekt dat vervolgens remmend inwerkt op de efficiëntie van het vaccin. In een 
eerste luik van deze thesis werden deze bevindingen verder gevalideerd uitgaande van een 
experimenteel tumormodel. Aldus toonden we aan dat de negatieve inwerking van type I IFN 
leidt tot een verminderde bescherming tegen de ontwikkeling van tumoren bij zowel een 
profylactische als een therapeutische toepassing van het mRNA vaccin. Het hoofddoel van dit 
doctoraal werk was dan ook het mechanisme dat aan de basis ligt van deze remmende werking 
van type I IFN beter te begrijpen en dusdanig strategieën te ontwikkelen die toelaten deze 
remmende werking te omzeilen en de efficiëntie van mRNA vaccins te verbeteren. Hiertoe 
werden verschillende strategieën uitgewerkt, waarbij zowel de focus lag op het antigeen-
coderende mRNA als op de drager van het mRNA. 
In een eerste benadering, werd gepoogd om door middel van gemodificeerd mRNA de activatie 
van een antiviraal type I IFN-antwoord door het aangeboren immuun systeem te vermijden. 
Gemodificeerd mRNA werd initieel ontwikkeld in het kader van gentherapie omwille van zijn 
verminderde herkenning door intracellulaire RNA-sensoren, wat resulteert in een verminderde 
opwekking van een antiviraal cellulair antwoord. Met behulp van een IFNβ reportermuis werd 
echter aangetoond dat de injectie van dergelijk gemodificeerd mRNA, geformuleerd met 
DOTAP/DOPE lipoplexen, niet resulteerde in een verminderde opwekking van type I IFN. In lijn 
met deze resultaten kon er verder ook geen versterkt cytotoxische CD8+ T cel antwoord worden 
waargenomen.  
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In een volgende luik van de scriptie werd gefocust op de validatie van een peptide-gemedieerde 
formulatie die berust op de interactie tussen cell penetrating peptides (CPPs) en mRNA-
antigenen. Hierbij werd een partikel ontwikkeld waarin het mRNA gecomplexeerd werd met het 
amfipatisch peptide RALA tot vorming van RALA mRNA nanocomplexen. Het amphipatische 
RALA-peptide vertoont een zuurafhankelijke cellytische activiteit waardoor RALA de translocatie 
van het mRNA uit de endosomen naar het cytosol bevordert. Deze translocatie richting cytosol is 
cruciaal om de translatie van het mRNA tot het antigeen eiwit toe te laten en de 
daaropvolgende verwerking en presentatie door MHC klasse I moleculen aan CD8+ T cellen. 
Injectie van RALA mRNA nanocomplexen resulteerde in de opwekking van een beduidend 
sterker CTL-antwoord vergeleken met de standaard lipide-gebaseerde formulering. Tevens bleek 
het immunogeen karakter van deze RALA gemodificeerde mRNA nanocomplexen geheel 
onafhankelijk te zijn van type I IFN. Verder mechanistisch onderzoek toonde aan dat het 
immunogene karakter van RALA mRNA nanocomplexen gekoppeld is aan het pH-afhankelijke 
amfipatische karakter van het RALA peptide.  
In een laatste luik van het doctoraal onderzoek werd tenslotte nagegaan in hoeverre RNA naast 
zijn functie van boodschapper eveneens kan fungeren als adjuvans voor vaccins gebaseerd op 
eiwitantigenen. Ons onderzoek toonde aan dat het formuleren van niet-coderend RNA in 
polymeer-gebaseerde complexen cruciaal is voor de efficiëntie waarmee het RNA wordt 
opgenomen door migrerende dendritische cellen. Tevens konden we aantonen dat deze RNA 
polymeer-complexen een uitgesproken CD8+ T cel antwoord opwekten tegen het toegediende 
eiwitantigeen.  
In globo hopen we dat de nieuwe inzichten verkregen via dit doctoraal onderzoek omtrent het 
gebruik van RNA als antigeen-coderende entiteit of als immuunstimulerende adjuvans nieuwe 
wegen openen voor toekomstige medische toepassingen in de vaccinologie.  
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1. VACCINES AND VACCINATION – AN HISTORICAL PERSPECTIVE 
The story of the history of vaccination mostly starts with the innovative contributions of Edward 
Jenner to the development of vaccines in 1796. But actually, the historical origins of 
immunization started long before the 18th century, by a primitive form of vaccination called 
variolation (Figure 1). Variolation was practiced in Africa, India and China by blowing smallpox 
skin scabs into the nose of healthy people who consequently contracted a mild form of the 
disease, but remained immune to smallpox afterwards1. Although variolation was not without 
any risk – 3 % of the persons died upon treatment – the technique reached Europe by Turkish 
travellers at the beginning of the 18th century and gained popularity in all layers of society2. In 
1721, a serious epidemic broke out in Massachusetts and despite great public protest against 
variolation, statistics showed that only 2 % among variolated individuals died, whereas the 
fatality rate for the non-treated population was 14 %3. 
Even so, all credits go to Edward Jenner who performed the first real vaccination study in 17964. 
In this study, he inoculated a young boy with pus from a cowpox lesion of a milkmaid’s hand by 
wounding him with a lancet. Two months later the boy was inoculated with pus from a smallpox 
lesion and stayed unaffected. Jenner reported his findings to the Royal Society but unfortunately 
the paper got rejected. One year later, Jenner had strengthened his research by collecting more 
than twenty cases of people who had received the same inoculation procedure. He reported in 
1798 his findings in a privately published booklet called ‘An Inquiry into the Causes and Effects of 
the Variolae Vaccinae, a disease discovered in some of the western counties of England, 
particularly Gloucestershire and Known by the Name of Cow Pox’4. In this booklet, Jenner called 
this new technique ‘vaccinia’, the Latin word for cowpox. He further described the applied 
scientific methods of observation and experiments and further stressed out the importance for 
a safer alternative to the variolation technique. By stating that cowpox protects the human 
constitution from infection with smallpox, he laid the foundation of modern vaccinology4. 
Despite the fact that the first reactions from the medical community to his report were rather 
negative, years later, the great value of vaccination compared to variolation became clear. As a 
consequence, Jenner got honoured worldwide and received multiple awards for his pioneering 
introduction to vaccination2,5. And rightly so, the findings of Jenner eventually contributed to a 
complete eradication of small pox from nature. 
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Despite the successful immunizations performed by Jenner, it took more than 100 years to 
discover a method to create a laboratory-developed vaccine (Figure 1). It was Louis Pasteur, a 
French chemist and microbiologist, who came up with the new concept of ‘attenuated vaccines’ 
in 1880. He used attenuated Pasteurella multocida, the causative agent of bird cholera, to 
protect chickens against the disease6. Like many other discoveries in the earliest years of 
science, the merit of using attenuated pathogens was discovered rather serendipitously. Pasteur 
was studying cholera by injecting chickens with live bacteria and subsequently following the 
progression of the disease. But when his assistant injected chickens with an old stock of the 
bacteria, they did not die, but showed only mild symptoms. When a new fresh stock of bacteria 
was injected in the same chickens, they survived and, more importantly, they did not even 
become ill. He extended his work to the attenuation of Baccilus Antracis (Antrax), but always 
kept his methods secret until 1881. At that moment, he published a few details about how he 
created this ‘atmospheric attenuated’ vaccine7. During the following years, together with Koch, 
Ramon and Merieux, he extended his knowledge to the creation of other vaccines based on 
inactivated pathogens (cholera, plague, typhoid) or toxins (diphtheria and tetanus)6,8.  
In the 1950’s cell culture techniques became available, allowing the development of effective 
techniques to create inactivated vaccines for polio9 as well as live-attenuated vaccines against 
mumps, rubella and measles. In the early 1970’s, a new revolution in the field of vaccination 
arrived with the polysaccharide-based vaccine as this vaccine format was the first non-whole 
organism-based vaccine approach. However, the first tests in children with polysaccharide-
based vaccines revealed unsuccessful immunization efficacies against pneumococcus and 
meningococcus. Afterwards, polysaccharide vaccines were optimized by covalently linking them 
to carrier proteins in order to improve the immunogenicity. Indeed, initially only B cell activation 
was elicited, but upon linking the polysaccharide with carrier proteins, the vaccine format 
gained potential to activate CD4+ T helper cells. In the late nighties, the golden age of modern 
biotechnology dawned10 and many new medical techniques were developed, including a new 
vaccine format based on self-assembling recombinant proteins forming non-infectious viral-like 
particles (VLPs)11. The first approved VLP vaccine came on the market in 1986 to protect against 
the hepatitis B virus (HBV). 
During Pasteur’s search to treat rabies in the 19th century, he introduced the use of prophylactic 
vaccines as a treatment. In rabies, symptoms can appear after several months or years. By 
immunizing a boy bitten by a rabid dog, he applied vaccines in order to prevent severe disease 
27 | Introduction
after acute infection12. Many years later, post exposure prophylaxis was extended to the 
treatment of other chronic infections, such as hepatitis B virus (HBV). Based on post exposure 
prophylaxis, the newest revolution are without doubt the therapeutic vaccines. Therapeutic 
vaccination aims to treat patients with infectious disease or cancer based on stimulating the 
immune system. Although clinical studies regarding therapeutic vaccines showed great 
potential, to date, the only therapeutic vaccine approved by the FDA is Sipuleucel-T 
(Provenge®), which came on the market in 2010 to treat prostate cancer patients (Figure 1). 
Sipuleucel-T was an innovative patient-specific treatment based on the modification of the 
patient’s own blood cells which are afterwards re-infused13. Nevertheless, five years after its 
launch in the USA, Dendreon, the company behind the vaccine, went bankrupt due to 
commercial failure of Provenge®. The cause of Dendron’s bankruptcy was multi-factorial, though 
two issues contributed the most: the delay in securing FDA approval and the high cost of the 
therapy ($100.000 per patient). In addition, the product was characterized by many potential 
barriers to market access, such as the mechanism of action which was previously unknown to 
the FDA, the complex administration, the limited manufacturing capacity and no proper markers 
of effective treatment response14. During the search for new developments in the field of 
therapeutic vaccination, nucleic acid-based vaccines came to the forefront. The first clinical trial 
using DNA vaccines for the treatment of HIV-infected patients was performed in 1995 (Figure 1). 
Two years earlier, a study by Martinon and colleagues, reported for the first time the use of 
mRNA as antigen-encoding device for vaccines. They showed that mice vaccinated with mRNA 
lipoplexes encoding the influenza virus nucleoprotein (NP) induced anti-influenza cytotoxic T 
lymphocytes (CTL) responses15.  
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Figure 1. History of vaccines and vaccination – A time line. 
2. REMARKABLE MERITS AND CRUCIAL CHALLENGES  
Prophylactic vaccination has significantly improved human health and continues to prevent 
millions of deaths worldwide. The impact of prophylactic vaccination is supported by the drastic 
reduction of many diseases like rabies, polio and measles and even a complete eradication of 
smallpox16. These merits makes vaccination the most relevant contribution of immunology to 
human health17. How big the impact of vaccine programs can be is clearly shown by the success 
of measles vaccination. Before the World Health Organization (WHO) organized worldwide 
vaccination programmes, measles caused more than two million deaths each year and formed 
one of the leading causes of death among young children. In 2014, 85 % of all children on earth 
received at least one vaccine dose by their first birthday, which made measles-caused death 
rates drop for 79 % over the last 14 years.  
However, despite these significant successes, there still remain some major challenges for the 
development of vaccines at many different levels. First, there is the need for a new generation 
of vaccines that target more conserved regions of highly mutational viruses, like the influenza 
virus. Due to influenza antigenic variation, yearly predictions need to be made to update the 
vaccine antigen composition and immunize the public with the most relevant multivalent 
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vaccine18. A second major challenge in vaccinology remains the development of new adjuvants, 
that are able to elicit broader and sustained immune responses19. Improving vaccines at these 
different levels should make it possible to elicit immune responses of adequate strength and 
quality for effective protection against HIV, Mycobacterium tuberculosis and malaria, diseases 
still forming a challenge for vaccinologists. 
3. VACCINE-ELICITED IMMUNE MEMORY  
Prophylactic vaccination has the essential goal to induce pathogen-specific adaptive immune 
responses and to provide an active long-term immune protection. Most effective vaccines 
approved today generate protection through high-affinity antigen-specific memory B cells and 
memory T cells. In this chapter we will describe shortly the role of B and T cells in immune 
memory. 
3.1 HIGH-AFFINITY MEMORY B CELLS 
An effective B cell memory response is characterised by different functional isotype classes of 
high-affinity plasma cells and a panel of non-secreting memory B cells20. The process of memory 
B cell programming starts with antigen priming of naïve B cells. A naïve B cells binds either to 
soluble proteins in the lymphoid fluid or to proteins presented by dendritic cells (DCs) and 
macrophages. Upon binding of the antigen on a naïve B cell receptor (BCR), the antigen gets 
internalized, where after the B cell gets activated followed by IgM-antibody secretion21. 
Subsequent contact with antigen-specific follicular helper CD4+ T cells (TFH) and cytokines, like 
interleukin (IL)-422, initiate immunoglobulin class switching and differentiation of the plasma cell 
into non-germinal centre plasma B cells. At this phase of B cell memory development, the 
initially pre-germinal centre-primed B cells split up into two groups. A first part of the pre-
germinal centre B cells continues differentiation into plasma cells via an extra follicular B cell 
pathway. A second part of the B cells migrate to the germinal centre of secondary lymph 
nodes23–25. During their stay in the germinal centre, these B cells will undergo antigen-specific 
clonal expansion and BCR diversification, followed by positive selection of high-affinity BCR 
variants, which will leave the germinal centre20. During this process, B cells differentiate into 
long-lived high-affinity antibody secreting plasma cells26 – which house in the bone marrow - or 
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long-lived non-immunoglobulin secreting memory B cells – which remain in lymphoid tissue27. 
Memory B cells do remain for many years upon infection or immunization and are responsible 
for the recognition of identical antigens in order to quickly reply on re-exposure to the 
pathogen. The increased affinity of the BCR on memory cells does contribute to the sensitivity of 
low-dose soluble antigens.  
3.2 EFFECTOR AND MEMORY CD8+ T CELLS 
The activation of CD8+ T cells requires three signals: TCR engagement (signal 1), co-stimulation 
(signal 2) and an inflammatory stimulus (signal 3). The first signal is converted by the initial 
interaction between the antigen presenting cell (APC) and the antigen-specific T cell. This 
interaction constitutes the binding between the APC MHC-I-epitope and MHC-II complex and 
the T cell receptor (TCR) - CD3 complex of CD8+ T cells or CD4+ T cells resp. In addition to this 
MHC-I presentation of the peptide, a co-stimulatory response, signal 2, is required to prevent 
anergic responses. Such co-stimulatory molecules are CD80 and CD86 expressed on the APC 
surface, which interact with the CD28 receptor on the T cell surface. Also the interaction 
between CD40-CD40 ligand is described to act as a critical signal 2 for proper T cell activation. 
The third signal for effector and probably also memory T cell differentiation is conveyed by the 
secretion of certain cytokines, which will ultimately determine the functionality of the evoked T 
cell response. Type I IFNs and IL-12 are the key cytokines that govern the differentiation of CD8+ 
T cells into IFN-γ secreting and cytolytic effector cells. Although type I IFNs and IL-12 can 
partially compensate for each other, their relative contributions in guiding T cell differentiation 
depend on the nature of the infecting pathogen28.  
Upon proliferation, most of the T cells will terminally differentiate into end-stage effector cells 
and die off after the infection is cleared. CD4+ T cells differentiate into different types of T helper 
cells, depending on the cytokine milieu29,30. In brief, Th1 skewed CD4+ T cells produce mainly 
IFNɣ, IL-2 and TNF to directly stimulate killing of pathogen-infected cells by i.e. cytolytic effector 
CD8+ T cells. Th2 skewed CD4+ T cells and TFH cells produce mainly IL-4, IL-5 and function as B cell 
supporting T helper cells31,32. Viral or intracellular bacterial infections promote differentiation of 
CD8+ T cells into effector CTLs that mediate viral clearance and a small percentage of memory 
precursors cells33–35. The effector CD8+ T cells destroy malignant or infected cells via the 
secretion of cytokines- such as IFNɣ and tumor necrosis factor (TNF)36 and via the excretion of 
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cytotoxic granules containing perforins37 and granzymes38,39. They further stimulate apoptosis 
via Fas/FasL40 interaction. A small percentage of effector CD8+ T cells that remain after the 
elimination of the pathogen will further differentiate into memory CD8+ T cells. The two 
broadest subsets of memory T cells have been identified as effector memory T cells (TEM; 
CD62LlowCCR7low), homing to non-lymphoid tissue, and central memory T cells (TCM; 
CD62LhiCCR7hi CD27+), homing to secondary lymph nodes and bone marrow41. TEM are memory 
cells that have lost the expression of CCR7 and CD62L. TEM are characterized by rapid effector 
function and they produce perforins and IFNɣ within hours following antigenic stimulation42. 
TCM are memory cells that, compared with naïve T cells, have higher sensitivity to antigenic 
stimulation, are less dependent on co-stimulation, and upregulate CD40L to a greater extent, 
thus providing more effective stimulatory feedback to DC and B cells. Following TCR triggering, 
TCM produce mainly IL-2, but after proliferation they efficiently differentiate to effector cells and 
produce large amounts of IFN-γ or IL-441,43,44. 
Different models exist predicting the differentiation of effector and memory T cells, which are 
nicely reviewed by Keach et al45. The identification of both populations and intermediate cell 
phases from naïve cells to terminally differentiated cells, is based on a set of cell markers: killer 
cell lectin-like receptor G1 (KLRG1), Interleukine 7 receptor subunit α (IL-7Rα), CXC chemokine 
receptor 3 (CXCR3), CD27 and CD62L. Memory CD8+ T cells are maintained in absence of antigen 
trough IL-7 and IL-15 cytokines, promoting cellular survival and self-renewal46. 
4. VACCINE ANTIGEN FORMAT 
To-date, different vaccine approaches are commercialised and in this thesis, they will be 
classified into four types depending on the nature and formulation of the antigen (Figure 2). The 
first group consists of whole organism vaccines, subdivided into live-attenuated vaccines and 
inactivated vaccines47. A second group, the subunit vaccines, contain selected pathogenic 
antigens, which can be encoded by proteins, peptides or nucleic acids46,55. Based on the  antigen 
formulation format, subunit vaccines can be subdivided into VLPs, nanoparticle-based vaccines 
and naked nucleic acid vaccines. Next, a third group compromises toxoid vaccines52-54, inducing 
protection to the secreted toxins rather than the pathogen itself. The last group presents the 
conjugated vaccines, which are polysaccharide-based vaccines conjugated to a carrier protein56-
57. 
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Figure 2. Based on the vaccine antigen format, four major groups of vaccines are classified.  The group 
of whole organism vaccines can be subdivided into live-attenuated vaccines and inactivated vaccines. 
The subunit vaccines are subdivide into VLPs, nanoparticle-based vaccines and nucleic acid vaccines. 
Toxoid vaccines aim to induce humoral immunity to neutralise secreted toxins, which are responsible 
for illness. The group of conjugated vaccines are based on polysaccharides linked to a protein carrier. 
4.1 WHOLE VIRUS VACCINES: LIVE-ATTENUATED OR INACTIVATED 
Live-attenuated vaccines consist of living bacteria or virus strains weakened to such extent that 
they are still able to transiently infect humans without causing disease. Due to the natural 
infection process, live-attenuated vaccines elicit both humoral and cellular immune responses 
and as a consequence, they can be considered as most immunogenic amongst all vaccine 
approaches. Furthermore, live-attenuated vaccines don’t need to be supplemented with 
separate adjuvants. 
Although live-attenuated vaccines form the biggest group on the market, they display an 
alarming safety profile and therefore, safer vaccine formats are needed (table 1). Risks of the 
use of living viruses although attenuated, include the chance on mutation to a more virulent 
form, causing disease especially in immune-compromised people include HIV+ subjects, 
transplant patients and people treated with an immune suppressive drug. Another drawback of 
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live-attenuated vaccines is the need for storage of living organisms at temperatures around 4-8 
degrees, which imposes limitations for the use in developing countries47.  
However, in contrast to live-attenuated vaccines, inactivated vaccines based on pathogens killed 
by chemicals, heat or radiation, are more stable and safer than their living counterparts. In 
addition, they can be stored in a freeze-dry state, making them accessible to people in 
developing countries. Yet, although inactivated vaccines are safer than live-attenuated vaccines, 
they are less immunogenic due to the lack of an infection process47. 
4.2 SUBUNIT VACCINES  
During the last years, significant progress has been made in the search for new approaches to 
circumvent the use of living organisms and to focus more on synthetic vaccine formats, namely 
subunit vaccines. Subunit vaccines constitute a broad collection of different vaccine formats 
using  recombinant antigens instead of a whole organism. These synthetic antigens can be 
encoded either by recombinant proteins, peptides or nucleic acids. Due to the controllable 
production process of synthetic antigens, the safety profile of subunit vaccines scores much 
better than live-attenuated vaccines. When a soluble antigen is administered, the specific 
pathogenic composition is lost. For this reason, the immunogenicity of the selected antigen 
drops significantly. To deal with this problem, subunit vaccines are formulated in nanostructures 
or accompanied with adjuvants, whose function is to increase and skew the immunogenicity of 
the vaccine proteins. In here, we categorize subunit vaccines in subgroups based on the antigen-
encoding device and the mechanism of formulation. 
Virus Like Particles (VLPs) 
First, there is the group of virus like particles (VLPs). The principle of VLPs is the spontaneous 
interaction and self-assembly of the capsid proteins into virion-like structures. Due to a viral 
mimicry, VLPs are able of inducing both humoral and cellular responses48 (table 1). A well-known 
VLP-based vaccine on the market is the nine-valent Gardasil 9® to protect against infection by 
nine different human papillomavirus (HPV) strains, all causing cervical cancer and neoplasia. 
Gardasil 9® is composed of strain-specific major capsid proteins L1, which are produced in yeast, 
and aluminium hydroxide-based adjuvants.  
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Nanoparticle-based subunit vaccines 
Besides the use of self-assembling proteins to form a virion-like structure, another strategy of 
antigen delivery is based on the formulating antigens into a carrier in order to obtain an 
immunogenic nanoparticle. Multiple carriers are studied, such as lipids and polymers, in order to 
deliver proteins, peptides or even RNA and DNA, all encoding antigens49–51. Nanoparticles have 
the great potential to be efficiently engulfed by APCs, which is crucial for antigen presentation 
to CD4+ and CD8+ T cells.  
Based on the antigen-encoding device, nanoparticle vaccines can be subdivided into protein 
vaccines and nucleic acid vaccines. For the latter subgroup, the vaccine antigens are expressed 
in the host cell upon translation of the administered DNA or RNA molecules. This intracellular 
process grants nucleic acid vaccines an intrinsic adjuvant character, caused by the interaction 
between the nucleic acids and endosomal and cytosolic pattern recognition receptors (PRRs) 
(table 1). In addition, priming of CD8+ T cell responses requires the antigen to enter the cytosolic 
route of antigen presentation. This route starts with the cleavage of cytosolic proteins into 
peptides, followed by the import of these peptides in the endoplasmic reticulum and their 
loading onto MHC-I molecules for presentation to CD8+ T cells. As plasmid DNA (pDNA) and 
messenger RNA (mRNA) vaccines enable the cytosolic expression of antigens, they possess a 
superior potential to elicit CD8+ T cell immunity compared to protein-based vaccines. Protein-
based vaccines largely fail to access the cytosolic route of antigen processing as they are 
degraded in the endolysosomal compartments by acidic proteases followed by presentation via 
MHC-II to CD4+ T cells.  
4.3 TOXOID VACCINES 
For some pathogens, illness is mainly caused by secreted toxins rather than the bacterium itself. 
For example, the principal toxin causing tetanus, tetanospasmin, binds to specific membrane 
receptors located on motor nerve cells to get internalized by the nervous system52. Once in the 
nervous system, the toxin blocks the glycine metabolism, which is essential for the working 
mechanism of neurons, and directly leads to the typical tetanus muscle spasms. To protect 
people from illness caused by pathogen-secreted toxins, toxoid vaccine were developed. A 
toxoid vaccine is based on the inactivation of toxins by formaldehyde-treatment in order to 
create minor molecular conformational changes without losing the physicochemical character of 
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the natural toxin. A prime and boost immunization promote humoral immunity driven by the 
induction of neutralizing cross-reactive antibodies. This means that the antibodies which are 
initially evoked by toxoid vaccination, will target and neutralize the natural toxins after exposure 
to the pathogen53. In general, toxoid vaccines are very effective and in addition, they are 
considered as a safe method to immunize the young and elderly as they do not mimic a bacterial 
infection (table 1). Toxoid vaccines are used to protect people against the highly infectious 
diphtheria, botulism, and tetanus.  
4.4 POLYSACCHARIDE-PROTEIN CONJUGATED VACCINES 
Polysaccharide-encapsulating bacteria cause disease mainly in children during their first years of 
life but become less immunogenic for infants54. Polysaccharides are T cell independent antigens 
which generally stimulate short-lived B cell responses by cross-linking the B cell receptor. In 
order to enhance the immunogenicity of polysaccharides for immunization, they are chemically 
attached to a protein carrier55. This carrier can be a toxoid or pathogen-outer membrane 
protein56. The chemical conjugation of the polysaccharide to a carrier allows direct processing of 
the protein by polysaccharide-specific B cells. After processing of the carrier protein, peptides 
will be presented to via MHC-II molecules to protein carrier-specific CD4+ T cells. For this reason, 
a conjugated polysaccharide vaccine induces both B cell and T cell responses, whereas the un-
conjugated polysaccharide shows shortcomings for the inducing of T cell responses55. Examples 
of FDA-approved polysaccharide conjugated vaccines are the Haemophilus influenza type b 
vaccine and the streptococcus pneumoniae vaccine (table 1). 
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Vaccine type Example vaccine Advantage Disadvantages 
Live- 
attenuated 
Measles-Mumps-
Rubella 
(M-M-RII, Merck) 
- Due to self-replicative 
properties, single dose is 
effective 
- Immune response against 
all antigens 
- Broad immune response 
- Since it is a living 
organism it may cause 
disease and storage at 
correct conditions is 
required 
- Risk of reversion to 
virulence by mutations 
- Not suitable for 
immunosuppressed 
patients 
Inactivated 
Hepatitis A  
(Havrix, GSK) 
 
- Safe use in 
immunosuppressed patients. 
- Better safety profile: no risk 
for reversion; no virulence 
- relative simple procedure 
- Less immunogenic; 
need for multiple 
doses and booster 
immunizations 
 
VLP 
Human papilloma 
virus  
(Gardasil9, VLP, 
Merck) 
- Safe in immunosuppressed 
patients. 
- Cannot cause disease 
- Less side-effects because of 
purified antigens 
- Most effective and 
suited antigens need 
to be identified  
- Less immunogenic; 
need for proper 
adjuvants 
Nucleic acid-
based vaccines 
Hematopoietic 
necrosis virus 
(Apex-IHN, DNA-
based, Novartis); 
approved for 
salmon 
- Intrinsic adjuvant character 
- Cannot cause disease 
- Very effective induction of 
CTL responses 
 
- Still, less 
immunogenic 
- Need to be protected 
from nucleases 
- DNA is not FDA-
approved for human 
use 
Toxoid 
Tetanus, Diphteria 
(DTaP,DT,Td,Tdap; 
Sanofi Pasteur; Ltd) 
- Stable 
- Safe in immunosuppressed  
patients 
/ 
Conjugated 
vaccines 
Haemophilus 
influenzae type B, 
Pneumococcen, 
Meningococcal 
vaccines 
-  Very effective  
- Relative easy production 
- Applicable for young 
children 
- Safe 
/ 
Table 1. Vaccine formats. VLP, Virus like particle; CTL, cytotoxic T cells. 
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5. ADJUVANTING THE VACCINE: CARRIERS AND PRR-AGONISTS 
When the focus of vaccine design shifted from whole organisms to the safer subunit format, the 
need for adjuvants was clear-cut. In general, all adjuvants aim to improve the immunogenicity of  
vaccine antigens in order to elicit effective and long lasting immune responses. To elicit an 
immune response, adjuvants employ one or more of the following mechanisms: i) sustained 
release of the antigen, ii) up-regulation of cytokines and chemokines, iii) cellular recruitment to 
the site of injection, iv) increased uptake and presentation of the antigens by APCs, and v) the 
maturation and activation of APCs followed by the migration to draining lymph nodes57. In this 
chapter, adjuvants will be classified into two groups dependent on how they fulfil their function 
as immune stimulators. A first group of adjuvants can be classified as antigen carriers and a 
second group contains the PRR-agonists (table 2). Yet, important to know is that most adjuvants 
are a combination of both classes, as PRR-agonists benefit from being formulated into 
nanoparticle carriers.  
5.1 ANTIGEN CARRIERS 
A first group of adjuvants includes the antigen carriers. Carriers might fulfil their role as adjuvant 
via different mechanism, including targeting the antigenic cargo to APCs. In this way, the 
amount of antigen reaching the target cells increases, which directly leads to improved immune 
responses. Another possible mechanism includes their role as an antigen depot58 as they 
encourage a slow release and prolong vaccine antigen exposure59. For most carriers, even to-
date, there is still a lot of debate about their effective mechanisms and how they adjuvant the 
vaccine. In here, we give an overview of the most applied carrier-based adjuvants. 
Liposome-based delivery vehicles 
Lipid vesicles comprise all formulations based on a lipid bilayer encapsulating an aqueous core60. 
Multiple liposome-based delivery vehicles exist, but the most common liposomes are composed 
of phospholipids and cholesterol61. One of them is AS01, a liposome-based adjuvant of 
GlaxoSmithKline that was tested in a clinical trial for Malaria vaccination (table 2). The most 
important advantage of liposomes are their versatility and plasticity, as their size and charge can 
be adapted in order to create the required conditions to entrap specific antigens or adjuvants60. 
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Water-soluble antigens, such as proteins, peptides and nucleic acids, are entrapped within the 
inner space of the liposomes, whereas lipophilic antigens or lipopeptides are located in the lipid 
bilayer. Liposomes, or nanoparticles in general, exert their immune stimulating effect by 
enhancing antigen delivery as well as by the activation of PRRs in DCs. Lipid-based vesicles can 
both induce Th1 and Th2 immunity, dependent on their size and cargo. Badiee and colleagues 
evaluated the impact of the particle size on immunity of liposomes containing a Leishmania 
surface glycoprotein. They showed that immunization with small liposomes induced Th2 
immune responses, whereas larger liposomes induced Th1 immunity62.  
Immunostimulatory complexes (ISCOMs) 
Another group of carrier-based formats which play a role in the adjuvant character of the 
vaccines, consists of immunostimulatory complexes or ISCOMS. ISCOMS are composed of 
saponins, cholesterol and phospholipids and form a cage-like structure in which the antigen is 
incorporated. It is still unclear whether ISCOMS stimulate immunity via the activations of PRRs 
or via the improvement of antigen uptake by DCs followed by maturation and rapid transport to 
the draining lymph nodes63,64. Upon uptake by DCs, ISCOMS have been proved to destabilize the 
endosomal membranes resulting in the endosomal escape of both antigen and adjuvant63,65. For 
this reason, ISCOMS are able to induce both humoral as well as cellular immunity without 
causing a biased Th1 or Th2 immunity (table 2)63.  
Aluminum salts  
The most applied adjuvants for human use are the Th2-skewing alum adjuvants (table 2). Alum 
absorbs proteins and generates antigen depots trapped at the injection site66,67. Alum is known 
to promote Th2 immune responses and differentiation of B cells, resulting in robust antibody 
production57. But surprisingly, despite the FDA-approval of alum, there is no consensus 
regarding the molecular mechanism behind the immunogenicity of Alum yet. To-date, several 
mechanisms have been put forward in order to explain the immunogenicity68–71. In brief, Alum 
has been proved to improve antibody production which might be associated with the depot 
effect of Alum72. Although, there is no direct evidence that a depot effect significantly 
contributes to adjuvant capacity73. Schijn and colleagues reported that surgical removal of the 
antigen-Alum depot, 2 hours after immunization, did not effected humoral or cell-mediated 
immunity74,75. A second underlying mechanism of the immunity of Alum, might be the induction 
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of inflammation and the recruitment of antigen presenting cells, more specifically monocyte-
derived DCs76,77. Thirdly, as Alum has the capacity to form nanoparticle complexes upon 
interaction with proteins, it may enhance phagocytosis by APCs. However, how Alum activates 
APCs and the role herein of NLRP3 and the inflammasome remains a matter of debate78–81. At 
last, Marichal and colleagues suggested that alum-induced cytotoxicity resulted in the release of 
host DNA, which acts as a DAMP, and as a consequence host DNA acts as an endogenous 
adjuvant in alum vaccination. Further, Immunizing Nlrp3-deficient (Nlrp3−/−) and Caspase 1–
deficient (Casp1−/−) mice resulted in the development of humoral responses comparable to 
those of WT mice, which was in contrast to the immunization of Irf3-deficient (Irf3−/−) mice, 
showing reduced IgE antibody responses, whereas IgG1 responses remained unaffected. These 
results indicated that the extracellular DNA-mediated adjuvant activity of Alum was dependent 
on IRF3 activation, rather than on inflammasomal activation. Although the recruitment of 
immune cell populations at sites of alum injection did not differ significantly between WT 
and Irf3−/− mice, a reduction of inflammatory monocyte (iMono)-derived inflammatory DCs 
(iDCs) in the draining lymph nodes was observed upon OVA and alum–treatment of 
Irf3−/−mice. Furthermore, a direct link between the recruitment of iDCs to the draining LNs and 
the percentage of cell death and DNA release upon Alum injection was suggested. Taken 
together, in this study the crucial role of IRF3 in the induction of Th2 cell and IgE responses to 
Alum is correlated to the recruitment of iMonos, the precursors of iDCs to the draining lymph 
nodes82. 
Oil-in-water (o/w) Emulsions  
Two FDA-approved examples of oil-in-water emulsions are MF59 and AS03 (table 2). Both 
formulations are based on squalene, a biosynthetic precursor of cholesterol and steroid 
hormones, completely degradable for humans. MF59 consists of squalene oil droplets stabilized 
by Tween80 and Span85, two non-ionic surfactants83,61. Calabro and colleagues reported that 
the combination of all three components are crucial for the adjuvanticity of MF5984. However 
oil-in-water emulsions are currently used in many human vaccines, likewise aluminum salts, the 
Th2-skewing mechanisms is largely unknown65,83,85. It has been reported that MF59 immunity is 
not based on a depot effect as MF59 is rapidly cleared out, independent of the vaccine-
antigen86. The MF59-mediated cellular recruitment to the injection site is been investigated in 
detail84, revealing that MF59 induces a local stimulation and recruitment of DCs, neutrophils and 
granulocytes, resulting in enhanced uptake of the antigen87. This is achieved by the upregulation 
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of CCR2, the receptor of chemoattractant CCL2, involved in monocyte infiltration87,88. Seubert 
and colleagues showed that, similar to Alum, MF59 recruits inflammatory Ly6C+ CD11b+ 
monocytes, which differentiate into CD11c+ MHC-II+ DCs upon antigen uptake, in a MyD88-
dependent manner. Furthermore, they proved that MF59 did not activate any of the Toll-like 
receptors in vitro, suggesting a role for cytosolic receptors in the MyD88-dependent signalling 
upon MF59 injection83.  
 Adjuvant 
Functional  
component 
Innate Immune 
 trigger 
Principal 
immune 
response 
Refs  
FD
A
 a
p
p
ro
ve
d
 
Alhydrogel 
Adju-Phos 
Aliminium salts 
(hydroxid or 
phosphate) 
NLRP3? Inflammasome? Ab, Th2 
68,71,89–92 
A
n
tigen
 carrier 
MF59, 
AS03 
Squaleen in water 
emulsion 
MyD88 dependent 
No receptors defined yet. 
Ab, Th2 
93–95
 
AS04 Alum and MPL 
NLRP3? Inflammasome? 
TLR4 
Ab, Th1 
96–98
 
H
u
m
an
 a
n
d
 m
ic
e 
st
u
d
ie
s 
AS01 Liposomes 
The broad variety of cargo 
- different immune 
activating strategies 
Ab, Th1, Th2 
60,62
 
ISCOMs 
Saponin, cholesterol 
phospholipids 
Unclear Ab, Th1, Th2 
63
 
IFA 
Mineral, paraffin oil+ 
surfactant 
undefined 
Ab, Th1 and 
Th2 
99–101
 
CFA 
IFA + peptidoglycan, 
trehalose dimycoltae 
NOD-2;  
inflammasome 
Ab, Th1, 
Th17 
99,102,103
 
Poly:IC 
Synthetic variant of 
dsRNA 
TLR3, MDA5 
Ab, Th1, 
CD8
+ 
T cells 
104–106
 
P
R
R
-ago
n
ists 
Imiquimod 
Imidazoquinoline 
derivate 
TLR7/TLR8 
Ab, Th1, 
CD8
+ 
T cells 
107,108
 
IC31, 
QB10 
DNA oligo’s with CpG 
motifs 
TLR9 
Ab, Th1, 
CD8
+ 
T cells 
109–112
 
Table 2.  Adjuvants currently employed in human vaccines licensed for use in the US and/or Europe and 
adjuvants used in pre-clinical and clinical studies. TLR, toll like receptor; MPL, monophosphoryl lipid A; 
IFA, Incomplete Freund’s adjuvant; CFA, complete Freud’s adjuvant;MDA5, Melanoma differentiation-
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associated protein 5; NLR, Nod-like receptor; NLRP3, NLR family pyrin domain containing 3; Ab, 
antibodies; Th, T helper cell response. Taken over from
113
. 
5.2 MOLECULAR ADJUVANTS : PRR AGONISTS 
To induce a cellular immune response rather than a humoral response, antigens need to enter 
the cytosolic pathway to be presented by MHC-I molecules to CD8+ T cells. Live-attenuated 
vaccines induce CD8+ T cell immunity through the endogenous MHC-I pathway. However, to 
obtain CD8+ T cell immunity upon recombinant protein vaccination, an adjuvant is needed in 
order to stimulate cross-presentation and push immunity towards Th1 responses. As classical 
adjuvants induce mainly strong Th2 responses and are less competent to induce Th1 immunity, 
the current challenge remains to develop adjuvants suitable for the induction of strong Th1 
skewed immune responses. To this end, new adjuvants are being developed based on the 
natural ligands or synthetic agonists of TLRs. However, not all TLRs skew immunity towards a 
Th1 response. For example, TLR2 and TLR5 enhance T cell and antibody responses without 
altering Th1/Th2 cell balance. Of note, important to know is that TLR-ligands generally benefit 
from being formulated into nanoparticles as formulation i) provides protection of the adjuvant, 
ii) allows interaction between the antigen and the adjuvant, promotes uptake in the same cell, 
and at last, iii) limits biodistribution of the agonists and promotes targeting to the draining 
lymph nodes, so it lowers cytotoxicity. In here, we will give a short overview of the some Th1-
skewing TLR-agonists. A more in depth description about how PRR receptors induce pro-
inflammatory cytokines and type I IFNs upon triggering will be discussed in chapter 2.    
PolyI:C. PolyI:C is a synthetic analogue of dsRNA and a ligand for TLR3, cytosolic retinoic acid-
inducible gene-1 (RIG-I) and melanoma differentiation factor associated gene 5 (MDA5)106,114,115. 
PolyI:C is characterized as an inducer of IL-1, IL-6, IL-12 and IFNβ upon transfection of DCs and is 
currently evaluated in preclinical research for his capacity to promote Th1 immunity and cross 
presentation in CD8+ T cells106,116. The polyI:C derivative Ampligen® (or polyI:C12U) has been 
under clinical investment for as a therapy for patients suffering from Chronic Fatigue Syndrome 
and HIV117–119. 
Monophosphoryl lipid A. Bacterial lipopolysaccharide are natural TLR4 agonists but are 
considered as a high-risk for toxicity, limiting their potency for human use. In the early 80’s a 
less toxic derivative was developed, called monophosphoryl lipid A (MPL). MLP forms a 
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component of the licenced adjuvant AS04, used in Cervarix® vaccines combined with Alum97. 
AS04 stimulates polarized Th1 immunity via MyD88 and TRAF6, leading to the recruitment of 
transcription factors, such as NF-ƘB to regulate the expression of pro-inflammatory cytokines 
(IL-1, IL-6, IL-12 and TNFα). Like almost all adjuvants, also AS04 induce DC maturation to 
enhance adaptive immunity97. 
TLR7/8-agonists. Uridine-rich ssRNA is identified as a natural ligand of TLR7 and TLR8107,120. 
During the last years, synthetic variants have been designed with same TLR7/TLR8-binding 
specificity as ssRNA but improved stability. One such example is imiquimod, a profound type I 
IFN inducer which has recently been heavily investigated in multiple pre-clinical trials121,122. 
CpG. DNA molecules or synthetic 18-25 oligonucleotides (ODN) containing CpG motifs have 
been studied intensively for their binding capacity to TLR9 and their capacity to induce Th1 
skewed immunity. Further, CpG activates DC maturation (via the upregulation of CD40, CD80, 
CD86) and increase antigen expression (via the upregulation of MHC-II)123. In order to target 
both antigen and CpG to the same cell, both components are mostly complexed into liposomes 
to force co-localized uptake in APCs109,124. 
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1. NUCLEIC ACIDS AS ANTIGEN-ENCODING DEVICES 
Because mRNA was considered too unstable for in vivo use, research into the nucleic acid 
vaccines has been strongly focused on pDNA vaccines in the past. Over the last decades, mRNA 
has however started to outcompete pDNA as nucleic acid format of choice to deliver antigenic 
information to the immune system. This paradigm shift is mainly driven by the enhanced 
stability of in vitro transcribed mRNA alongside with serious safety concerns regarding the use of 
pDNA. In this chapter we will provide a first impression of nucleic acid vaccines and how they 
elicit antigen-specific immunity.  
1.1 DNA AS ANTIGEN-ENCODING DEVICE 
1.1.1 Mode of action 
Following intramuscular or intradermal injection, antigen-encoding plasmid DNA (pDNA) is taken 
up by both structural and antigen presenting cells (APCs)1. Upon intracellular translation, the 
antigenic proteins will be cleaved by the proteasome into peptides, which are presented to CD8+ 
T cells via major histocompatibility class I (MHC-I) molecules on structural cells and professional 
APCs2,3. Secreted proteins that ended up in the extracellular matrix will be endocytosed by APCs 
and presented via MHC-II to activate CD4+ T cells and B cells. For this reason, pDNA vaccination 
is able to induce both humoral and cellular immune responses. This renders DNA vaccines much 
more effective than current vaccines in evoking a long-term immune response4–7. Generally, 
pDNA vaccines favour Th1 responses as mostly IgG2a titres are promoted upon DNA 
vaccination8,9. Nevertheless, some parameters, such as the type of antigen and the delivery 
method can skew this preferential IgG2 profile towards dominated IgG1 titres. Th2 skewed 
immunity has been shown for pDNA vaccines encoding secreted proteins as well as for pDNA 
vaccines which have been delivered by gene gun technology10,11. 
pDNA vaccination provides important advantages compared to whole organism-based vaccines 
or protein-mediated subunit vaccines. First, pDNA vaccines seem to approach the capacity of 
live-attenuated vaccines to induce MHC-I-restricted CD8+ T cell responses, without the risk of 
causing infections or mutations which might result in a virulent organism. Furthermore, in 
addition to a prophylactic response, pDNA vaccines can also be applied therapeutically. Second, 
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the production and storage of DNA-based vaccines is relative easy and cost-effective due to 
their high stability. Finally, full-length nucleic acid-based vaccines are not restricted by the 
patient’s HLA type, unlike peptide-based vaccination. However, the major drawback of pDNA 
vaccines is the risk on genome integration by insertion mutagenesis. At last, pDNA vaccination 
require cell proliferation for the expression of the encoded protein as the pDNA vector needs to 
enter the nucleus in order to get transcribed and translated. Although it has experimentally 
been shown that the chance on plasmid integration is lower than the chance on spontaneous 
mutation12, at this moment, DNA vaccination is not generally used for the treatment of cancer 
patients, although a select number of clinical trials are ongoing. 
1.1.2 DNA Vector Construct 
DNA vaccines consist of antigen-encoding genes cloned into a bacterial plasmid under the 
control of a strong eukaryotic promoter to guarantee optimal expression in mammalian cells13. 
The two most prominently used promoters are originally derived from the cytomegalovirus 
(CMV) and simian virus 40 (SV40) genome. The CMV promoter enables high constitutive 
expression levels in a wide range of mammalian tissue and does not suppress downstream read-
through mechanisms14,15. Further, the antigen-encoded gene is flanked at the 3’ end by a 
polyadenylation sequence to stabilize the mRNA transcript upon translation16. Next, a DNA 
vector also contains an origin of replication to allow large copy numbers and a bacterial 
antibiotic resistance gene (ampicillin or kanamycin) for plasmid selection during bacterial 
culture17. 
1.1.3 DNA Vaccine Delivery Systems 
As mentioned before, a delivery system can improve vaccine immunogenicity via two ways. 
First, they enhance the delivery efficiency of the antigen, as a consequence, they enable larger 
amounts of antigen reaching the target cells. On the other hand, they promote the 
immunogenicity of the vaccine by activating innate immunity. For the administration of DNA as a 
vaccine, different approaches can be applied. First of all, some physical DNA delivery approaches 
have been developed, including magnetic beads, gene gun delivery18, microneedle injection19, 
electroporation and sonoporation. Sonoporation, or cellular sonification, refers to the use of 
ultrasound to permeabilize the cell membrane in order to deliver nucleic acids into the cell20. 
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The combination of sonoporation and manose lipoplex-based delivery of DNA vaccines has been 
tested in a clinical study including relapsed melanoma patients21. This study revealed enhanced 
secretion of Th1 cytokines (IFNɣ and TNFα) and the effector function of cytotoxic CD8+ T cells 
upon treatment. Besides physical approaches, a broad panel of nanoparticle-based formulation 
has been extensively tested in preclinical studies, including polymers, peptides and liposomes22. 
In this section we will highlight the use of electroporation and cell penetrating peptide-based 
delivery of DNA vaccines and describe how these strategies contribute to the improvement of 
DNA vaccine immunogenicity.  
In Vivo Electroporation 
Electroporation (EP) is the most commonly used – 45 % of all clinical trials concerning DNA 
vaccination deliver DNA via EP23,24 - and most powerful delivery method for DNA vaccines25,26. 
EP-mediated delivery is based on membrane destabilization, mediated by electric pulses 
resulting in uptake of DNA. Mostly APCs are in vitro electroporated and subsequently 
transferred to the patient. Beside this in vitro approach, DNA may also be directly delivered via 
injection, followed by in vivo EP. The success of in vivo EP may be explained by the high 
transfection efficacy combined with the induction of pro-inflammatory cytokines27 and local 
recruitment of immune cells28,29. The in vivo induction of type I IFNs upon electroporation is 
documented by Lambricht and colleagues using an IFNβ reporter mouse model5. They showed 
that the combination of both EP and plasmid (empty or coding for an antigen) injection is 
required for the induction of significant type I IFN responses.  
Like other carrier systems, the site of administration influences both the type and the 
magnitude of the immune response induced by DNA vaccine electroporation17. Multiple delivery 
routes concerning the EP-based delivery of DNA vaccines have been tested in the past4,30–33. 
Vandermeulen and colleagues performed a study in which multiple antigens (ovalbumin, gp160 
and P1A) encoded by pDNA were injected, followed by EP at three different sites: tibial cranial 
muscle, abdominal skin and ear pinna4. They observed the highest gene expression levels and 
IgG titres in mice that were intramuscularly vaccinated. However, the strongest CD8+ T cell 
responses and IgG antibody titres were generated in mice that were electroporated in the ear 
pinna. Although the strongest CTL responses were generated via ear pinna electroporation, 
when tumor protection was compared, electroporation of muscle and ear pinna were equally 
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efficient in delaying P815 growth and prolonging mice survival. Taken together, this study 
showed the need for the validation of a specific administration route dependent on the aimed 
type of immunity. However, in the context of in vivo EP, injecting DNA intramuscularly or in the 
ear pinna is preferred for the induction of an effector CD8+ T cell response capable of 
destructing infected or malignant cells.  
Cell Penetrating Peptides  
Cell penetrating peptides (CPPs) are peptides of 8 to 30 residues that unlike other peptides have 
membrane disruptive abilities, making them perfectly suitable to transport cargo molecules – 
like siRNA, pDNA, and proteins - across cellular membranes. There are three groups of CPPs, 
namely cationic, amphipathic and hydrophobic CPPs. 
The first reported cationic CPP was the HIV-1 protein TAT, an arginine-rich peptide34. Futaki 
reported in a study about arginine-rich peptide-delivered proteins that at least eight positive 
charges are needed for efficient uptake of the cationic CPP-complexed cargo35. The uptake is 
mediated by the electrostatic interaction between CPPs and glycosaminoglycans (GAGs) on the 
cellular surface to enter the cell via endocytosis36. Besides endocytosis-mediated uptake, CPPs 
can also enter the cell directly. This direct translocation is suggested to be dependent on acid 
sphingomyelinase activation, followed by a change in composition of the membrane lipids37. 
Nucleus localization sequence (NLS) peptides are a well-known family of cationic peptides. NLS 
peptides are mainly based on arginine-, lysine- and proline-rich profiles and promote the 
translocation of molecules through the nuclear pore complex. Although they naturally function 
as a transport molecule, NLS-peptides do not efficiently disrupt membranes and only gain 
effective CPP features when they are covalently attached to hydrophobic sequences in order to 
create a chimeric amphipathic CPP. For example, Crombez and colleagues described the use of 
the amphipathic MPG-8 peptide to deliver siRNA to target B1 cyclin transcripts in vivo to prevent 
tumor growth. MPG-8 is composed of the fusion domain of HIV gp41 and the nuclear import 
sequence of SV40 T antigens38.  
The hydrophobic CPPs consist a small group of peptides, whose uptake is based on apolar 
residues or hydrophobic motifs. It has been shown, at least for some hydrophobic CPPs, that 
they can translocate directly through the membranes39. Direct crossing of the membrane is 
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advantageous for the delivery of cargo straight in the cytosol without risking to be trapped by 
the endosome40.  
Amphipathic CPPs can be classified into two groups based on their secondary structures; the α-
helical and the β-sheet amphipathic CPPs. The α-helical group can be further subdivided into 
primary and secondary helixes. The primary α-helix is composed of hydrophilic and hydrophobic 
parts at separate faces of the helix41, whereas secondary α-helixes have hydrophobic parts on 
one face, but the hydrophilic face can be either cationic, anionic or polar41. Although mostly all 
amphipathic CPPs are cationic, Scheller and colleagues proved that the membrane 
permeabilization character was not dependent on the charge of the peptide but rather on the 
amphipathic nature of the peptides42. Indeed, via the replacement of arginine by lysine residues, 
he created neutral and anionic amphipathic peptides whose cell penetrating capacities 
remained. Nevertheless, not all amphipathic peptides enable membrane permeabilization. So to 
date, the main requirements for the uptake capacities of amphipathic CPPs still remain to be 
determined. Besides α-helical structures, also β-sheet-structured amphipathic peptides are 
identified43, but these are less studied than their helical counterparts. The different forms of 
amphipathic CPPs can influence the mechanism of uptake but in general, endocytosis and direct 
translocation are considered as the major cellular membrane crossing processes of amphipathic 
CPPs.  
The Ph-Driven Amphipathic CPP: RALA 
McCarthy and colleagues successfully optimized the use of CPPs for in vivo delivery of pDNA by 
circumventing the frequently observed endosomal trap effect. They started their study using a 
pH-driven CPP, called GALA. GALA assumes a random coil α-helix at pH lower than 6. Due to this 
conformation, GALA can oligomerize within the membrane to form pores and cause membrane 
leakage40,44. When GALA arrives in the cytosol, where pH is higher than 6, the α-helical structure 
is destabilized due to deprotonation. As a consequence GALA obtains a negative charge and 
becomes membrane inactive45. Nevertheless, due to its anionic nature, GALA is not suited to 
efficiently condense nucleic acids, a crucial feature to deliver antigen-encoding pDNA. In order 
to create a stronger capacity to bind nucleic acids, GALA was modified by replacing the 
glutamate with lysine residues, resulting in a new peptide named KALA. KALA was shown to 
assist oligonucleotide nuclear delivery in many cell types46. However, due to the replacement of 
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the glutamate acids with lysine residues, the increased positive charge on KALA improved KALA’s 
membrane disruptive capacities47. As a result, KALA loses its endosomal specificity and causes 
toxicity48. To further optimize the perfect pH-driven CPP to deliver pDNA, the McCarthy group 
searched for KALA-inspired peptides able to bind nucleic acids but without losing the pH-specific 
endosomal disruption capacity. As arginine is found in most natural DNA binding motifs, they 
tested the replacement of lysine residues to arginine residues, to create the RALA peptide47. 
RALA is composed of 30 amino residues: N-WEARLARALARALARHLARALARALRACEA-C. The 
hydrophilic arginine (R) facilitates nucleic acid binding, whereas the hydrophobic Leucine (L) 
interacts with lipid membranes. These two regions are separated by alanine (A), resulting in an 
α-helical structure. The glutamic acids (E) at each terminus enhance solubility in water (pH 7,4). 
RALA peptide has been proven to efficiently condensate pDNA into nanoparticles which enable 
high in vivo antigen expression levels upon intravenous delivery47. Although cell-penetrating 
peptides have been extensively studies as delivery enhancers for nucleic acid-based vaccines, 
currently RALA is only validated as a DNA and siRNA delivery format in the context of nucleic 
acid therapeutics49. As far as we know, no research is performed yet concerning the use of RALA 
peptides as a nucleic acid carrier to evoke CD8+ T cell immunity. 
1.2 MRNA AS ANTIGEN-ENCODING DEVICE 
1.2.1 Mode Of Action 
mRNA vaccination is a potent vaccine format for the activation of antigen-specific cellular CTL 
responses, due to the followed intracellular track upon uptake by DCs. The intracellular track 
starts with the translation of mRNA antigens in the cytosol followed by antigen processing and 
presentation via the MHC-I molecules to CD8+ T cells. Still, due to cytosolic autophagy, a fraction 
of the proteins will be presented via MHC-II to CD4+ T cells. This CD4+ T cell activation is crucial 
for eliciting a robust cellular immune response since CD4+ T helper cells stimulate CD8+ T cells by 
producing IL-2 and activating DCs through CD40/CD40L interaction50. Further, mRNA has an 
intrinsic adjuvant character due to its ability to trigger intracellular PRRs, whose activation leads 
to the secretion of inflammatory cytokines and type I IFNs. 
The last two decades, much effort was put in the optimization of the mRNA molecules and the 
delivery formats of mRNA vaccines. Due to this progress, at present, mRNA vaccination shows 
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multiple benefits compared with pDNA vaccination. First, mRNA vaccines are safer than pDNA 
vaccines due to the negligibly small chance on genome integration causing insertional 
mutagenesis. Second, mRNA does not need to cross the nuclear membrane to be functional, in 
contrast to pDNA. As a consequence, mRNA is perfectly suitable for the transfection of slowly 
growing and even non-dividing cells. Third, due to the transient expression character of mRNA 
sequences, mRNA antigen delivery is far more controllable than pDNA-mediated delivery51–53. 
1.2.2 mRNA Constructs 
In vitro transcribed (IVT) mRNA is processed by an RNA polymerase-based reaction started from 
a DNA template vector. Generally, this DNA template consists of a RNA-polymerase-specific 
promoter, untranslated regions (UTRs) flanking the gene coding sequence, and a poly(A) tail54. In 
the following paragraph, a short overview is given about the latest optimizations regarding the 
mRNA constructs. 
All endogenous mRNA sequences do include a 5’ and a 3’ UTR, flanking the open reading frame 
(ORF) in order to enhance RNA stability and translational efficacy55. The use of the β 5’ UTR and 
α 3’ UTR of the globin gene of Xenopus is widely applied and has been proved to instigate strong 
translation efficiencies56–58. Still, in order to further enhance translational efficacy, multiple 
structural elements can be inserted in the 5’ and 3’  UTR regions55, such as Translation Enhancer 
(TE) elements and Expression and Nuclear Retention Elements (ENEs). Translation enhancers are 
a broad group of features which all aim to increase the translation efficacy of mRNA, such as 
internal ribosome entry sites (IRES). Besides TE elements, the RNA transcription vector can be 
further optimized by the incorporation of (ENEs) as patented in 201459. The ENE of nuclear 
restricted RNA sequences of the Kaposi's sarcoma associated Herpes virus (KSHV) is responsible 
for enhanced viral RNA abundance60. The underlying mechanism is based on specific U-rich 
hairpin structures interacting with the poly(A) tail of the mRNA sequences. Due to this 
interaction, a secondary structure is obtained resulting in the retention of RNA in the nucleus. 
But even more important for the application of in vitro transcribed mRNA, whenever the hairpin 
structure interact with the poly(A) tail, a ‘shield’ is created which protects the RNA from 
degradation by the host59. 
Next, the 5’methylated m7GpppN cap structure at the 5’ end of the mRNA molecule plays a 
crucial role in mRNA stability, RNA splicing and most importantly, in the recruitment of 
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ribosomes, and thus in the translation efficacy61. At present, the original cap structure is 
replaced by an anti-reverse cap analogue (ARCA). A conventional Cap can ligate to the sequence 
in two directions due to their ability to bind both via the methylated as well as the of 
unmethylated guanine residue. However, only the binding of the unmethylated guanine residue 
will result in a functional mRNA sequence as the eukaryotic initiation factor (eIF4A) does only 
recognise a methylated base at the 5’ end of the mRNA62. Thus, using a conventional Cap, 
statistically only half of the produced RNA sequences are functional. In contrast, ARCA cannot 
bind with the 3’ OH methylated guanosine to the RNA sequence, so is forced to insert with the 
unmethylated guanosine residue, leading to 100% functional mRNA molecules. As a 
consequence, by adding ARCA to the in vitro RNA transcription reaction, the efficacy of 
translation does increase dramatically63–65.  
At least, the poly(A) tail positively influences the mRNA stability by protecting RNA against 
nuclease activity. It has been proven that a poly(A) tail should consist of at least 20 adenosine 
residues66,67. However, the translation efficacy can be dramatically enhanced using poly(A) tails 
of 100 nucleotides and more67,68. Moreover, it has been shown that the combination of a 5’ cap 
and 3’ poly(A) tail synergistically effects the translation efficacy due to the essential formation of 
a cap-eIF4E-eIF4G-PAPB-poly(A) loop-structured complex, which enables the recycling of 
ribosomes and protects the mRNA against enzymatic degradation55,69.  
1.2.3 mRNA Vaccine Delivery Systems 
In theory, exogenous RNA needs to cross one lipid bilayer to become internalized by target cells 
and translated into a functional antigen. This is in contrast to pDNA, which needs to enter the 
nucleus in order to get transcribed. Naked mRNA is spontaneously taken up by many different 
cell types70–72. It has been shown that the uptake of naked RNA by immature DCs is an active 
process, which involves scavenger receptor-mediated endocytosis and micropinocytosis70,73. 
Both pathways lead to endolysosomal localization, where after only a small fraction of intact 
RNA sequences enter the cytoplasm72. To deal with this, multiple formats have been designed to 
both target the mRNA to antigen presenting cells as well as to augment the amount of RNA 
reaching the cytosol after uptake. Mostly all developed approaches are based on nanoparticle 
formation, such as the use of liposomes, polymers and peptides. Table 3 presents the most 
abundant lipid- and peptide-based formulations for mRNA vaccines which have been tested in 
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animal studies and clinical trials. In this section, we will shortly describe cationic lipid- and 
protamine-based delivery of mRNA to elicit effective CD8+ T cell responses for both prophylactic 
as well as therapeutic vaccination strategies. 
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DOTAP OVA / iv. / id. 
74
 
DOTAP/DOPE 
OVA 
HIV gag 
100  iv./ sc./ id. 
74–76
 
DOTMA+DOTAP+DOPE+cholesterol 
OVA 
influenza-HA 
200- 
230 
iv. 
77
 
Lipofectamin RNAiMAX 
HPV-E7 
OVA 
TRP2 
nanosize iv. 
78
 
PBAE+ DOTAP/DOPC Lipid + shell + 
DSPE-PEG2000 
OVA 280  In. 
79
 
Tween80 + oil phase containing 
Span85 + DOTAP + squaleen 
RSV-F 86  Im. 
80
 
Lipid+ 
peptide 
Lipid-protamine  HSV1-TK / iv. 
81
 
peptide Unifectin and protamine β-gal 100  iv./sc./ id. 
82–84
 
Table 3. Nanoparticle-based mRNA vaccine delivery systems used in animal studies and clinical trials. 
DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DOPE, 1,2-dioleoyl-sn-glycero-3-phospho 
ethanolamine; PBAE, Polyβ-amino ester poly-1; DOPC, L-α-Di-oleoyl phosphatidyl choline; SDPE-PEG, 
1,2-Distearoyl-sn-glycero-3-phosphoethanol amine-N-amino(polyethylene glycol)-2000;  OVA, 
ovalbumin, HIV gag, gag protein of Human immunodeficiency virus; β-gal, β galosidase; RSV-F, fusion 
glycoporotein of respiratory syncytial virus; TRP2, tyrosinase related protein-2; HSV-TK1, herpes 
simplex virus 1 thymidine kinas HPV-E7, human papilloma virus-E7; i.v, intravenous; id., intradermal; 
sc., subcutaneous; in., intranodal; im., intramuscular. Table adapted from
85
. 
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Cationic Lipid-Based Delivery Of mRNA Vaccines 
To complex negatively charged mRNA, cationic lipids are perfectly suited as both components 
spontaneously interact to form lipoplexes85. Lipoplex-based delivery of mRNA has two main 
benefits. First, the mRNA is condensed into particles within the range of micro-organisms, 
resulting in efficient targeting and uptake by professional APCs. Second, in a condensed state, 
the mRNA is less vulnerable for intracellular and extracellular enzyme-mediated degradation.  
The cationic lipid 1,2 dioleoyl-3-trimethylammonium-propane (DOTAP) is one of the most 
extensively studied lipid carriers for cellular delivery of nucleic acids and may be considered as 
the bench mark lipid-based delivery vehicle for mRNA vaccines75,76,86. For multiple years, 
researchers have been trying to optimize DOTAP-mediated mRNA transfection. For example, 
DOTAP mixed with carbonate apatite – a pH-sensitive inorganic crystal with strong affinity for 
nucleic acids – resulted in a ten-fold increase in expression levels of mRNA luciferase due to 
enhanced cellular uptake, compared to DOTAP alone87,88. The transfection efficiency was further 
optimized adding 1,2 dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol to the 
DOTAP mRNA lipoplexes to function as neutral helper lipids. DOPE has a phosphoethanol amine 
head group whose size is smaller than its hydrophobic diacyl chain. This formation enables DOPE 
to induce membrane fusion89. Adding DOPE to the DOTAP lipoplexes resulted in enhanced 
endosomal escape of the nucleic acid cargo and consequently higher transfection efficacies. We 
and others showed that intradermal, subcutaneous and intravenous immunization with cationic 
DOTAP-based lipoplexes resulted in effective CTL responses against the mRNA encoded antigens 
in mice studies74–77.  
Until now, it is still not fully understood how the structural organization between mRNA and 
cationic lipids occurs. It appeared to be difficult to analyse the interaction due to the unstable 
character of mRNA and its RNAse sensitivity. Nevertheless, it has been demonstrated that DNA 
and cationic lipids undergo topological transformation to form compact quasi-spherical vesicles 
with a 100-300 nm diameter and a multi-lamellar structure85,90. The chance that mRNA lipid 
complexation might exhibit another type of supramolecular organization is quite high, as single 
stranded RNA forms secondary structures and therefore not behaves as supercoiled pDNA. 
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Protamine- based delivery of mRNA vaccines 
Complexing mRNA with the membrane-translocation peptide protamine has been successfully 
applied by Curevac®. They demonstrated that complexing mRNA with protamine enabled the 
induction of Th1 responses against the mRNA-encoded antigens84. However, the protamine-
mRNA interaction is very tight in such extent that the adjuvant effect comes at the cost of weak 
antigen expression levels83. To solve this problem, a two-component format was developed, 
whereby mRNA was only partially complexed to protamine. As the uncomplexed mRNA appears 
to be responsible for antigen expression, whereas the complexed mRNA attributes a strong 
immunogenic signal, it is highly suggested that both mRNA components follow distinct 
intracellular pathways after endocytosis by APCs91,92. Immunizing mice with a two-component 
protamine-based vaccine resulted in the induction of a strong and balanced humoral immune 
response consisting of high IgG1 and IgG2a antibody titres, which suggested that both Th1 and 
Th2 immune responses were elicited83. Although evoked T cell responses comprise both IFNɣ-
secreting functional CD4+ and CD8+ T cells, only the CD8+ T cell responses have further increased 
with repeating immunizations83. This protamine-format has been proven to have potential to 
instigate CTL responses in clinical research93 (see 1.2.5). Besides the use of cancer models, 
protamine-based mRNA vaccination has further been evaluated in a prophylactic context to 
study its protection capacity for infectious disease. In this study, mice were immunized via the 
intradermal route with influenza hemagglutinin (HA) mRNA and showed effective 
seroconversion and presence of virus-neutralizing antibodies94. 
1.2.4 Delivery routes for mRNA vaccines 
Local delivery – intradermal and subcutaneous 
Since the skin serves as a first line of protection against invaders, macrophages, DCs, pDCs, 
Langerhans cells and T cells are present. For this reason, intradermal and subcutaneous delivery 
of mRNA has formed the focus of mRNA vaccine delivery for many years. The uptake 
mechanisms upon intradermal delivery of ‘free’ mRNA are still not fully understood. Probst and 
colleagues showed that uptake of i.d. injected mRNA in Ringer lactate was dependent on the 
presence of calcium in the injection solution73. They further showed that this dermal uptake of 
‘free’ mRNA was mediated by an active mechanism specific for nucleic acids. The question 
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remains if RNA in Ringer lactate can be considered as free mRNA, as the need for calcium 
suggests that some form of aggregation might occur, creating particulate structures which are 
known to enhance the uptake of mRNA. Besides the formulation of mRNA in Ringer lactate, also 
protamine-based and lipid-based delivery of mRNA has been described to lead to high antigen 
expression levels upon dermal injection82,85. The potential of intradermal delivery of mRNA-
based vaccines is supported by the successful outcome of many (pre)-clinical studies82,92,95. 
Targeted delivery – Intranodal  
Another rewarding route for mRNA vaccines includes direct intranodal injection. The strength of 
intranodal injection is based on the targeted delivery of mRNA to resident DCs in the draining 
lymph nodes. Indeed, a bio distribution study showed that a 100-fold increase of RNA reaching 
the lymph node occurred after intranodal delivery compared with injection near by the lymph 
node96. The mechanisms of uptake upon intranodal delivery is partially cleared out by the Diken 
and colleagues who reported that mRNA injected into the lymph node is directly taken up by the 
resident CD11c+ DCs in a macropinose-mediated way, resulting in the activation of the DC70. 
More specific, Van Lint and colleagues showed that intranodal injection of mRNA in Ringer 
lactate or Ca+ containing balanced salt solution showed far stronger and longer expression 
profiles compared to mRNA in phosphate buffered saline97. These data are in line with the ion-
dependent uptake of ‘free mRNA’ after intradermal injection, described by Probst73. The main 
drawback of intranodal delivery to mice, is the need for surgery to make a precise injection 
possible. During this step, it is hard to circumvent minor bleedings, which are ruinous for 
unprotected free mRNA due to their high susceptibility to nucleases in the serum. Furthermore, 
in view of applicability to treat patients, it is obvious that the easy practicability of intradermal 
injections are preferred over intranodal injections which require ultrasound-mediated 
visualization of the lymph nodes. However, new strategies are under investigation to target the 
mRNA to the draining lymph nodes after subcutaneous administration via ultrasound-guided 
microbubble-assisted drug delivery98. 
Systemic delivery – intravenous  
Recent reports demonstrated that systemic delivery of lipid-based mRNA particles resulted in 
strong and effective CTL responses77,78. Kranz and colleagues showed that the injection of 
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intravenously administered mRNA-DOTMA/DOPE lipoplexes induced strong effector and 
memory T-cell responses, and mediate potent IFNα-dependent rejection of progressive tumours 
in mice. The authors suggested that the intravenously delivered mRNA lipoplexes are targeted 
to APCs in the lymphoid compartments, solely by adjusting the negative charge of the particle77. 
Furthermore, Broos and colleagues showed that systemically delivered cationic mRNA lipoplexes 
(encoding three different tumor associated antigens) elicited strong antigen-specific T cell 
responses. Moreover, in line with the results of Kranz, they showed that the uptake and 
translation of the mRNA-encoded protein in the spleen and liver occurred predominantly by 
CD11c+ cells upon intravenous delivery78. 
1.2.5 Currently completed and ongoing clinical trials 
In contrast to the many clinical trials concerning the adoptive transfer of RNA-modified DCs (not 
discussed in this thesis)99–101, so far, only a few trials have been performed regarding the direct 
administration of mRNA vaccines92,102. The first clinical study concerning mRNA vaccination was 
based on the intradermal injection of total tumor mRNA extracts of melanoma patients103. 
Although enhanced humoral and cellular responses were demonstrated, no clinical regression 
was observed. In a follow-up study, a cocktail of protamine-complexed mRNA sequences 
encoding six different melanoma antigens (Melan-A, Tyrosinase, gp100, Mage-A1, MA-age-A3 
and survinin) was administered intradermally in 21 metastatic melanoma patients, followed by 
the injection of GM-CSF 24 hours after immuniztion93. In this study a decrease in myeloid 
suppressor cells was registered in peripheral blood of patients after the treatment. Further, an 
increase of antigen-specific T cells was detected in a subset of treated patients. Still, in general, 
the few number of patients and the individual differences made the clinical outcome uncertain. 
Nevertheless, one out of seven stage IV patients showed a complete clinical response93. At the 
same time, the lab of Brossart performed a phase I/II trial to assess feasibility, safety and 
immunological responses to mRNA-based vaccines in 30 patients with stage IV renal cell cancer. 
Also in this study GM-CSF was applied as an adjuvant and a mixture of 6 different tumor 
associated antigens (TAAs; MUC1, CEA, her-2/neu, telomerase, surviving and MAGE-A1) was 
injected intradermally104. No severe side effect of the vaccine was detected and in addition, the 
induction of CD4+ and CD8+ T cell responses for several TAAs increased in all patients. 
Furthermore, 7 out of 30 patients showed clinical response upon vaccination. In 2013 a clinical 
study started to test IVAC MUTANOME, a poly-epitopic RNA vaccine which targets patient-
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specific mutations105. In this study, all melanoma patients received an individual vaccine 
composition via direct intranodal injection. As this study is planned to end in December 2016, no 
data are available yet. Further, Curevac® has started a study to test the intradermal delivery of 
the protamine-two-component mRNActive® vaccine in non-small cell lung cancer (NSCLC) 
patients106. In this study patients were injected 5 times in a 15 week interval with self-
adjuvanted mRNA molecules encoding five NSCLC-associated tumor antigens. In 65 % of the 
patients, antigen-specific immune responses against at least one antigen were detected (39 % 
cellular and 49 % humoral). Still, in general, the clinical studies concerning direct mRNA 
vaccination to treat cancer patients, have been showing clearly mixed achievements. In general, 
suboptimal antitumor immune responses have been elicited, a disappointing observation in 
view of the promising pre-clinical data. One of the major reasons for the limited clinical success 
of cancer vaccination is the influence of the immunosuppressive tumor microenvironment. In 
view of this limitation, more recent studies have been focussing on the administration of 
immunosuppressive blocking antibodies in combination with cancer vaccines. For example, 
ipilumumab, an FDA-approved therapy based on the anti-cytotoxic T lymphocy-associated 
antigen (CTLA)-4 inhibitory antibody, showed clinical response in treated cancer patients107. 
CTLA-4 is homologue to B7 molecules and also binds to CD28, like B7. However, CTLA-4 is a 
negative regulator for T cell proliferation and is naturally upregulated upon T cell activation to 
create a negative feedback-loop. As a future perspective, the co-administration of anti-CTLA-4 
(and anti-PD-1) antibodies with mRNA vaccines might lead to highly efficient vaccine formats 
with great clinical responses108–110.  
Besides the use of RNA-based therapeutic vaccines for the treatment of cancer, in the field of 
prophylactic vaccines for preventing infectious diseases, Curevac® is currently testing the 
RNActive® approach for prophylactic vaccination in a first clinical phase111. Preclinical data 
revealed that immunization of mice and pigs with non-replicating rabies virus glycoprotein 
(RABV-G) encoding messenger RNA (mRNA)  resulted in both specific CD4+ T cell as well as CD8+ 
T cell responses112.  
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2. NUCLEIC ACIDS AS ADJUVANTS 
2.1 THE IMMUNOGENICITY OF DNA VACCINES 
In contrast to studies in small mammalian animals, which proved that DNA vaccination induced 
strong humoral and cellular immune responses, studies in patients showed much weaker 
immunogenicity113,114. In order to enhance the immunogenicity of DNA vaccines, two different 
strategies have been worked out. First, as described before, multiple carriers and delivery 
methods have been optimized in order to promote and skew the induction of immune 
responses to DNA vaccination. Second, currently almost all DNA vaccines are co-formulated with 
an adjuvant. Importantly, the currently benchmark-followed strategy includes the combination 
of a carrier and an adjuvant in order to gain efficacy. In this section we give an overview of the 
intrinsic adjuvant features of pDNA and the different strategies to enhance the immunogenicity 
of DNA vaccines. 
2.1.1 Intrinsic Adjuvant Characteristics 
Cytosine-phosphate-guanosine (CpG) motifs in pDNA vectors are the main contributors to the 
immunogenicity of DNA vaccines7,9. It is clearly proven that intrinsic CpG motifs acts as an 
adjuvant by triggering TLR9 in the endosomes of pDCs and B cells115–118 and signals via the 
downstream myeloid differentiation factor-88 (MyD88) pathway, resulting in the expression of 
pro-inflammatory cytokines, such as IL-6, IL-12 and TNF-α, regulated by the transcription factor 
IFN regulator factor 7 (IRF7; Figure 3).  
Since it was demonstrated that TLR9 knock-out mice still responded to DNA vaccination119, 
Babiuk and colleagues suggested that the TLR9 function was redundant and can be taken over 
by cytosolic sensors120. Indeed, DNA motifs in the cytosol can be recognized by multiple 
receptors, including DNA-dependent activator of IFN-regulatory factors (DAI), the cytosolic 
GAMP synthase (cGAS), PHYN IFN-inducible protein 16 (IFI16) and DDX417,8,24,121–127. Two 
signalling pathways are involved, one resulting in the induction of type I IFNs and the other 
leading to induction of NF-κB. The first involves DAI-mediated phosphorylation of TBK1 via the 
stimulator of interferon genes (STING) and subsequent activation of the transcription factor 
IRF3. IRF3 will migrate to nucleus to start transcription of type I IFNs128. The second pathway 
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requires phosphorylation of the receptor interacting protein-1 kinase (RIPK1), leading to 
phosphorylation of IκB-α and subsequent activation of the transcription factor NF-κB, which 
regulates the expression of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), IL-6 
and IL-12 (Figure 3). Further, in vitro studies in a human pDC line revealed an important role for 
aspartate-gutamate- any amino acid-aspartate/histidine (DExD)-box helicase 9 (DHX9) and 
DHX36 receptors as cytoplasmic sensors of CpG. Both DHX36 and DHX9 directly interact with the 
receptor domain of MyD88. They are both associated with IRF7 nuclear translocation and IFNα 
production, whereas DHX9 appeared to be crucial for TNFα and IL-6 production via NF-κB 
activation129. 
At last, binding of dsDNA to absent in melanoma (AIM2) leads to the formation of an 
inflammasome complex together with ASC to activate caspase-1 and NF-κB130 (Figure 3). 
Although AIM2 is known for their role in the ASC-dependent inflammasome-mediated catalytic 
cleavage of pro-forms of IL-1β and IL-18, it was recently suggested that AIM2 is also indirectly 
involved in type I IFN production in response to DNA vaccination131. 
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Figure 3. Innate sensing of DNA sequences. dsRNA, double stranded RDA; TLR, Toll-like receptor; TBK1, 
TRAF family-associated NF-kB activator (TANK)-binding kinase-1. TRIF, TIR domain-containing adaptor 
inducing IFN-β; MyD88, myeloid differentiation factor-88; IRF, interferon regulatory factor; DDX, 
DExD/H helicase box; IFI16, PHYN IFN-inducible protein 16; STING, stimulator of interferon genes; 
DAI, activator of IFN-regulatory factors; cGAS, cytosolic GAMP synthase; AIM2, absent in melanoma. 
Figure based on
118
. 
2.1.2 Improving the immunogenicity of DNA vaccines 
Since the immunogenicity of DNA vaccines appeared to be suboptimal, multiple studies have 
been performed regarding the use of conventional adjuvants to enforce the immunogenicity. 
The use of physical delivery systems - such as in vivo electroporation5,24, nanoparticle 
formulation30,47 or a combination of those strategies24,25,30 - to stimulate immunity has showed 
mixed successes depended on the experimental set up and conditions. An overview of these 
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studies is provided by Saade and colleagues14. The most important strategy to enhance DNA 
vaccine immunity is the co-delivery of molecular adjuvants, such as CpG, cytokines, chemokines, 
co-stimulatory molecules and heat-shock proteins20. In this section we describe how the co-
delivery of immune stimulatory cytokines, IL-2 and GM-CSF can enhance the immunogenicity of 
pDNA vaccines.  
The co-delivery of immune stimulatory cytokines  
If cytokine induction remains rather low upon vaccination, one possibility is to co-deliver them 
with the antigen, both encoded by the same pDNA vector125. This approach has multiple 
advantages, such as the non-complex vaccine composition as a simple insertion of an extra gene 
in the DNA vector is sufficient. Moreover, as both the antigen as well as the adjuvant is encoded 
by the same vector, they will be both targeted to the same cell. Furthermore, the production 
and purification of cytokines is expensive, so the in vivo expression of cytokines is also cost-
effective. A large number of studies have been focussing on the incorporation of Th1-inducing 
cytokines such as IFNɣ, GM-CSF, IL-2, IL-12 and TNF-α to stimulate immunity of pDNA-based 
cytotoxic T-lymphocyte-inducing vaccines125. 
IL-2.    The co-delivery of DNA plasmids encoding the pro-inflammatory cytokine IL-2 has been 
proven to be very potent in multiple pre-clinical studies132,133. IL-2 enhances Th1 responses by 
stimulating T cell IFNɣ-production. Interestingly, to increase the half-life time of IL-2 from 
approximately ten minutes to two days, IL-2 has been fused to an immunoglobulin Fc-segment. 
This prolonged half-life of IL-2 resulted in significantly increased memory T cell responses132,134. 
A pDNA-based vaccine encoding the HIV-related Gag–Pol–Nef antigens and IL-2/Ig conjugates 
has been successfully evaluated in a clinical trial135. Importantly, the timing of IL-2-encoding 
plasmid injection relative to the antigen, is a crucial mediator for the different types of evoked 
immunity. It has been shown that the delivery of IL-2/Ig resulted in decreased humoral and CTL 
responses when injected prior to, or simultaneously with the DNA vaccine. However, these 
results are in sharp contrast to the increased responses observed when IL-2/Ig was injected five 
days after DNA antigen vaccination125,134. 
GM-CSF.  GM-CSF is a pro-inflammatory cytokine, crucial for DC development and maturation136. 
Furthermore, GM-CSF is also directly linked to anti-tumoral activities. These activities of GM-CSF 
were shown to be based on increased DC density in the draining lymph node, and increased 
71 | Introduction
frequency of antigen-specific T cells secreting IFN-ɣ. In addition, GM-CSF has the capacity to 
increase antigen-induced immune response and to alter the Th1/Th2 cytokine balance136. The 
co-delivery of GM-CSF has been shown to promote priming of potent antigen-specific CD4+ T 
cell responses followed by increased migration. Santana and colleagues showed that pGM-CSF 
co-immunization improved both the magnitude and IFNɣ-production of the CD4+ T cell response 
to HIV-vaccination137. Of note, also the capacity of GM-CSF to stimulate immunity is dependent 
on the relative timing of injection. Likewise IL-2, the administration time of GM-CSF-encoding 
plasmid relative to the time of antigen administration affects the type of the elicited immune 
responses125. Kusakabe and colleagues showed that injection of GM-CSF encoded by pDNA three 
days prior to DNA vaccination induced mainly Th2 immune responses and increased IgG levels, 
whereas the injection of GM-CSF three days after DNA vaccine administration, enhanced Th1 
immunity138. Importantly, these findings seem to differ dependent on the setting as Barouch and 
colleagues showed rather reduced humoral responses when injecting GM-CSF-encoding DNA 
five days before the DNA vaccine134.  
2.2 THE IMMUNOGENICITY OF MRNA VACCINES  
Likewise pDNA vaccination, the immunogenicity of RNA vaccines is established on one hand by 
the intrinsic adjuvant character of the RNA molecule and on the other hand by the applied 
delivery method. In this chapter we will describe how both features affect the immune 
stimulatory character of mRNA vaccines and how the immunogenicity can be further enhanced 
by the co-delivery of co-stimulatory molecules. 
2.2.1 Intrinsic adjuvant characteristics 
The innate immune activating capacity of RNA is based on their interaction with intracellular 
PRRs, resulting in the expression of pro-inflammatory cytokines or inflammasome activation 
(Figure 4). The first identified and best characterized group of PRRs are the membrane-bound 
TLRs139. In the endosomal compartments, TLR3 and TLR7/ TLR8 respond to double-stranded and 
single-stranded RNA, respectively. TLR3 signals via the TIR domain-containing adaptor inducing 
IFN-β (TRIF) pathway. The TRIF pathway signals mainly through tumor necrosis factor (TNF) 
receptor-associated factor 3 (TRAF3) and TRAF6. TRAF activation leads to the formation of a 
complex composed of IKKε and TRAF family-associated NF-kB activator (TANK)-binding kinase-1 
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(TBK1), to activate the interferon regulatory factor 3 (IRF3) and IRF7 transcription factors (Figure 
4). Sensing of RNA by the TLR7 receptor activates NF-κB downstream the myeloid differentiation 
primary response-88 (MyD88) pathway. In pDCs, MyD88 signalling upon the activation of TLR7 
and TLR8 leads to the IRF7 dependent expression of type I IFNs118,140. It has been shown for both 
protamine- and lipoplex-based vaccines to support immune stimulation via TLR7-dependent 
type I IFN induction77,78. Further, Wagner and colleagues showed that simultaneous activation of 
both TLR3 an TLR7 signalling cascades synergized with respect to DC activation and induce 
superior cytotoxic T cell responses in vivo141.  
Less research is reported about the activation of cytosolic receptors upon IVT mRNA vaccination. 
To our knowledge, only nucleic binding oligomerization domain-like (NOD)-like receptors (NLRs) 
have been described to sense IVT mRNA, namely the NLRP3 and NOD2142–144. They interact both 
with cytosolic dsRNA and signal through the adaptor molecule ASC to form a complex with 
caspase-1145. The activation of caspase-1 mediates catalytic cleavage of proIL-β and proIL-18 in 
order to create the functional pro-inflammatory IL-β and IL-18 (Figure 4). Caspase-1-mediated 
pyroptosis can potentially increase the vaccination efficacy as cell lysis results in the release of 
the produced antigens in the extracellular space. Furthermore, cross-presentation will occur 
upon uptake of the apoptotic antigen-containing cells by freshly recruited APCs. 
It is highly assumable that IVT mRNA might be detected by cytosolic RNA-specific aspartate-
glutamate-any amino acid-aspartate/histidine (DExD/H)-box helicases, such as retinoic acid-
inducible gene- I (RIG-I) and melanoma differentiation–associated protein 5 (MDA5) 
receptors146–148 (Figure 4). Although the binding criteria for RIG-I are not fully clear yet, it 
appears to recognise an uncapped triphosphate group at the 5’ end149. As IVT mRNA solutions 
consist of partially uncapped RNA molecules, IVT mRNA might be a possible target of RIG-I. The 
cytosolic RNA sensors RIG-I and MDA5 rely on the adaptor mitochondrial antiviral signalling 
protein (MAVS; or IPS1) for the activation of the IRF3, IRF7 and NF-κB transcription factors in 
order to express pro-inflammatory cytokines. Downstream MyD88, TRIF and the cytosolic 
signalling pathways, the phosphorylated and activated IRF3 and IRF7 transcription factors 
translocate to the nucleus to regulate the expression of type I IFN genes. NF-κB binds to the 
promoter region of other pro-inflammatory cytokines, like IL-6, IL-12 and TNFα79,150 . These 
inflammatory cytokines are forming the basis of the immunogenicity of RNA vaccines, as they 
are crucial for DC activation, T cell proliferation and differentiation. To be precise, besides RIG-I 
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and MDA5, other (DExD/H)-box helicases DDX1, DDX21 and DHX36 were reported to be 
triggered by polyI:C (Figure 4)151.  
 
 
Figure 4. Innate sensing of RNA sequences via different pattern recognition receptors. RNA-specific 
PRRs include TLR3 and TLR7/8 in the endosome and RIG-I and MDA5 in the cytosol. Activation leads 
downstream phosphorylation and activation of transcription factors IRF3, IRF7 and NFκB which bind 
to the promoter region of type I IFN and other pro-inflammatory genes. Activation of the NOD-like 
receptors lead to the maturation of pro-Ilβ and pro-IL-18. ssRNA, single stranded RNA; dsRNA, dubble 
stranded RNA; TLR, Toll-like receptor; NOD2, nucleic-binding oligomerization domain-like receptor 2; 
RIG-I, retinoic acid-inducible gene- I; MDA5, melanoma differentiation – associated protein 5, MAVS, 
mitochondrial antiviral signalling protein; TBK1, TRAF family-associated NF-kB activator (TANK)-
binding kinase-1. TRIF, TIR domain-containing adaptor inducing IFN-β; MyD88, myeloid differentiation 
factor-88; IRF, interferon regulatory factor; NLRP3, Nacht, LRR, PYD domain containing protein. Figure 
based on
150
. 
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2.2.2 Improving the immunogenicity of mRNA vaccines 
As mentioned above, mRNA sequences feature an intrinsic adjuvant character as they do 
activate PPRs in the endosomal and cytosolic compartments. Nevertheless, injecting 
uncomplexed mRNA seems to be insufficient to efficiently activate and mature DCs92. 
Nanoparticle-mediated delivery affects the immunogenicity of mRNA vaccines due to their 
ability to target the mRNA cargo to the endosomes where it can bind efficiently to TLRs. Indeed, 
Scheel and colleagues claimed that a mixture of partially protamine-complexed RNA is most 
optimal for immunization as free mRNA is responsible for the expression of the antigen and 
complexed RNA is needed for innate activation via triggering of endosomal TLRs84. Furthermore, 
the nanoparticle material itself may also cause immunity. This observation has been made by 
Chen and colleagues, who reported the upregulation of CD80 and CD86 co-stimulatory 
molecules upon DOTAP treatment of DCs in absence of nucleic acids or CpG motifs155. The 
researchers claimed that the cationic lipid DOTAP alone serves as an efficient vaccine, based on 
the activation of mitogen-activated protein kinase/extracellular signal regulated kinase 
(MAPK/ERK), chemokine induction and reactive oxygen species (ROS)155. However, we showed 
that the injection of DOTAP liposomes in the absence of nucleic acids induces no pro-
inflammatory cytokines75,76.  
To improve the immunogenicity of mRNA vaccines, the complexation of mRNA into 
nanoparticles is often combined with the co-delivery of additional adjuvants, such as cytokines 
and co-stimulatory molecules. In the most elegant way, these adjuvant molecules are encoded 
by mRNA rather than being added as a protein. A first study about the co-delivery of mRNA 
encoded adjuvants showed stimulatory effects of GM-CSF, IL-2 and CD80 on evoked CD8+ T cell 
responses. Nevertheless, despite the enhanced CTL responses, the formulation appeared to be 
insufficient to overcome tolerance in a tumor model74.  
The TriMix adjuvant consists mRNA encoding three adjuvant components; namely CD40 ligand, 
CD70 and constitutive active (ca)TLR497. The potential of TriMix vaccines can be explained by the 
individual role of the co-stimulatory molecules in the activation of innate immunity. First, the 
CD40 receptor is expressed on DCs and interacts with the CD40 ligand on CD4+ T cell surfaces. 
Simulating DCs with soluble CD40 ligand, induces co-stimulatory molecules and cytokines156. 
Signalling via CD40-CD40 ligand results in Th1 activation of CD4+ T cells, which enforce the 
generation of primary CD8+ T cell responses. Furthermore, it has been proved for peptide and 
75 | Introduction
protein-based vaccines that the co-delivery of CD40 ligand-stimulating antibodies results in 
enhanced tumor protection due to improved CD4+ and CD8+ T cell responses157,158. Next, the co-
stimulatory molecule CD70 is located on B cells, T cells and APCs and interacts with CD27, which 
is expressed on activated B cells and a subset of memory T cells97,159. Mice studies revealed an 
important role for CD70-CD27 signalling in the expansion of CD8+ T cells and formation of 
effector and memory immunity159,160. At last, LPS-triggered TLR4 signalling has been proven to 
mature DCs and enhance specific T cell responses by blocking regulatory T cell activity161. 
Unfortunately, due to its high toxic character, LPS-based adjuvants are not suitable for clinical 
use. For this reason, the expression of a constitutive active TLR4 receptor instead of the 
administration of LPS constitues a safer alternative162.  
Earlier, TriMix has been evaluated as in a clinical trial via in vitro electroporation of DCs 
(TriMixDC-MEL), followed by intradermal99 and later mixed intradermal and intravenous transfer 
to melanoma patients163. In here, DCs were ex vivo electroporated with mRNA encoding multiple 
tumor associated antigens (MAGE-A3, MAGE-C2, tyrosinase and gp100) and TriMix adjuvant. 
The latter study revealed objective tumor responses in 4 out of 15 patients (27%). Two of these 
patients showed complete responses and two patients showed partial responses. These four 
tumor responders, and one patient with a disease stabilization, were progression free at least 28 
months after the treatment163,164. Skin infiltrating T lymphocytes were observed in 6 out of 12 
patients, whereas tumor-specific CD8+ T cells were detected in the blood of 4 out of 5 studied 
patients. Although these clinical validation proved that TriMixDC-MEL is safe and results in 
clinical responses, the development of a patient-specific vaccine is expensive and therefore 
direct administration of mRNA offers a big advantage. In a more recent study, TriMix was 
evaluated upon direct intranodal immunization. 
However, the development of a patient-specific vaccine is expensive and therefore direct 
administration of mRNA offers a big advantage. In a more recent study, TriMix was evaluated 
upon direct intranodal immunization. In here they showed that the uptake and translation of 
antigens was inhibited by the co-delivery of classical maturation stimuli, like MPL, LPS and 
PolyI:C, whereas TriMix did not inhibited uptake and translation97. This success is associated with 
the relative timing of antigen uptake and adjuvant activity. It is generally accepted that the 
maturation of DCs abrogates uptake and translation of exogenous mRNA. In here, the adjuvant 
needs to be translated to become functional, thus after antigen uptake and translation, causing 
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a delay of DC activation, allowing the antigen-encoding mRNA to be efficiently engulfed and 
translated. 
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Abstract: Nucleic acid-based vaccines show superior potency to induce cytolytic T cell 
responses to destroy malignant or infected cells. The intrinsic adjuvant character of nucleic acid-
based vaccines appears to be based on their capacity to evoke type I IFNs. However, recently 
opposing results have been reported about the role of type I interferons in regulating T cell 
immunity to nucleic acid-based vaccines. In this review, we will attempt to reconcile recent 
discrepant observations regarding the role of type I IFNs in steering T cell immunity to mRNA 
vaccination. Moreover, we will discuss the growing body of evidence indicating that the impact 
of type I IFN induction on T cell immunity is determined by its kinetics of induction and its 
anatomical distribution.   
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1. INTRODUCTION 
Over the past decade, interest in using nucleic acids as a mean to encode antigenic information 
or as adjuvant for protein vaccines has exponentially boomed. Vaccines that use nucleic acids to 
encode antigenic information display a far superior potential to elicit cytolytic T cell responses 
compared to protein-based vaccines and are thus intensively explored to combat cancer1,2. 
Whereas historically the nucleic acid vaccination field has been dominated by pDNA, mRNA 
vaccines have now clearly taken the lead with numerous clinical trials ongoing3–6. The paradigm 
shift from pDNA to mRNA as means to deliver antigenic information has been driven mainly by 
the superior safety profile of mRNA alongside technical breakthroughs that have improved the 
in vivo stability of IVT mRNAs7,8. Non-coding nucleic acids and their synthetic analogues in turn 
have been explored as adjuvants for protein vaccines and as immunotherapeutics for cancer 
due to their capacity to skew CD4+ T cell responses towards a Th1 oriented phenotype9–11. 
Overall, the efficacy of any vaccine to instigate T cell immunity is determined by the early 
interplay between vaccine and innate immune cells and the nature of the inflammatory 
environment hereby created. In terms of the inflammatory environment they produce, all 
nucleic acid containing vaccines have a common theme: the generation of a potent type I IFN 
response11–14. Type I IFNs are highly pleiotropic cytokines that on top of their well-known direct 
antiviral effects also profoundly impact T cell responses. The consequences of type I IFNs on T 
cell responses are highly diverse and can be both stimulatory and inhibitory. Much akin to the 
role of type I IFNs in the context of infectious disease, the effects of type I IFNs on the T cell 
response elicited by nucleic acid-based vaccines are complex and context dependent. In this 
review, we will elaborate on the functional relevance of type I IFN induction on the vaccine 
elicited T cell response. Important discrepancies between pDNA and mRNA-based vaccines will 
be highlighted. In addition, we will attempt to reconcile recent conflicting observations 
regarding the role of type I IFNs in steering T cell immunity to mRNA vaccination. Finally, we will 
discuss the growing body of evidence indicating that the impact of type I IFN induction on T cell 
immunity is determined by its kinetics of induction and its anatomical distribution.  
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2. THE OMNIPOTENT TYPE I IFNS: LESSONS LEARNT FROM CANCER AND 
INFECTIOUS DISEASE 
The type I IFN family is composed of multiple IFNα variants, IFNβ and the poorly characterized 
IFNε, IFNτ, IFNκ, IFNω, IFNδ and IFNζ. Type I IFN production is triggered upon sensing of 
microbial nucleic acids by various pattern recognition PRRs located in endosomal membranes 
and the cytosol. All type I IFNs signal through the heterodimeric IFNα receptor (IFNAR) 
composed of IFNAR1 and IFNAR2, except for IFNβ, which binds to IFNAR1 homodimers15. IFNα/β 
binding to their transmembrane receptor leads to the activation of the janus kinase (JAK) – 
signal transducers and activators of transcription (STAT) pathway16–18, which induces the 
transcription of interferon stimulated genes (ISGs) (Box 1)16,19.  
Although type I IFNs originally were described as host components interfering with viral 
replication20, it became evident that type I IFNs also regulate anti-viral T cell responses through 
modulation of DC function or through direct signalling in T cells, thus modulating T cell 
expansion, differentiation and survival. Over the past years, type I IFNs have been identified as 
critical host factors that instigate anti-tumor T cell immunity.   
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BOX 1: IFNAR signalling; creating broad variety of outcomes 
The canonical type I IFN signalling pathway is the JAK-STAT pathway, named after the involved 
Janus kinases (JAKs), which phosphorylate signal transducers and activators of transcription 
(STATs). The type I IFNs receptor IFNAR is composed of a low affinity IFNAR1 and a high affinity 
IFNAR2. The IFNAR1 subunit receptor interacts with tyrosinase kinase (Tyk2), whereas the 
IFNAR2 subunit interacts with JAK1. The activation of JAK kinase results in the recruitment, the 
phosphorylation and dimerization of STAT proteins, controlling different gene-expression 
programmes. The first STAT dimer is composed of STAT1 and STAT2, which binds with IRF9 to 
form the interferon-stimulated gene factor 3 (ISGF3) complex. This complex will translocate to 
the nucleus and bind to the IFNs-stimulated response elements (ISREs) to initiate transcription 
of interferon-stimulated genes (ISGs). Furthermore, also STAT1-STAT2 homodimers are formed 
in response of IFNα. They bind to gamma-activated sequences (GASs) for the transcription of 
pro-inflammatory genes. In total, six different STAT proteins have been described, which means 
a great variety of homo- and hetero-dimer STAT complexes can be formed in response to type I 
IFNs21–25. This combination of different STAT complexes in turn will determine the transcriptional 
and functional consequences of type I IFNs. Moreover, it is becoming increasingly evident that 
activation of the JAK-STAT pathway is not sufficient for the transcription of all type IFNs 
inducible genes. In fact, many ‘alternative’ pathways are activated by IFNAR signalling. Some of 
these pathways interact with the different STATs, but others function fully independent of STAT 
proteins26.  
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2.1 TYPE I IFNS REGULATE DENDRITIC CELL FUNCTION 
DCs are the most potent antigen presenting cells and have a unique potential to activate naïve T 
cells. Type I IFNs influence multiple aspects of DC function including antigen presentation, co-
stimulation, cytokine secretion and DC turnover. Treatment of in vitro differentiated DCs with 
type I IFNs upregulates co-stimulatory ligands and promotes antigen presentation (Figure 5)27–31. 
The strongest evidence that type I IFNs act through DCs to promote T cell immunity derives from 
the cancer immunology field. DNA released from dying tumor cells has been shown to result in 
the release of IFNβ from tumor cells and DCs in a stimulator of IFN genes (STING) dependent 
fashion32,33. In 2011, the Schreider and Gajewski labs independently demonstrated that 
spontaneous T cell responses against tumors strictly rely on IFNAR triggering in the CD8α+ DC 
subset34,35. Ever since, the vital role of type I IFNs in mediating anti-tumor T cell responses has 
been extended to various cancer treatment modalities, including radiotherapy, chemotherapy 
and intra-tumoral injections with nucleic acids36,37. Type I IFNs have also the ability to regulate 
DC turnover. Strong type I IFN responses elicited upon systemic viral infection or upon injection 
with TLR agonists inflict apoptosis in plasmacytoid DCs (pDCs)38 and CD8α+ DCs39. Such transient 
DC loss might be a mean to avoid excessive immune activation by dampening T cell immunity. 
Conversely, antigen-containing apoptotic DCs may be efficiently cross-presented by newly 
recruited DCs and thereby elicit T cell immunity. With the consequences of DC apoptosis still 
being a matter of debate, clear-cut cases have been described where the actions of type I IFNs 
on DCs are malicious to T cell immunity. Bacterial sepsis has been shown to cause a profound 
type I IFN release that blocks antigen presentation by DCs and thereby weakens T cell 
responses40. Also, infection with Plasmodium parasites curtails DC function and the priming of 
Th1 immune responses. T cell immunity in this setting was restored in mice lacking IFNAR on 
DCs. Chronic infection with LCMV causing a sustained expression of type I IFNs similarly imposes 
an immune suppressive phenotype in DCs, a feature that could be reversed by treatment with 
IFNAR blocking antibodies restored DC function and improved T cell immunity 41.   
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Figure 5. Type I IFNs regulate DC function. IFNα/β binding on IFNAR receptor promotes antigen 
presentation by the upregulation of major histocompatibility molecules-I and –II (1) and the 
expression of co-stimulatory ligands (2). Further, they will also stimulate the expression of pro-
inflammatory cytokines, including type I IFNs (3). Strong type I IFN responses inflict apoptosis by 
enhancing the expression of pro-apoptotic genes (4). Ag, antigen; DC, dendritic cell; IFN, interferons; 
IFNAR, IFNα/β receptor; MHC major histocompatibility complex; TCR, T cell receptor 
2.2 TYPE I IFNS REGULATE T CELL FUNCTION: A MATTER OF TIMING? 
The complex consequences of type I IFN signalling in CD8+ T cells in response to viral infection 
have been extensively reviewed by Crouse42. In brief, type I IFNs can exert either stimulatory or 
inhibitory actions on antigen experienced T cells dependent on the timing of IFNAR signalling 
relative to TCR signalling. If TCR signalling shortly precedes or co-incides with IFNAR signalling, 
type I IFNs function as true signal 3 cytokines promoting the expansion and subsequent 
differentiation of antigen primed CD8+ T cells into cytolytic effector cells43–45. Proof that type I 
IFNs also suport memory T cell formation is less strong. In LCMV infected mice, type I IFNs 
promote the expansion of antiviral CD8+ T cells by increasing their survival, which might enlarge 
the final memory T cell pool generated. Nonetheless, high levels of type I IFNs might drive 
antigen primed T cell into terminally differentiated effector cells rather than into long-lived 
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memory T cells46. In case IFNAR signalling precedes TCR signalling, the inhibitory properties of 
type IFNs on T cell immunity seem to prevail21,23,47. Out of sequence exposure of T cells to type I 
IFNs imposes an anti-proliferative status21,23,47 and activates a pro-apoptotic program48–50. On a 
molecular level, this differential outcome can be traced back to a distinct profile of STATs that 
get activated (Figure 6). Upon TCR stimulation, CD8+ T cells upregulate STAT4 whilst maintaining 
low levels of STAT1. Subsequent IFNAR triggering mainly activates STAT4, resulting in a 
proliferative and anti-apoptotic program. If IFNAR signalling precedes TCR stimulation, signalling 
through STAT1 dominates, instigating a pro-inflammatory yet anti-proliferative and pro-
apoptotic program23,25,51,52. 
 
 
 
Figure 6. Type I IFNs regulate T cell function. In case T cell receptor signalling precedes with type I IFN 
signalling, type I IFNs may function as signal 3 cytokines, promoting expansion and subsequent 
differentiation of CD8
+
 T by expression a specific cluster of genes, regulated by STAT4 activation (left). 
Signalling of type I IFNs prior to T cell receptor activation imposes an anti-proliferative status and 
activates a pro-apoptotic program, characterized by STAT1 activation (right); TCR, T cell receptor; 
IFNAR, IFNα/β receptor; STAT, signal transductors and activators of transcription. Figure based on
28
. 
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3. TYPE I IFNS AND THE REGULATION T CELL IMMUNITY TO ANTIGEN 
ENCODING NUCLEIC ACID VACCINES 
3.1 TYPE I IFNS AND PDNA VACCINES: A SETTLED CASE? 
Administration of pDNA vaccines is characterized by high levels of type I IFNs53–55.  In a 
pioneering study, Tudor et al. demonstrated that ifnar-/- mice respond to DNA vaccination with 
lower IgG2a/IgG1 antibody ratios and weaker CD8+ T cell responses55. These findings were 
confirmed by other reports showing that DNA vaccinated ifnar-/- mice fail to generate cytolytic T 
cell responses55–57. Although the beneficial role of type I IFNs in pDNA immunogenicity is 
uncontested, the underlying PRRs and signaling pathways are still a matter of debate. Over 20 
years ago, TLR9 was the first PRR described to recognize pDNA vaccines58. Triggering of TLR9 by 
unmethylated CpG motifs in the pDNA vector induces a MyD88 dependent signaling cascade 
that culminates in the release of inflammatory cytokines including type I IFNs59–61. Nonetheless, 
pDNA vaccinated Tlr9-/-and MyD88-/- mice mount adaptive immune responses comparable to 
wild type mice pDNA vaccination, arguing against a major contribution of TLR962. Instead, pDNA 
immunogenicity appears to largely rely on DNA sensing by cytosolic DNA sensors that activate 
type I IFN responses via the stimulator of IFN genes (STING) and the non-canonical IkB kinase, 
TANK binding kinase-1 (TBK1)63,64. The exact nature of the initial cytosolic sensor mediating DNA 
recognition remains ill defined. Multiple proteins have been described as cytosolic DNA sensors 
that activate STING, including DAI65, cGAS66 and Ifi1653, but none of these sensors has been 
conclusively linked to pDNA immunogenicity. Also inflammasomes have been implicated in 
steering pDNA immunogenicity through modulation of cell death. Mice lacking AIM2 
inflammasomes display decreased numbers of IFNγ secreting T cells upon pDNA vaccination 
against Influenza HA67,68. This effect was shown to be independent of the caspase1 targets IL-1β 
and IL-18. Moreover, Aim2-/- mice showed decreased levels of IFNα/β at the immunization site67. 
Although suggestive, the authors did not address whether this deficit in type I IFN production is 
at the basis of the decreased adaptive immune response. The failure to narrow pDNA 
immunogenicity down to a single cytosolic DNA sensor best agrees with a mechanism in which 
multiple cytosolic DNA sensors coexist that all can recognize the vaccine pDNA and induce type I 
IFNs63. In such a setting, knocking down a single DNA sensor will not strongly affect pDNA 
immunogenicity, as other DNA sensors will compensate for its function.  
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3.2 REGULATION OF T CELL IMMUNITY TO MRNA VACCINES: TYPE I IFNS SHOW 
THEIR JANUS FACE 
Like pDNA vaccines, mRNA vaccines elicit profound type I IFN responses12–14. Unlike the 
unisonous reports on the beneficial impact of type I IFNs on pDNA vaccines, the role of type I 
IFNs in regulating T cell immunity to mRNA vaccines is however ambivalent. Earlier, type I IFNs 
were shown to negatively interfere with the induction of IFNγ-secreting T cells upon 
subcutaneous immunization with Gag-encoding mRNA lipoplexes69. More recently, these 
observations were extended to intradermal and intranodal vaccination with mRNA lipoplexes14. 
Immunization studies in Ifnar-/- mice revealed an increased initial priming of vaccine-specific 
CD8+ T cells in the absence of IFNAR signalling. Furthermore, vaccine-primed Ifnar-/- T cells 
acquired full cytolytic effector function. Interference with type I IFN signalling through co-
administration of an IFNAR blocking antibody further confirmed the finding made with Ifnar-/- 
mice, thus resulting in amplified cytolytic T cell responses and an increased vaccine-elicited 
melanoma control14. These findings are in sharp contrast with two recent studies which have 
demonstrated that type I IFNs actually promote T cell immunity to systemic immunization with 
mRNA lipoplex vaccines. Kranz et al. observed a profound secretion of type I IFNs by splenic 
pDCs and macrophages upon intravenous injection of mRNA lipoplex vaccines 12. Preventing 
IFNAR signalling by the administration of an IFNAR blocking antibody, did not affect the 
magnitude of the vaccine antigen-specific CD8+ T cell response. Yet, CD8+ T cells primed under 
IFNAR deficient conditions failed to acquire effector function indicating type I IFNs act as true 
signal 3 cytokines in this setting. In line with these findings, Broos and colleagues independently 
identified the vaccine mRNA elicited type I IFNs as necessary for instigating cytolytic T cell 
responses upon intravenous immunization with mRNA lipoplexes13.   
Reconciling these discrepancies - type I IFNs counteracting versus supporting cytolytic T cell 
responses to the vaccine mRNA-encoded antigen – is a challenging task (Figure 7). Whereas 
differences in the exact composition of the mRNA lipoplexes applied may be involved, the main 
discriminating factor between the aforementioned studies clearly is the route of vaccine 
administration: local versus systemic. Without doubt, the different routes of vaccination affect 
the type of cells that encounter the vaccine, express the encoded antigen and secrete type I 
IFNs. Upon intradermal mRNA injection, mRNA gets ingested by non-leukocytes and by DCs70. 
Upon intravenous injection, DCs are the dominant cell type  internalizing and expressing the 
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mRNA12,13. The route of lipoplex administration also alters the sequence of antigen expression 
and type I IFN secretion. Broos et al. showed peak antigen expression levels in splenic DCs 
already at one hour post intravenous injection, meaning antigen presentation and TCR 
stimulation can occur very rapidly13. IFNα titres in serum became detectable at two hours and 
peaked at six hours. Similar kinetics of IFNα induction were reported in the parallel study by the 
Sahin lab12. After intradermal administration of mRNA lipoplexes, we found that type I IFNs peak 
with similar kinetics but antigen expression now takes longer to unfold. In addition, upon 
intradermal injection, skin DCs that take up the mRNA lipoplexes need to migrate to the draining 
lymph node in order to present the antigen70. The bulk of antigen presentation is thus likely 
occured after T cell exposure to type I IFNs. Addressing the functional relevance of these 
differential kinetics will require experimental effort, but one may speculate that intravenous 
injection causes concomitant T cell stimulatory TCR and IFNAR signalling whereas intradermal 
injection rather results in a T cell inhibitory out-of-sequence signalling. 
In contrast to pDNA vaccines, TLR recognition appears to be indispensable for the efficacy of 
mRNA vaccines. Similar to viral ssRNA, IVT mRNA complexed to protamine or to cationic 
liposomes activates TLR7/812,71,72. Tlr7-/- mice showed reduced but not totally abrogated IFNα 
titers upon intravenous injection of mRNA lipoplexes12. TLR3, which recognizes dsRNA, was not 
implicated in IFNα production. Unfortunately, no data on the quality and magnitude of the 
cytolytic T cell response in mRNA vaccinated Tlr7-/- mice have been reported. As IFNα was still 
induced in Tlr7-/- mice – albeit to a much lower level – additional RNA sensors must be involved 
in the recognition of mRNA lipoplexes. As IVT mRNAs mimic in many aspects viral ssRNAs, also 
cytosolic RNA sensors are probably implicated in the type I IFN response to mRNA vaccines. 
Nonetheless, firm experimental data to support a role for cytosolic RNA sensors in the type I IFN 
response or in the regulation of the ensuing T cell response upon vaccination are currently 
lacking.  
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Figure 7: Parameters that govern type I IFN- mediated regulation of T cell immunity to mRNA-based 
vaccines. mRNA vaccines elicit profound type I IFN responses upon pattern recognition receptor 
activation (1). The role of type I IFNs in regulating T cell immunity to mRNA vaccines is ambivalent, 
illustrated here by the Janus face. Plausible causes may be the composition of the mRNA 
nanoformulations (2) or the route of injection, which is directly linked to the bio distribution of 
evoked type I IFNs (3). Bio distribution might influence the relative timing of T cell receptor activation 
and type I IFN signalling (4), directly leading to the activation of different T cell gene clusters resulting 
in pro-apoptotic processes or pro-proliferative and differentiating programmes.  
3.3 NON-CODING NUCLEIC ACIDS AS ADJUVANTS AND IMMUNOTHERAPEUTICS: 
KEEPING TYPE I IFNS LOCAL? 
Non-coding nucleic acids promote Th1 and cytolytic T cell responses and are intensively 
evaluated as adjuvants for protein vaccines or as immunotherapeutics for cancer treatment. 
Oligo’s containing unmethylated CpG motifs trigger TLR9 and potently stimulate IFNα secretion 
by pDCs. PolyI:C and polyA:U are synthetic dsRNA that trigger TLR3 in the endosomes. In 
addition, polyI:C is also recognized by melanoma differentiation associated protein (MDA5) in 
the cytoplasm. As an adjuvants for protein vaccines, polyI:C induces durable Th1 CD4+ T cell and 
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cytolytic CD8+ T cell responses, which depend on type I IFN secretion by hematopoietic and by 
stromal cells31. Direct IFNAR signaling was found to be crucial for DC activation. Expansion of 
CD8+ T cells to primary immunization with soluble antigens and polyI:C depended largely on 
TLR3 activation in DCs, although MDA5 also contributed to effector T cell differentiation. 
Remarkably, MDA5 activation and type I IFN secretion by stromal cells were found crucial to 
boost memory CD8+ T cell formation73. Intratumoral injection of polyI:C promotes anti-tumor 
immunity in an IFNAR dependent way, which can be further improved by injection of FMS-like 
tyrosine kinase 3 ligand (Flt3L) that recruits DCs to the tumor bed37. Similarly, intra-tumoral 
injection of polyA:U required  IFNAR signaling to yield anti-tumor T cell responses74. TLR7 and 
TLR8 naturally recognize ssRNAs present in endosomal compartments and elicit a potent type I 
IFN response upon activation by their ligands. Synthetic ssRNAs stabilized by a phosphorothioate 
backbone75 or by complexation to cationic carriers76 have been developed as adjuvants that 
promote Th1 and cytolytic T cell responses against co-delivered antigens. Besides synthetic 
RNAs, also small molecule components of the imadozoquinoline family (e.g. imiquimod) activate 
TLR7/8. Topical application of imidazoquinolines into tumors activates pDCs77  and provokes 
systemic anti-tumor T cell responses78. Direct involvement of IFNAR in this process was 
demonstrated using IFNα/β blocking serum. Besides TLR agonists, also synthetic cyclic 
dinucleotides (CDNs) that activate STING have also entered the immunotherapy arena, based on 
the recognition that triggering of the STING pathway in CD8α+ DCs is required to raise 
spontaneous anti-tumor immunity79. Intra-tumoral injection of these synthetic CDNs was 
demonstrated to induce tumor rejection in multiple murine tumor models and required IFNAR 
signaling80.  
Although these nucleic acid-based adjuvants possess the capacity to promote cellular immunity, 
they suffer from one major drawback: the induction of a systemic type I IFN response that 
causes inflammatory toxicity and interferes with clinical application. To resolve inflammatory 
toxicity, various research groups have been formulating nucleic acids or imidazoquinolines in 
such a way that inflammation is restricted to the injection site and its draining lymph nodes81–84. 
Strikingly, such formulations also dramatically improved the strength of the evoked T cell 
response. Coupling of the TLR7 agonist imiquimod to nanogels restricted the type I IFN response 
to the intradermal injection site and its draining lymph node, whereas soluble imiquimod 
provoked systemic type I IFN responses. When admixed with the Mycobacterium tuberculosis 
antigen PPE44, superior Th1 immunity was elicited using the nanogel coupled imiquimod11. A 
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similar system was developed by Seder group, who showed that polymer coupled imiquimod 
resulted in a prolonged DC activation in the draining lymph node and in superior adjuvant 
capacity83. Imiquimod formulated as a cream (Aldara) outperforms soluble imiquimod in the 
priming of melanoma specific CD8+ T cells85. Along the same line, particulate polyI:C86 and CpG87 
outperformed their soluble counterparts in eliciting cytolytic T cells against a co-injected 
antigen.  
The anatomical distribution of type I IFNs (local versus systemic) might be linked to the capacity 
of these nucleic acid-based adjuvants to promote T cell responses. Remarkably, we 
demonstrated that type I IFNs do play a beneficial role when RNA-encoding antigens are 
administered systemically, whereas the administration of nucleic acid adjuvants seemed to 
benefit from being formulated in order to create a local type I IFN induction and inflammation. 
Whether and how the presence of local versus systemic type I IFNs alter the expansion and 
survival of antigen-primed T cells in an apparently opposing way compared to antigen-encoding 
mRNA, remains to be established. Strong and systemic type I IFNs might drive antigen-primed T 
cells into the short-lived effector pool rather than into the memory pool, which will be 
detrimental for the outcome of vaccination88. Alternatively, limiting inflammation to the vaccine 
draining lymph nodes might focus the relevant immune cells to the place antigen resides and 
where TCR triggering is initiated. Conversely, systemic inflammatory responses will divert 
resources and immune cells to non-antigen containing lymph nodes.  
4. CONCLUDING REMARKS  
Nucleic acids-based vaccines and adjuvants have shown great promise in pre-clinical and clinical 
studies but have yet to fulfil their potential in real clinical practice. To achieve this, 
improvements in efficacy and safety are required. Deciphering the cellular network and the 
critical host factors that determine potency and inflammatory toxicity should pave the way for a 
more rational design of nucleic acid-based vaccines and boost their clinical development. Type I 
IFNs are the most prominent cytokines elicited by nucleic acid-based vaccines. The impact of 
type I IFNs on T cell immunity can be beneficial or detrimental, depending on their kinetics of 
induction, intensity and anatomical distribution. For pDNA vaccines, the outcome of IFNAR 
signalling is univocally beneficial. For mRNA vaccines, the situation is more ambiguous with type 
I IFNs exerting profound stimulatory effects upon intravenous injection yet potent inhibitory 
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effects upon topical injection. The mechanisms behind this differential outcome are still 
unresolved. Given the important safety issues associated with intravenous injection – which is 
unseen within the vaccination field – it will be essential to design topically applied mRNA 
vaccines that are either capable of harnessing the positive effects of type I IFNs or that avoid 
type I IFN induction and activate the innate immune system in an alternative way. Finally, 
nucleic acid-based adjuvants and immune-therapeutics clearly require type I IFNs for their 
immune-potentiating effects. Nonetheless, in this case the capacity of type I IFN responses in 
promoting T cell immunity might depend on the anatomical distribution of type I IFN induction. 
Localized type I IFN responses appear to be linked to superior T cell immunity induction when 
compared to systemic type I IFN responses, but the real causalities between the anatomical 
distribution of type I IFNs and T cell immunity remain to be established.  
 
  
103 | Introduction
5. REFERENCES 
1. Bolhassani, A., Safaiyan, S. & Rafati, S. Improvement of different vaccine delivery systems for 
cancer therapy. Mol. Cancer 10, 3 (2011). 
2. Restifo, N., Ying, H., Hwang, L. & Leitner, W. The promise of nucleic acid vaccines. Gene Ther. 7, 
89–92 (2000). 
3. RNActive® Rabies Vaccine (CV7201) in Healthy Adults - Full Text View - ClinicalTrials.gov. 
Available at: https://clinicaltrials.gov/ct2/show/NCT02241135?term=RNA+vaccines&rank=29. 
(Accessed: 20th November 2016) 
4. Sebastian, M. et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine 
(RNActive®) combined with local radiation as consolidation and maintenance treatment for 
patients with stage IV non-small cell lung cancer. BMC Cancer 14, 748 (2014). 
5. Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer. Available at: 
https://clinicaltrials.gov. (Accessed: 12th September 2016) 
6. Rausch, S., Schwentner, C., Stenzl, A. & Bedke, J. mRNA vaccine CV9103 and CV9104 for the 
treatment of prostate cancer. Hum. Vaccines Immunother. 10, 3146–3152 (2014). 
7. Davis, D. R. Stabilization of RNA stacking by pseudouridine. Nucleic Acids Res. 23, 5020–5026 
(1995). 
8. Anderson, B. R. et al. Incorporation of pseudouridine into mRNA enhances translation by 
diminishing PKR activation. Nucleic Acids Res. 38, 5884–5892 (2010). 
9. Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. & Klinman, D. M. CpG DNA as a vaccine adjuvant. 
Expert Rev. Vaccines 10, 499–511 (2011). 
10. Klinman, D. M. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense 
Nucleic Acid Drug Dev. 8, 181–184 (1998). 
11. Nuhn, L. et al. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused 
immune activation. Proc. Natl. Acad. Sci. U. S. A. 113, 8098–8103 (2016). 
12. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer 
immunotherapy. Nature 534, 396–401 (2016). 
13. Broos, K. et al. Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong 
Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol. Ther. Nucleic 
Acids 5, e326 (2016). 
14. De Beuckelaer, A. et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines 
to elicit cytolytic T cell responses. Mol. Ther. J. Am. Soc. Gene Ther. (2016). 
15. de Weerd, N. A. et al. Structural basis of a unique interferon-β signaling axis mediated via the 
receptor IFNAR1. Nat. Immunol. 14, 901–907 (2013). 
16. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 
36–49 (2014). 
17. Decker, T., Müller, M. & Stockinger, S. The Yin and Yang of type I interferon activity in bacterial 
infection. Nat. Rev. Immunol. 5, 675–687 (2005). 
18. Devoldere, J., Dewitte, H., De Smedt, S. C. & Remaut, K. Evading innate immunity in nonviral 
mRNA delivery: don’t shoot the messenger. Drug Discov. Today 21, 11–25 (2016). 
  
104 | Introduction 
19. Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. 
Immunity 33, 492–503 (2010). 
20. Isaacs, L. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147, 258–67 (1957). 
21. Tanabe, Y. et al. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-α β responses in T 
lymphocytes. J Immunol 174, 609–613 (2005). 
22. Brierly, M., Fish, E. STATs multifaceted regulators of transcription. J Interferon Cytokine Res 25, 
733–744 (2005). 
23. Bromberg, J. F., Horvath, C. M. & Wen, Z. Transcriptionally active Stat1 is required for the 
antiproliferative effects of both interferon α and interferon γ. Proc Natl Acad Sci 93, 7673–7678 
(1996). 
24. Kim, H. S. & Lee, M.-S. STAT1 as a key modulator of cell death. Cell. Signal. 19, 454–465 (2007). 
25. Gimeno, R., Lee, C.-K., Schindler, C. & Levy, D. E. Stat1 and Stat2 but not Stat3 arbitrate 
contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol. Cell. Biol. 
25, 5456–5465 (2005). 
26. platanias, L., C,. Mechanisms of type I  and II interferon mediated signalling. Nat. Rev. Immunol. 
5, 375–386 (2005). 
27. Rescigno, M., Granucci, F., Citterio, S., Foti, M. & Ricciardi-Castagnoli, P. Cordinated events 
during bacteria-induced DC maturation. Immunol. Today 20, 200–203 (1999). 
28. Pantel, A. et al. Direct Type I IFN but Not MDA5/TLR3 Activation of Dendritic Cells Is Required for 
Maturation and Metabolic Shift to Glycolysis after Poly IC Stimulation. PLOS Biol 12, e1001759 
(2014). 
29. Le Bon, A. et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. 
Immunol. 4, 1009–1015 (2003). 
30. Zietara, N. et al. Absence of IFN-beta impairs antigen presentation capacity of splenic dendritic 
cells via down-regulation of heat shock protein 70. J. Immunol. Baltim. Md 1950 183, 1099–1109 
(2009). 
31. Longhi, M. P. et al. Dendritic cells require a systemic type I interferon response to mature and 
induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206, 1589–1602 (2009). 
32. Woo, S.-R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition 
of immunogenic tumors. Immunity 41, 830–842 (2014). 
33. Andzinski, L. et al. Growing tumors induce a local STING dependent Type I IFN response in 
dendritic cells. Int. J. Cancer 139, 1350–1357 (2016). 
34. Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses 
through CD8α+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011). 
35. Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune 
rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011). 
36. Gungor, B., Yagci, F. C., Gursel, I. & Gursel, M. Forging a potent vaccine adjuvant: CpG 
ODN/cationic peptide nanorings. Oncoimmunology 3, (2014). 
37. Salmon, H. et al. Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor 
Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity 44, 924–
938 (2016). 
105 | Introduction
38. Swiecki, M. et al. Type I interferon negatively controls plasmacytoid dendritic cell numbers in 
vivo. J. Exp. Med. 208, 2367–2374 (2011). 
39. Marraco, S. A. F. et al. Type I Interferon Drives Dendritic Cell Apoptosis via Multiple BH3-Only 
Proteins following Activation by PolyIC In Vivo. PLOS ONE 6, e20189 (2011). 
40. Schwandt, T. et al. Expression of type I interferon by splenic macrophages suppresses adaptive 
immunity during sepsis. EMBO J. 31, 201–213 (2012). 
41. Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV 
infection. Science 340, 202–207 (2013). 
42. Crouse, J., Kalinke, U. & Oxenius, A. Regulation of antiviral T cell responses by type I interferons. 
Nat. Rev. Immunol. 15, 231–242 (2015). 
43. Tough, D. F. Modulation of T-cell function by type I interferon. Immunol. Cell Biol. 90, 492–497 
(2012). 
44. Wiesel, M. et al. Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. 
Eur. J. Immunol. 42, 320–329 (2012). 
45. Agarwal, P. et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in 
programming for CD8 T cell effector function and memory. J. Immunol. Baltim. Md 1950 183, 
1695–1704 (2009). 
46. Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J. & Murali-Krishna, K. Type I interferons 
act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral 
infection. J. Exp. Med. 202, 637–650 (2005). 
47. Gil, M. P., Salomon, R., Louten, J. & Biron, C. A. Modulation of STAT1 protein levels: a mechanism 
shaping CD8 T-cell responses in vivo. Blood 107, 987–993 (2006). 
48. Terawaki, S. et al. IFN-α directly promotes programmed cell death‑1 transcription and limits the 
duration of T cell-mediated immunity. J Immunol 186, 2772–2779 (2011). 
49. A., Kaser & H. Tiljf. Interferon-α augments activation-induced T cell death by upregulation of Fas 
(CD95/APO‑1) and Fas ligand expression. Cytokine 11, 736–743 (1999). 
50. Fraietta, J. A. et al. Type I Interferon Upregulates Bak and Contributes to T Cell Loss during 
Human Immunodeficiency Virus (HIV) Infection. PLOS Pathog 9, e1003658 (2013). 
51. Matikainen, S. et al. Interferon-alpha activates multiple STAT proteins and upregulates 
proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 93, 1980–
1991 (1999). 
52. Sironi, J. J. & Ouchi, T. STAT1-induced Apoptosis Is Mediated by Caspases 2, 3, and 7. J. Biol. 
Chem. 279, 4066–4074 (2004). 
53. Unterholzner, L. et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11, 
997–1004 (2010). 
54. Ishii, K. J. et al. A Toll-like receptor-independent antiviral response induced by double-stranded 
B-form DNA. Nat. Immunol. 7, 40–48 (2006). 
55. Tudor, D. et al. Type I IFN Modulates the Immune Response Induced by DNA Vaccination to 
Pseudorabies Virus Glycoprotein C. Virology 286, 197–205 (2001). 
56. Leitner, W. W., Bergmann-Leitner, E. S., Hwang, L. N. & Restifo, N. P. Type I Interferons are 
essential for the efficacy of replicase-based DNA vaccines. Vaccine 24, 5110–5118 (2006). 
  
106 | Introduction 
57. Shirota, H., Petrenko, L., Hattori, T. & Klinman, D. M. Contribution of IRF-3 Mediated IFNβ 
Production to DNA Vaccine Dependent Cellular Immune Responses. Vaccine 27, 2144–2149 
(2009). 
58. Klinman, D., M,. Use of CpG oligonucleotides as immunoprotective agents. Expert Opin Biol Ther 
4, 937–946 (2004). 
59. Öhlschläger, P., Spies, E., Alvarez, G., Quetting, M. & Groettrup, M. The combination of TLR-9 
adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses 
after vaccination with HPV-16 E7 encoding DNA. Int. J. Cancer 128, 473–481 (2011). 
60. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C. & Vogel, J. C. Activation of Cutaneous Dendritic 
Cells by CpG-Containing Oligodeoxynucleotides: A Role for Dendritic Cells in the Augmentation 
of Th1 Responses by Immunostimulatory DNA. J. Immunol. 161, 3042–3049 (1998). 
61. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. 
Nature 441, 101–105 (2006). 
62. Babiuk, S. et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. 
Immunology 113, 114–120 (2004). 
63. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I 
interferon-dependent innate immunity. Nature 461, 788–792 (2009). 
64. Ishii, K. J. et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA 
vaccines. Nature 451, 725–729 (2008). 
65. Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune 
response. Nature 448, 501–505 (2007). 
66. Suschak, J. J., Wang, S., Fitzgerald, K. A. & Lu, S. A cGAS-Independent STING/IRF7 Pathway 
Mediates the Immunogenicity of DNA Vaccines. J. Immunol. Baltim. Md 1950 196, 310–316 
(2016). 
67. Suschak, J. J., Wang, S., Fitzgerald, K. A. & Lu, S. Identification of Aim2 as a sensor for DNA 
vaccines. J. Immunol. Baltim. Md 1950 194, 630–636 (2015). 
68. Hornung, Ablasser, V & Charelle-Denis, M. AIM2 recognizes cytosolic dsDNA and forms a 
caspase-1-activating inflammasome with ASC. Nature 458, 514–518 (2009). 
69. Pollard, C. et al. Type I IFN counteracts the induction of antigen-specific immune responses by 
lipid-based delivery of mRNA vaccines. Mol. Ther. J. Am. Soc. Gene Ther. 21, 251–259 (2013). 
70. Kübler, H. et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-
in-man phase I/IIa study. J. Immunother. Cancer 3, 26 (2015). 
71. Scheel, B. et al. Toll-like receptor-dependent activation of several human blood cell types by 
protamine-condensed mRNA. Eur. J. Immunol. 35, 1557–1566 (2005). 
72. Fotin-Mleczek, M. et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 
dependent adaptive immune responses and provide antitumor activity. J. Immunother. 
Hagerstown Md 1997 34, 1–15 (2011). 
73. Wang, Cella, M. & Gilfillan, S. Cutting edge: Polyinosinic:polycytidylic acid boosts the generation 
of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in 
stromal cells. J Immunol 184, 2751–2755 (2010). 
107 | Introduction
74. Nocera, D. A. et al. In Vivo Visualizing the IFN-β Response Required for Tumor Growth Control in 
a Therapeutic Model of Polyadenylic-Polyuridylic Acid Administration. J. Immunol. 1501044 
(2016). doi:10.4049/jimmunol.1501044 
75. Scheel, B. et al. Immunostimulating capacities of stabilized RNA molecules. Eur. J. Immunol. 34, 
537–547 (2004). 
76. Heidenreich, R. et al. A novel RNA-based adjuvant combines strong immunostimulatory 
capacities with a favorable safety profile. Int. J. Cancer 137, 372–384 (2015). 
77. Oh, J. Z., Kurche, J. S., Burchill, M. A. & Kedl, R. M. TLR7 enables cross-presentation by multiple 
dendritic cell subsets through a type I IFN-dependent pathway. Blood 118, 3028–3038 (2011). 
78. Jeught, K. V. der et al. Intratumoral administration of mRNA encoding a fusokine consisting of 
IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget 
5, 10100–10113 (2014). 
79. Hanson, M. C. et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine 
adjuvants. J. Clin. Invest. 125, 2532–2546 (2015). 
80. Corrales, L. et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and 
Systemic Tumor Regression and Immunity. Cell Rep. 11, 1018–1030 (2015). 
81. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. 
Nature 507, 519–522 (2014). 
82. Wu, T. Y.-H. et al. Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med. 6, 
263ra160 (2014). 
83. Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked 
TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33, 1201–1210 (2015). 
84. De Geest, B. G. et al. Surface-Engineered Polyelectrolyte Multilayer Capsules: Synthetic Vaccines 
Mimicking Microbial Structure and Function. Angew. Chem. Int. Ed. 51, 3862–3866 (2012). 
85. Fehres, C. M. et al. Topical rather than intradermal application of the TLR7 ligand imiquimod 
leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming. Eur. J. Immunol. 
44, 2415–2424 (2014). 
86. Jewell, C. M., López, S. C. B. & Irvine, D. J. In situ engineering of the lymph node 
microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc. Natl. 
Acad. Sci. U. S. A. 108, 15745–15750 (2011). 
87. de Titta, A. et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and 
memory recall at low dose. Proc. Natl. Acad. Sci. U. S. A. 110, 19902–19907 (2013). 
88. Huber, J. P. & Farrar, J. D. Regulation of effector and memory T-cell functions by type I 
interferon. Immunology 132, 466–474 (2011). 
 
 
 
  
108 | Research Aims 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109 | 
 
 
RESEARCH AIMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
110 | Research Aims 
 
 
 
  
 111 | 
mRNA-based vaccines have a great potential to elicit antigen-specific cytotoxic CD8+ T cell (CTL) 
responses and therefore are under intensive (pre)clinical investigation. mRNA has the advantage 
to possess a high safety profile due to a low risk on genomic integration and transient antigen 
exposure. Nevertheless, for a long time mRNA was considered to be too unstable for direct in 
vivo administration. As a consequence, most applications were based on adoptive transfer of in 
vitro mRNA-modified dendritic cells rather than on direct injection of the mRNA into a patient. 
However, during the last years, novel encapsulation and targeting techniques came to the 
forefront, rendering a direct administration of mRNA vaccines a feasible alternative. The overall 
aim of this thesis therefore was to explore new strategies and mechanisms to increase the 
efficacy of mRNA-based vaccines, administered directly to the patient.  
Previously, our research group has shown that subcutaneous injection of mRNA lipoplexes 
induces type I IFNs which negatively interfered with the immunogenicity of mRNA lipoplex 
vaccines (chapter 4). In this thesis we further aimed (i) to understand how this vaccine-induced 
type I IFN response negatively affects the efficacy of the mRNA-based vaccine and (ii) to develop 
new strategies that may circumvent this negative effect of type I IFNs and thereby increase the 
strength of mRNA vaccine-elicited CTL responses. Different approaches to reach both goals were 
tested, based on either modifying the mRNA itself or modifying the mRNA carrier. The impact of 
modifying the vaccine mRNA, by replacing cytidine and uridine with chemically modified 
variants, on vaccine efficacy and type I IFN induction, was assayed. The results obtained are 
described in chapter 5 and 6 of this thesis. Next to modifying the mRNA, we validated in chapter 
6 a RALA peptide-based delivery format as an alternative to the mRNA lipoplex vaccine 
approach. Our mechanistic studies not only highlighted the importance of the amphipathic 
nature of the RALA peptide for the efficacy of the vaccine but also demonstrated the absence of 
type I IFNs. This absence of inhibiting type I IFNs may underlie the higher efficacy of this RALA 
peptide-based vaccine strategy compared to the type I IFN-sensitive conventional lipoplex 
format. 
As a last objective of this thesis, we addressed the question whether RNA, besides a role as 
antigen-encoding device, may also function as a Th1 immunity skewing adjuvant. This 
proposition was based on several reports describing a role for non-coding RNA in the activation 
of innate immunity. Here, we aimed to develop a nanoparticulate formulation that not only 
protects the RNA from degradation, but also efficiently delivers to RNA to lymph node dendritic 
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cells. We further investigated the efficacy of these RNA complexes as novel adjuvant for the 
eliciting of cytolytic CD8+ T cell responses against co-delivered protein antigens (chapter 7).
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Abstract 
Given their high potential to evoke cytolytic T cell responses, tumour antigen-encoding mRNA 
vaccines are now being intensively explored as therapeutic cancer vaccines. mRNA vaccines 
clearly benefit from wrapping the mRNA into nano-sized carriers such as lipoplexes that protect 
the mRNA from degradation and increase its uptake by DCs in vivo. Nevertheless, the early 
innate host factors that regulate the induction of cytolytic T cells to mRNA lipoplex vaccines 
have remained unresolved. Here, we demonstrate that mRNA lipoplexes induce a potent type I 
IFN response upon subcutaneous, intradermal and intranodal injection. Regardless of the route 
of immunization applied, these type I IFNs interfered with the generation of potent cytolytic T 
cell responses. Most importantly, blocking type I IFN signalling at the site of immunization 
through the use of an IFNAR blocking antibody greatly enhanced the prophylactic and 
therapeutic anti-tumour efficacy of mRNA lipoplexes in the highly aggressive B16 melanoma 
model. As type I IFN induction appears to be inherent to the mRNA itself rather than to unique 
properties of the mRNA lipoplex formulation, preventing type I IFN induction and/or IFNAR 
signalling at the site of immunization might constitute a widely applicable strategy to improve 
the potency of mRNA vaccination. 
1. INTRODUCTION 
The induction of strong cytolytic CD8+ T cell responses capable of killing transformed cells is 
considered vital for the success of therapeutic cancer vaccines1. As CD8+ T cells guard the 
intracellular proteome, their efficient induction typically requires the presence of antigens in the 
cellular cytosol, where they can enter the classical route of proteasome degradation and MHC-I 
mediated antigen presentation. In contrast to protein based vaccines, vaccines based on 
messenger RNA (mRNA) enable protein expression inside the cytosol of transfected cells and 
thus show great potential to evoke cytotolytic T cell responses2. Due to the limited stability of 
early in vitro transcribed (IVT) mRNAs, mRNA vaccines have been predominantly delivered in the 
format of ex vivo electroporated DCs for most of the time3. Over the past years, technical 
improvements in the way IVT mRNA is prepared (5’ Cap modifications, optimized GC content, 
improved polyA tails, stabilizing UTRs) have increased the stability of IVT mRNA to such extent 
protein expression can now be achieved for days after direct in vivo administration of the 
mRNA4-6. These breakthroughs have revolutionized the mRNA vaccination allowing direct 
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injection of antigen-encoding mRNA to be explored for the treatment of patients with prostate 
cancer, non-small lung cell carcinoma and melanoma7-13.  
When applied directly in vivo, mRNA vaccines strongly benefit from wrapping the mRNA into 
nano-sized carriers.  Within this context, our group previously demonstrated that condensing 
mRNA into cationic lipoplexes increases the potency of the mRNA vaccine evoked T cell 
response by several orders of magnitude14. One of the typical hallmarks of IVT mRNAs 
condensed into nano-formulations is their capacity to elicit intense secretion of Type I IFNs in 
murine and human DCs14,15. Indeed, IVT mRNA appears to mimic viral RNA in its capacity to 
trigger a variety of cellular endosomal and cytosolic RNA sensors that all induce a signalling 
cascade culminating in the release of type I IFNs14-17. Type I IFNs are highly pleiotropic cytokines 
that can either promote or inhibit T cell responses dependent on the context. Type I IFNs can 
augment T cell immunity by activating DCs and increasing antigen presentation. 
Conversely, the antiviral actions of type I IFNs - production of RNAses and instigation of 
translation arrest – might interfere with the expression of the mRNA encoded antigen and 
therefore negatively impact T cell immunity. Type I IFN signalling on antigen experienced T cells 
can promote T cell proliferation, survival and differentiation into effector cells18. Nevertheless, 
type I IFN exposure prior to T cell receptor activation can induce anti-proliferative and apoptotic 
programmes in T cells18-21. How type I IFNs impact the characteristics of the T cell responses to 
mRNA lipoplex vaccines and their efficacy to control tumour growth is therefore far from 
forgone conclusion and constitutes the main goal of this study. 
Using an IFN-β reporter mouse strain, we were able to demonstrate that mRNA lipoplexes 
instigate profound type I IFN responses upon subcutaneous, intradermal and intranodal 
injection. In sharp contrast to the beneficial role of type I IFNs in protein and peptide based 
vaccines22-25, type I IFNs severely hampered priming of vaccine specific T cell responses and the 
generation of anti-tumour immunity to lipoplex based mRNA vaccination. Preventing type I IFN 
induced signalling through co-administration of an IFNAR blocking antibody at the site of mRNA 
vaccination amplified the cytotolytic T cell response and significantly strengthened vaccine 
elicited tumour control in prophylactic and therapeutic settings.  
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2. RESULTS 
2.1. MRNA LIPOPLEXES INDUCE A POTENT TYPE I IFN RESPONSE IN VIVO 
Cationic liposomes have been reported to increase T cell responses to mRNA encoded 
antigens26. In this study, liposomes composed of the cationic lipid 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP) and the neutral helper lipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were used to condense mRNA into lipoplexes. Preliminary 
research was done to determine the nitrogen/phosphate ratio most suited for in vivo application 
and is shown as additional data (Figure S1). We evaluated two N/P ratios that give yield to mRNA 
lipoplexes of similar size (± 300-400 nm) but opposite charge, namely lipoplexes at N/P1 had a 
negative zeta-potential of -18 mV and N/P10 lipoplexes displayed a positive charge of +32 mV 
(Figures S1a,b). Further, we addressed mRNA lipoplexes of ratio N/P1 as most suited to yield 
high expression levels of the delivered mRNA (Figure. S1c) and to induce proper induction of 
IFN-ɣ producing CD8+ and CD4+ T cells upon subcutaneous injection (Figure S1d). As a 
consequence, N/P1 was selected in all further experiments aimed at addressing the impact of 
type I IFNs on the efficacy of mRNA lipoplexes to yield T cell immunity.  
Previously, we have demonstrated that DOTAP-based mRNA lipoplexes elicit strong type I IFN 
secretion upon incubation with bone marrow derived DCs in vitro14. To address to which extent 
mRNA lipoplexes would trigger type I IFNs in vivo upon subcutaneous injection, we used an IFN-
β reporter mouse in which a firefly luciferase encoding sequence has been placed under the 
control of the IFN-β promoter (Figure 1a)27. As type I IFN production is regulated by self-
enforcing feedforward loops, heterozygous reporter mice (IFN-β+/Δβ-luc) were used to allow signal 
amplification by early induced IFN-β. Mice were injected subcutaneously with respectively 
DOTAP liposomes (no mRNA), unformulated mRNA or mRNA lipoplexes. In vivo bioluminescence 
imaging revealed a strong induction of the IFN-β promoter to injection of naked mRNA and of 
mRNA lipoplexes, but not to liposomes without mRNA (Fig. 1b,c). Strikingly, naked OVA mRNA 
elicited the most prominent induction of type I IFNs, clearly indicating that type I IFN induction 
to mRNA is inherent to the mRNA itself rather than to unique features of the mRNA lipoplexes. 
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Figure 1. mRNA lipoplexes induce a potent type I IFN response in vivo. (a) Graphical scheme of the IFN-
β reporter construct. The  myc-tagged luciferase gene is brought under the control of the IFN-β 
promoter by the Cre-Lox system. (b-c) IFN-
+/-luc mice
 
were s.c. injected with 10 ug of OVA mRNA, 
mRNA lipoplexes and liposomes. Luminescence was measured 6 hours post-injection.  Data are 
shown as mean ± SD of 4 mice. ** p < 0,001. * p < 0,05 (Mann- Whitney test). Control = 5% glucose 
water; liposomes = DOTAP/DOPE lipids; mRNA lipoplexes = messenger RNA complexed to liposomes. 
 
2.2 TYPE I IFNS IMPACT THE MAGNITUDE AND FUNCTIONAL CHARACTERISTICS 
OF THE VACCINE ELICITED CD8+ T CELL RESPONSE. 
Depending on the context, type I IFNs have been reported to either promote or interfere with 
the generation of T cell responses. As a consequence, we thoroughly addressed the impact of 
type I IFN signalling on the magnitude and functionality of the T cell response generated by 
mRNA lipoplex vaccination through comparative immunization studies in wild type mice and in 
mice lacking he common IFN-α/β receptor IFNAR1 (Ifnar-/-). First, we addressed the effects of 
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type I IFNs on the initial priming of antigen-specific T cells. To this end, CFSE labelled transgenic 
OVA-specific CD8+ T cells (OT-I T cells) were transferred to respectively wild type and Ifnar-/- 
mice, which were subsequently immunized with OVA mRNA lipoplexes. Four days post 
immunization, the draining popliteal lymph nodes were dissected and OT-I T cell proliferation 
was analysed by flow cytometry (Figure 2a). As shown in Figure 2b, Ifnar-/- mice showed strongly 
elevated OT-I proliferation when compared to wild type mice. This negative impact of type I IFNs 
on the magnitude of the vaccine evoked CD8+ T cell response was confirmed by quantification of 
vaccine elicited OVA-specific CD8+ T cells in the blood of wild type versus Ifnar-/- mice (Figure 2c). 
Five days after boost immunization, OVA-specific CD8+ T cells were hardly detectable in the 
blood of wild type mice but reached up to 3% of all CD8+ T cells in the blood of Ifnar-/- mice. No 
significant numbers of OVA-specific T cells were detected in response to unformulated OVA 
mRNA. Next we analysed the impact of IFNAR deficiency on the functional properties of the 
vaccine induced CD8+ T cell response. As type I IFNs have been reported to stimulate the 
differentiation of primed CD8+ T cells into effector cells20,21,28,29, the increased numbers of 
vaccine elicited CD8+ T cell response observed in Ifnar-/- mice not necessarily translate into 
increased effector function in these mice. To address this issue, we compared OVA-specific IFN-ɣ 
secretion and target cell specific lysis between immunized wild type and Ifnar-/- mice. ELISPOT 
assays were performed on splenocytes two weeks after a booster immunization with OVA mRNA 
lipoplexes to quantify the numbers of IFN-ɣ producing OVA-specific T cells. As depicted in Figure 
2d, immunized Ifnar-/- mice showed a strong increase in the numbers of OVA-specific IFN-ɣ 
secreting T cells. The cytolytic capacity of the evoked CD8+ T cell response was analysed through 
an in vivo killing assay. In brief, two weeks following a booster immunization with OVA mRNA 
lipoplexes, mice were challenged with a 1:1 ratio of OVA peptide-pulsed CFSEhi splenocytes 
(target cells) and non-pulsed CFSElow splenocytes (non-target cells). Two days later, spleens were 
dissected and the ratio of target cells versus non-target cells was analysed by flow cytometry to 
determine the extent of killing of the target cells. Whereas immunization of wild type mice with 
OVA mRNA lipoplexes resulted only in a limited killing of the target cells, virtually all target cells 
were eliminated in immunized Ifnar-/- mice (Figures 3e-f). Taken together, these data clearly 
demonstrate that IFNAR deficiency increases initial T cell priming to subcutaneously 
administrated mRNA lipoplex vaccines and that type I IFN are not required for these antigen-
experienced T cells to acquire effector function. 
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As we earlier observed an increase in the expression of lipoplex delivered mRNA in bone marrow 
derived DCs lacking IFNAR, we decided to quantify mRNA expression after subcutaneous 
injection of mRNA lipoplexes in wild type and Ifnar-/- mice. If Ifnar-/- mice would show strongly 
increased mRNA expression levels, increased antigen expression might well underlie the raise in 
initial T cell proliferation we observed in Ifnar-/- mice. To address this issue, luciferase encoding 
mRNA was condensed into lipoplexes at N/P1 and luciferase expression was assessed through in 
vivo bioluminescence measurement. Although luciferase expression was slightly elevated in the 
IFNAR deficient setting, this increase was very subtle and did not reached significance (Figure 
S2). As a consequence, events downstream of antigen expression must be at the origin of the 
dramatically raised T cell responses in Ifnar-/- mice. 
 
 
 
Figure 2. Type I IFNs impact the magnitude and functional characteristics of the vaccine elicited CD8
+
 T 
cell response. (a) Gating strategy used for OVA- specific CD8
+
 T cell counting and proliferation. Cells 
are gated based on FSC and SCC, before single cells are gated based on SSC-area and height. Living 
cells are selected and gated for CD3
+
CD19
- 
T cells. Within CD8
+
 T cells, OVA-specificity is gated by 
labelling with MHC-I SIINFEKL – PE dextramer. Proliferation of CFSE positive OVA-specific CD8
+
 T cells 
is shown. (b) Two days prior to immunization CFSE-labelled OT-I cells were adoptively transferred to 
wild type (WT) and Ifnar
-/-
 mice. Subcutaneous (s.c.) immunization was performed at tail base with 10 
µg OVA mRNA lipoplexes, naked mRNA or liposomes alone. Four days after immunization inguinal 
lymph nodes were isolated and CD8
+
 T cell proliferation was analyzed by flow cytometry. Data are 
shown as mean of 2-3 mice. *** p < 0.001 (Chi-square test). (c) Wild type (WT) and Ifnar
-/-
 mice were 
s.c. injected twice with 20 ug OVA mRNA lipoplexes or naked OVA mRNA as a control in a two week 
interval. Blood was isolated 5 days later and the percentage OVA-specific CD8
+
 T cells was determined 
by dextramer staining followed by flow cytometry. Data are shown as mean of 4 mice per group. *** 
p < 0.001 (Chi-square test). (d) Wild type (WT) and Ifnar
-/- 
mice were immunized s.c. with 20 µg OVA 
mRNA lipoplexes or  naked mRNA as a control. Two weeks later, mice were boosted with the same 
formulation. Spleens were isolated two weeks after boost immunization, and the number of OVA-
specific interferon-γ spot-forming  CD8
+
 and CD4
+
 T cells (SFC) was determined by enzyme-linked 
immunosorbent spot (ELISPOT). Data are shown as mean of 2-4 mice per group. *** p < 0.001 (Chi-
square test). (e,f) Wild type (WT) and Ifnar
-/-
 mice were immunized with a two-week interval with 
naked OVA mRNA or OVA mRNA lipolexes. Two weeks after boost immunization, a mixture of CFSE-
labelled cells pulsed with control (CFSE
low
) or OVA peptide (CFSE
high
) were adoptively transferred. 
Specific killing was measured 2 days later by flow cytometry. Data are presented as means of 100 -
100x ((CFSE
high
/CFSE
low
)
immunized mice
/(CFSE
high
/CFSE
low
)
mock-mice
) of 3-4 mice per group. ** p < 0.01 (Chi-
square test). mRNA = OVA-coding messenger RNA; mRNA lipoplexes = messenger RNA complexed to 
DOTAP/DOPE liposomes. 
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2.3 IMPACT OF TYPE I IFNS ON THE EFFICACY OF ANTI-TUMOUR IMMUNITY 
ELICITED BY MRNA LIPOPLEX VACCINATION. 
The functional impact of type I IFNs on anti-tumour immunity mediated by mRNA lipoplex 
vaccination was addressed in the highly aggressive B16.OVA melanoma model. Mice were either 
vaccinated prophylactically or therapeutically according to the schedule shown in Figures 3a,d. 
In wild type mice, prophylactic vaccination significantly increased the median survival time from 
17 to 29 days (Figure 3b). In line with their elevated vaccine elicited T cell responses, Ifnar-/- mice 
benefited even more from vaccination than wild type mice, as the median survival time 
increased from 14 to 40 days (Figure 3c). This observation is highly striking as Ifnar-/- mice 
notoriously lack spontaneous anti-tumour immune responses and succumb much faster to 
tumours when left untreated28-31. Therapeutic vaccination caused a small though non-significant 
improvement in median survival time from 34 to 47 days in wild type mice (Figure 3e). 
Conversely, therapeutic vaccination yielded a significant survival benefit in Ifnar-/- mice with an 
increase in median survival time from 20 to 35 days (Figure 3f). Nevertheless, in the therapeutic 
vaccination setting, vaccinated wild type mice still controlled tumours better than vaccinated 
Ifnar-/- mice, a feature that can be most likely ascribed to the lack of spontaneous anti-tumour 
responses in the IFNAR deficient setting. 
 
 
 
 
 
Figure 3. Impact of type I IFNs on the efficacy of anti-tumour immunity elicited by mRNA lipoplex 
vaccination. (a) Prophylactic vaccination scheme. Wild type (WT) mice (b) and Ifnar
-/-
 mice (c) were 
either mock s.c. immunized (i.e. injected with PBS only) or immunized with 20 g of mRNA lipoplexes. 
Two weeks later, mice were boosted with the same formulation. At week 4, mice were inoculated 
with 100.000 OVA-expressing B16 melanoma cells. (n= 12-16 mice/group). (d) Therapeutic 
vaccination scheme.  Wild type (WT) mice (e) and Ifnar
-/-
 mice (f) were inoculated with 75.000 
B16.OVA melanoma cells. 4 and 6 days later immunization was performed with similar preparations 
as in the prophylactic setting. (n = 5-6 mice/group).  mRNA lipoplexes = OVA- coding messenger 
mRNA complexed to DOTAP/DOPE liposomes. ** p < 0,01; *** p < 0,001; ****p < 0,0001 (Mantel-Cox 
log-rank test). 
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2.4 ANTIBODY MEDIATED IFNAR BLOCKADE IMPROVES THE EFFICACY OF THE 
MRNA VACCINE EVOKED ANTI-TUMOUR IMMUNE RESPONSE. 
Results of the experiments in the previous paragraph illustrated that in immunized wild type 
mice tumour growth control is determined by the combined strength of the spontaneous and 
vaccine elicited immune responses, whereas in Ifnar-/- mice tumour control will entirely depend 
on the vaccine elicited immune response. As a consequence, direct comparisons of tumour 
growth rates between immunized wild type and Ifnar-/- mice do not allow a reliable assessment 
of the impact of type I IFNs on vaccine mediated tumour control. To circumvent the detrimental 
effect of genetic IFNAR deficiency on spontaneous anti-tumour immunity, we therefore decided 
to switch to antibody mediated inhibition of IFNAR signalling at the spot of vaccination in wild 
type mice. Local interference with IFNAR signalling should leave the spontaneous anti-tumour 
response intact and thereby allow us to specifically address the impact of type I IFN signalling on 
vaccine mediated tumour control.  
First, we validated whether antibody-mediated IFNAR blockade would indeed amplify the CD8+ T 
cell response elicited by the mRNA lipoplex vaccine in wild type mice. As can be appreciated 
from Figure 4a,b co-injection of the IFNAR blocking antibody increased the proliferation of OVA-
specific OT-I cells in response to mRNA lipoplexes, whilst the isotype matched antibody had no 
impact on OT-I proliferation. We next determined if blocking IFNAR at the site of immunization 
would improve the anti-tumour efficacy of the lipoplex mRNA vaccines in case of prophylactic 
(Figure 4c,d) and therapeutic vaccination (Fig. 4e,f) In the prophylactic vaccination setting, co-
injection of the IFNAR-blocking antibody MAR1-5A3 with the OVA mRNA lipoplexes significantly 
improved the survival rate of immunized mice (Figure 4d). Importantly, the benefit of blocking 
IFNAR was preserved in the therapeutic vaccination setting, as mice immunized with mRNA 
lipoplexes in the presence of MAR1-5A3 displaying an improved outcome compared to mice 
receiving the same mRNA vaccine alone or combined with an isotype control antibody (Figure 
4f). Taken together, these findings demonstrate that type IFNs induced by mRNA lipoplex 
vaccines negatively impact the vaccine elicit T cell response and its efficacy to control tumour 
growth upon subcutaneous vaccination. 
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Figure 4. Antibody-mediated blocking of IFNAR improves the efficacy of the mRNA vaccine evoked anti-
tumour immune response. (a,b) Two days prior to immunization CFSE-labelled OT-I cells were 
adoptively transferred to wild type (WT) mice. Immunization was performed in the footpad with 10 
µg mRNA lipoplexes in the absence or presence of 20 µg IFNAR blocking antibody or isotype control. 
Four days after immunization inguinal lymph nodes were isolated and CD8
+
 T cell proliferation was 
analysed by flow cytometry. Data are shown as mean of 3-6 mice per group.*** p < 0,001 (Chi-square 
test). (a) A representative sample out of 3-6 mice each group is presented. (c) Prophylactic 
vaccination scheme. (d) Wild type (WT) mice were immunized s.c with 20 g of mRNA lipoplexes in 
absence or presence of 20 µg of the IFNAR blocking antibody or isotype control. Two weeks later, 
mice were boosted with the same formulation. At week 4, mice were inoculated with 100.000 
B16.OVA melanoma cells (n= 6-8 mice/group). * p < 0,05 (Mantel-Cox log-rank test). (e) Therapeutic 
vaccination scheme. (f) Wild type (WT) mice were inoculated with 75.000 B16.OVA melanoma cells. 
Four and 9 days later immunization was performed using 20 g of mRNA lipoplexes in absence or 
presence of the IFNAR blocking antibody or isotype control (20 ug) (n = 6-8 mice/group). * p < 0,05 
(Mantel-Cox log-rank test). mRNA lipoplexes = OVA- coding messenger mRNA complexed to 
DOTAP/DOPE liposomes. 
2.5 TYPE I IFNS DAMPEN CYTOLYTIC T CELL RESPONSES TO INTRADERMAL 
AND INTRANODAL MRNA LIPOPLEX VACCINATION. 
As the route of immunization has a dramatic impact on the type of innate immune cells the 
mRNA lipoplexes encounter and thereby potentially also on the ensuing T cell response, we 
decided to evaluate the impact of type I IFNs on the cytolytic T cell response to intradermal and 
intranodal immunization with mRNA lipoplexes. mRNA lipoplexes also instigated a profound 
type I IFN response to intradermal (Figure 5a) and intranodal (Figure 5c) injection. In terms of T 
cell immunity, intradermal immunization with mRNA lipoplexes behaved much alike 
subcutaneous immunization, with the strength of the cytolytic T cell response shifting from near 
absent in wild type mice to virtually complete in Ifnar-/- mice (Figure 5b). In line with reports of 
the Thielemans32 and Sahin33 groups, intranodal immunization turned out to be by far the most 
potent route of immunization with strong cytolytic T cell responses now being evident in 
immunized wild type mice (Figure 5d). Nevertheless, even intranodal immunization was aided by 
IFNAR deficiency, as the cytolytic T cell response was even further enlarged in Ifnar-/- mice. 
Taken together, these data firmly demonstrate that type I IFNs dampen the strength of the 
cytolytic T cell response evoked by lipoplex-based mRNA vaccination, regardless of whether the 
mRNA lipoplexes are delivered subcutaneous, intradermal or intranodal. 
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Figure 5. Type I IFNs inhibit the induction of cytolytic T cells upon intradermal and intranodal delivery of 
mRNA lipoplexes. (a) IFN-
+/-luc mice
 
were intradermally injected with 10 µg of OVA mRNA lipoplexes 
complexed or PBS. In vivo bioluminescence was measured 6 hours post-injection.  Data are shown as 
mean ± SD of 3 mice. *** p < 0,001 (t-test). (b) Wild type (WT) and Ifnar
-/-
 mice were immunized with 
a two-week interval with 10 µg of mRNA lipoplexes. Two weeks after boost immunization, a mixture 
of CFSE-labelled cells pulsed with control (CFSE
low
) or OVA peptide (CFSE
high
) were adoptively 
transferred. Specific killing was measured 2 days later by flow cytometry. Killing percentages were 
calculated with the following formula: 100 - 100x ((CFSE
high
/CFSE
low
)
immunized mice
/(CFSE
high
/CFSE
low
)
mock-
mice
) of 5 mice per group. **** p < 0.0001 (t-test). (c) IFN-
+/-luc mice
 
were intranodally injected with 
10 µg of OVA mRNA lipoplexes or mock treated. In vivo bioluminescence was measured 6 hours post-
injection.  Data are shown as mean ± SD of 3 mice. *** p < 0,001 (t-test). (d) Wild type (WT) and 
IFNAR
-/-
 mice were immunized with a two-week interval with 10 µg of OVA mRNA lipoplexes and 
killing was performed as previously described. * p < 0,05 (t-test).  mRNA lipoplexes = OVA- coding 
messenger mRNA complexed to DOTAP/DOPE liposomes. 
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3. DISCUSSION 
Condensing mRNA into lipoplexes significantly improves the strength of the T cell response 
against the mRNA encoded antigen upon in vivo immunization. Nevertheless, the key innate 
host factors that determine the potency of lipoplex mRNA vaccines and their efficacy to instigate 
anti-tumour immunity have remained unresolved. Earlier, we have shown that type I IFNs are 
the most prominent cytokines secreted by DCs when incubated with mRNA lipoplexes14,15. As 
type I IFNs are major regulators of T cell immunity to viruses and to tumours, we decided to 
address their functional impact on the T cell response to mRNA lipoplex vaccines. Vaccination 
studies in Ifnar-/- mice revealed a dramatically increased priming of vaccine specific T cells in the 
absence of IFNAR signalling. These vaccine primed T cells acquired full effector function and 
efficiently eliminated target cells. When challenged with the highly aggressive B16 melanoma 
model, vaccinated Ifnar-/- mice benefited more from mRNA lipoplex vaccination compared to 
wild type mice in terms of increase in survival time to non-treated controls. Nevertheless, 
therapeutically vaccinated Ifnar-/- mice still succumbed earlier to B16 challenge when compared 
to vaccinated wild type mice. Ifnar-/- mice however lack spontaneous anti-tumour immunity, 
making direct comparisons between Ifnar-/- en wild type mice concerning the effects of 
vaccination on tumour control difficult to interpret. To avoid any confounding effects of genetic 
IFNAR deficiency on spontaneous versus vaccine elicited anti-tumour immunity, we therefore 
shifted to co-administration of an IFNAR blocking antibody at the time and spot of immunization 
in wild type mice.  
Blocking IFNAR at the vaccination site conferred a substantial survival benefit in response to 
both prophylactic and therapeutic vaccination, thereby establishing type I IFNs as host factors 
that severely hamper the efficacy of mRNA lipoplexes as anti-tumour vaccines.  
The exact mechanism by which type I IFNs exert their negative impact remains largely 
unresolved. Type I IFNs can affect the instigation of effector T cell immunity at multiple levels. 
First, as type I IFNs are potent antiviral cytokines that typically activate RNAses and block 
translation to prevent viral replication35, they might hamper T cell immunity to mRNA vaccines 
by lowering the amount of antigen expressed, a feature we have reported on using in vitro BM-
DCs incubated with mRNA lipoplexes14. Nevertheless, the impact of IFNAR deficiency on the 
mRNA expression level in vivo was very  limited and thus most likely does not constitute the 
major factor behind the dramatically improved cytolytic T cell response in Ifnar-/- mice. A 
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potential explanation is that type I IFNs exert their negative impact directly at the level of the T 
cell. Indeed, whereas type IFNs can clearly act as signal 3 cytokines that promote the 
differentiation of antigen primed CD8+ T cells into cytolytic effectors29, they can also block T cell 
proliferation and even instigate T cell apoptosis19-21. Which of these opposing effects prevails, 
depends on the kinetics of T cell exposure to type I IFNs17. If IFNAR triggering precedes TCR 
triggering, the T cell inhibitory properties prevail. In case of mRNA lipoplex vaccination, type I 
IFN release occurs rapidly – TLRs and other RNA sensing receptors can be triggered in the 
endosomal compartments even before the mRNA leaves the endosomes for translation – and 
most likely before DCs that have taken up the mRNA lipoplexes have reached the lymph nodes 
to present the antigen. Nevertheless, studies using mice selectively deficient in IFNAR in DCs or 
in T cells are required to shed further light at which stage type I IFNs exactly interfere with T cell 
immunity to mRNA lipoplexes.  
In summary, we have firmly established type I IFNs as host factors that negatively regulate the 
capacity of mRNA lipoplex vaccines to instigate cytolytic T cells upon subcutaneous, intradermal 
and intranodal administration. As type I IFN induction is inherent to IVT mRNAs, our findings can 
likely be extended to many other nano-formulations explored for mRNA vaccination. If so, 
strategies to prevent or reduce type I IFNs might be of great value to improve the clinical 
efficacy of mRNA vaccines. 
4. MATERIALS AND METHODS 
Mice 
Female wild type C57BL/6 mice were purchased from Janvier (Le Genest Saint Isle, France). OT-I 
mice carrying a transgenic CD8+ T cell receptor specific for the MHC I-restricted ovalbumin (OVA) 
peptide SIINFEKL were donated by Dr. Bart Lambrecht from Ghent University (Ghent, Belgium). 
Ifnar1-/-mice were bred at the breeding facility of the Vlaams Instituut voor Biotechnolgoy (VIB, 
Ghent, Belgium). C57BL/6 luciferase reporter mice (IFN-+/-luc) were bred at the Helmholtz 
Centre for Infection Research (HZI). All mice were 7-12 weeks old at the start of the experiment 
and maintained under specific pathogen-free conditions. Animals were treated according to the 
European guidelines for animal experimentation. All experiments were approved by the local 
ethical committee for animal experiments of Ghent University (Ghent, Belgium) or of the 
Helmholtz Center for Infection Research (Braunschweig, Germany). 
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Production of IVT mRNA 
The pGEM4Z-OVA-A64 and the pGEM4Z-EGFP-A64 plasmids were kindly donated by dr. David 
Boczkowski from Duke University (Durham, NY). The pBluescript-luc-A64 plasmid was provided 
by Dr. Joanna Rejman from Ghent University (Ghent, Belgium). All plasmids were propagated in 
E. coli competent cells (Stratagene, La Jolla, CA, USA) and purified using endotoxin-free QIAGEN-
tip 500 columns (Qiagen, Chatsworth, CA, USA). The pGEM4-OVA-A64 and pGEM4Z-EGFP-A64 
plasmids were linearized with SpeI (MBI Fermentas, St Leon-Rot, Germany), whereas the 
pBluescirpt-luc-A64 plasmid was linearized with DraI (MBI Fermentas, St Leon-Rot, Germany). 
Linearized plasmids were purified using a PCR purification kit (Qiagen, Venlo, The Netherlands) 
and RNA was transcribed using the T7 mMessage Machine Kit (Ambion, Austin, TX, USA) 
according to the manufacturer’s instructions. The in vitro transcribed mRNA was purified by 
lithium chloride precipitation. 
Immunizations and injections of mRNA lipoplexes 
Subcutaneous immunizations were performed in C57BL/6 mice twice at tail base in a 2 week 
interval. According to the experiment 10 or 20 μg of OVA-encoding mRNA was complexed with 
DOTAP/DOPE lipids in a N/P ratio of 1 (Avanti Polar Lipids, Alabaster, AL, USA) and injected in a 
total volume of 40 μl of 5% glucose water (Ambion, Life technologies, USA). For intranodal 
delivery of mRNA, C57BL/6 mice were anesthetized with ketamine (70 mg/kg; Ceva) and xylazine 
(10 mg/kg; Bayer). The inguinal lymph node was surgically exposed and injected with 10 µg RNA 
lipoplexes in a total volume of 15 µl. Subsequently, the wound was closed. For intradermal 
immunization, 10 µg of mRNA lipoplexes was injected into the ear dermis in a total volume of 20 
µl. Accordingly to the experiments, the total vaccine volume included 20 g of MAR1-5A3 (anti-
mouse IFNAR) or mouse IgG1 isotype control (both from Leinco Technologies, St. Louis, MO, 
USA). For in vivo measuring of mRNA expression levels wild type and Ifnar-/- mice were injected 
s.c. with 10 µg of luciferase encoded mRNA. mRNA expression levels were measured 8 hours 
after injection via in vivo biolumenescence. 
Flow cytometry 
All flow cytometric experiments were performed on a triple-laser (B-V-R) LSR-II (Becton 
Dickinson, San Jose, CA, USA) and analyzed with FlowJo (Treestar, OR). Cells were stained with 
α-CD16/CD32 (BD Biosciences, San Diego, CA, USA) to block non-specific FcR binding, and with 
Live/Dead Fixable Aqua stain (Invitrogen) to eliminate dead cells from analysis. Antibodies used 
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are α-CD8 PerCP, α- CD3 pacific blue, α-CD19 APC-Cy7, α-CD11c PerCP-Cy5.5, α-F4/80 APC (all 
BD Biosciences, San Diego, CA, USA) and MHC dextramer H-2 Kb/SIINFEKL-PE (Immudex, 
Copenhagen, Denmark). 
In vivo imaging of IFNβ induction 
Heterozygous luciferase reporter mice (IFN-+/-luc) were injected subcutaneously, with PBS, 10 
µg of OVA-mRNA complexed with DOTAP/DOPE liposomes at an N/P ratio of 1 (Avanti Polar 
Lipids, Alabaster, AL, USA), DOTAP/DOPE alone or naked OVA-mRNA in a total volume of 20 μl 
5% glucose water. Intradermal or intranodal injections were performed with 10 µg of mRNA 
lipoplexes at an N/P ratio of 1 (Avanti Polar Lipids, Alabaster, AL, USA), DOTAP/DOPE alone or 
naked OVA-mRNA in a total volume of 10-20 μl 5% glucose water. IFNβ induction was measured 
at 0, 3 and 6 hours after injection via in vivo biolumenescence.  
In vivo bioluminescence imaging 
For in vivo imaging, mice were injected intravenously with 150 mg/kg of D-luciferin 
(PerkinElmer, Waktham, MA, USA) in PBS and monitored using an IVIS lumina II imaging system. 
Photon flux was quantified using the Living Image 4.4 software (all from Caliper life sciences, 
Hopkinton, MA, USA). 
ELISPOT 
C57BL/6 mice were immunized twice with 20 µg of DOTAP/DOPE-complexed OVA-encoding 
mRNA in a two week interval. Two week after the boost immunization, spleens were isolated 
and passed through 70 μm nylon strainers (BD Biosciences, San Diego, CA, USA) to obtain single 
cell suspensions. Red blood cells were lysed using ACK red blood cell lysis buffer (BioWhittaker, 
Wakersville, MD, USA) and 2.5 x 105 cells were cultured for 24 hours on IFN-γ (Diaclone, 
Besançon, France) pre-coated 96-well plates in the presence of 10 μg/ml OVA peptides 
(Anaspec, Fremont, CA, USA). To quantify the amount of OVA-specific CD8+ and CD4+ T cells we 
pulsed the splenocytes with resp. 10 µg/ml MHC-I and MHC-II OVA peptides. Spots were 
analyzed according to the manufacturer’s instructions using ELISPOT reader. 
CD8+ T cell dextramer staining 
Mice were immunized twice with 20 µg of DOTAP/DOPE complexed OVA-encoding mRNA as 
described previously. Five days later, blood samples were taken and red blood cells were 
removed using ACK lysis buffer (BioWhittaker, Wakersville, MD, USA). Cells were stained with α-
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CD16/CD32 (BD Biosciences, San Diego, CA, USA), Live/Dead Fixable Aqua stain (Invitrogen), α-
CD8 PerCP, α- CD3 pacific blue, α-CD19 APC-Cy7 (all BD Biosciences, San Diego, CA, USA) and 
MHC dextramer H-2 Kb/SIINFEKL-PE (Immudex, Copenhagen, Denmark). 
In vivo T cell proliferation assay 
Two days before immunization OT-I cells were labelled with 5 µM carboxyfluorescein diacetate 
succinimedyl ester (CFSE; Invitrogen, Merelbeke, Belgium). Two million CFSE-labelled OT-I cells 
were i.v. injected into wild type and Ifnar-/- mice two days before immunization. Immunization 
was performed as previously described. Four days after immunization draining lymph nodes 
were isolated and CD8+ T cell division was analysed by flow cytometry. Cells were stained with α-
CD16/CD32 (BD Biosciences, San Diego, CA, USA), Live/Dead Fixable Aqua stain (Invitrogen), α-
CD8 PerCP, α- CD3 pacific blue, α-CD19 APC-Cy7 (all BD Biosciences, San Diego, CA, USA) and 
MHC dextramer H-2 Kb/SIINFEKL-PE (Immudex, Copenhagen, Denmark). 
In vivo killing assay 
Splenocytes from female wild type mice were pulsed with 1 µg/ml of MHC-I OVA peptide or HIV-
1 Gag peptide as a control before labeling with 5 µM or 0,5 µM CFSE (Invitrogen, Merelbeke, 
Belgium), respectively. Labelled cells were mixed at a 1:1 ratio, and a total of 1,5 x 107 mixed 
cells were adoptively transferred into immunized mice two weeks after boost. Splenocytes from 
host mice were analyzed two days later by flow cytometry after staining with -F4/80 (BD 
Biosciences, San Diego, CA, USA) to exclude auto-fluorescent macrophages. Percentage antigen-
specific killing was determined using the following formula: 100 – 100* ((% CFSEhi cells / % 
CFSElowcells)immunized mice /(% CFSEhi cells / % CFSElow cells)non-immunized mice. 
Tumour challenge 
For the prophylactic tumour experiments, immunized mice were inoculated s.c. in the flank with 
105 B16-OVA melanoma cells (VIB cell bank) in 200 µl PBS two weeks after boost immunization. 
Immunizations were performed as described above. Tumour growth was followed by measuring 
the tumour size index (TSI), i.e. the product of the largest perpendicular diameters, with a 
caliper. For assessment of therapeutic efficacy, 7.5 x 104 B16-OVA melanoma cells in 200 µl PBS 
were administered 4 days prior to immunization. Boost immunizations were given 2-5 days after 
priming. 
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6. SUPPLEMENTARY DATA 
 
Supplementary data S1. (a-b) Particle size and zetapotential of DOTAP liposomes and OVA-encoding 
mRNA lipoplexes at ratios nitogen/phosphate of 1 (N/P1) and N/P10 were measured using zetasizer 
software. (c) Luciferase expression was measured in wild type mice after s.c injection of 10 ug 
luciferase-encoding mRNA and luciferase-encoding mRNA lipoplexes at ratios N/P1 and N/P10. 8 
hours after injection luciferase accumulation was measured via in vivo bioluminescence.  Data are 
shown as mean ± SD of 3 mice. * p < 0,05 (unpaired t-test). (d) Wild type mice were immunized with 
20 µg OVA-encoding mRNA or OVA-encoding mRNA lipoplexes at both ratios N/P1 and N/P10. Two 
weeks later, mice were boosted with the same formulation. Spleens were isolated two weeks after 
boost immunization, and the number of OVA-specific interferon-γ spot-forming CD8
+
 and CD4
+
 T cells 
(SFC) was determined by enzyme-linked immunosorbent spot (ELISPOT). Data are shown as mean of 4 
mice per group. * p < 0.05 (Chi-square test). liposomes = DOTAP/DOPE lipids; mRNA lipoplexes = 
messenger RNA complexed to liposomes; N/P = Nitrogen/phosphate ratio.  
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Supplementary data S2. Luciferase expression was measured in wild type (WT) en Ifnar
-/-
 mice after s.c 
injection of 10 µg luciferase encoding mRNA lipoplexes at ratio N/P1. 8 hours after injection luciferase 
accumulation was measured via in vivo bioluminescence. Data are shown as mean ± SD of 10 mice; 
unpaired t-test. mRNA lipoplexes = OVA- coding messenger mRNA complexed to DOTAP/DOPE 
liposomes 
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9. ADDITIONAL DATA 
TYPE I IFNS EXERT THEIR NEGATIVE IMPACT ON VACCINE-EVOKED CD8+ T CELL 
RESPONSES AT THE LEVEL OF HEMATOPOIETIC AND STRUCTURAL CELLS. 
The exact mechanism by which type I IFNs exert their negative impact on the instigation of 
effector T cell immunity remains largely unresolved. Up to now, our research was performed in 
Ifnar-/- mice, which show IFNAR deficiency in all cell types. Although it is highly assumable that 
the negative effects of IFNAR signalling occur at the level of DCs and T cells, this has not been 
established yet. To verify what cell type - hematopoietic versus non-hematopoietic cells – are 
implicated in the T cell immunity dampening activity of type I IFNs, we created bone marrow 
chimera mice between Ifnar-/- and wild type mice. As a control, bone marrow was transferred 
from WT to WT mice and from Ifnar-/- to Ifnar-/- mice. Eight weeks after bone marrow transfer to 
the acceptor mice, the chimeric mice were vaccinated twice with OVA mRNA lipoplexes. Four 
days later, the percentages of OVA-specific CD8+ T cells were determined in the blood by 
tetramer staining (Figure A1). Control WT to WT and Ifnar-/- to Ifnar-/- chimeric mice displayed a 
similar profile as their WT and Ifnar-/- counterparts, with Ifnar-/- to Ifnar-/- mice showing 
significantly higher percentages of tetramer positive cells compared to WT to WT mice. 
Remarkably, WT to Ifnar-/- and Ifnar-/- to WT chimeric mice both displayed intermediate levels of 
OVA-specific CD8+ T cells, thus indicating that the negative impact of type I IFNs on the T cell 
response is exerted at the level of non-hematopoietic structural cells as well as hematopoietic 
cells. Further studies using T cell and DC conditional Ifnar-/- mice should help to further pinpoint 
the cell types that are targeted by the vaccine induced type I IFN.  
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Figure A1. Bone marrow chimeras between WT and Ifnar
-/-
 mice show the contribution of IFNAR 
signalling both at the level of hematopoietic cells and non-hematopoietic cells. WT and Ifnar
-/- 
mice 
were irradiated and reconstituted with bone marrow of either WT or Ifnar
-/- 
mice. Eight weeks after 
bone marrow transfer, mice received a prime and boost vaccination. Four days after the boost 
immunization, blood was collected and analysed to determine the percentages of OVA-specific CD8
+
 T 
cells. Means ± SD of 5 mice/group, * p < 0,05; ** p < 0,001 One way ANOVA. 
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1. INTRODUCTION 
1.1 REDUCING TYPE I IFN INDUCTION AT THE IMMUNIZATION SITE 
Earlier, we have shown that induced type I IFN signalling upon lipoplex-based immunization 
hampered antigen-specific CD8+ T cell priming1. Moreover, in the absence of type I IFN 
signalling, the evoked CD8+ T cells acquired full effector function and efficiently eliminated 
target cells. However, using a tumor model to validate these findings, it became clear that losing 
the endogenous anti-tumor activity of type I IFNs masked the negative effects of type I IFNs on 
the strength of the vaccine elicited anti-tumor response. To address the problem concerning the 
loss of crucial endogenous type I IFN activity, an IFNAR blocking antibody was co-administered 
at the site of immunization, resulting in prolonged survival rates in both a prophylactic as well as 
a therapeutic setting1. In the present study, we tested alternative strategies to circumvent type I 
IFN induction at the site of immunization without compromising the endogenous anti-tumor 
activity of type I IFNs. To this end, we modified the mRNA by the replacement of uridine and 
cytidine with pseudouridine and 5’ methylcytidine respectively. The incorporation of modified 
nucleotides in mRNA sequences has been shown to reduce the binding capacity of RNA to PRRs, 
resulting in weakened induction of inflammatory cytokines. 
1.2 PSEUDOURIDINE AND 5’ METHYLCYTIDINE 
Pseudouridine-5’ triphosphate (ψ-UTP) is found in structural RNAs such as transfer RNA (tRNA) 
and ribosomal RNA. ψ-UTP is an isomer of UTP in which the uracil is attached via carbon to 
carbon instead of a carbon to nitrogen bound (Figure 1a,b). 5-methyl-cytidine-5’-triphosphate 
(5-met-CTP) is a common post transcriptional modified CTP, present in many mRNA, micro RNA 
(miRNA) and tRNA in which the 5’ carbon is attached to an extra methyl group (Figure 1d). The 
insertion of both nucleotides into IVT mRNA has been evaluated in order to suppress innate 
immunity as well as to increase mRNA stability and translation efficacy2–4. 
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Figure 1. Chemical modification of uridine and cytidine. a) Uridine; b) Pseudo (ψ) uridine in which the 
uracil is attached via carbon to carbon instead of a carbon to nitrogen bound, resulting in a free 
amine group (red); c) Cytidine; d) 5’ Methyl-cytidine is a derivate of cytidine in which the cytosine is 
attached to an extra methyl group at the 5’ carbon. 
 
1.2.1 THE INCORPORATION OF MODIFIED NUCLEOTIDES REDUCES THE INTRINSIC 
ADJUVANT CHARACTER OF MRNA VACCINES. 
Due to the intrinsic adjuvant character of mRNA vaccines, clinical applications have so far been 
limited to therapeutic vaccination. However, recent studies showing that modified mRNA is less 
immunogenic initiated the use of mRNA for gene therapy2,5–7. Thus, replacing uridine and 
cytidine with 2’-thiouridine and 5’-methyl-cytidine synergistically decreased RNA recognition by 
TLR3, TLR7, TLR8 and RIG-I in human peripheral blood mononuclear cells (PBMCs)2,6. In line with 
this in vitro results, upon intravenous administration of modified mRNA, lower levels of pro-
inflammatory cytokines (IFNɣ, IL-12 and IFNα) were detected in the blood compared to 
unmodified RNA. This data confirmed that insertion of the modified nucleotides resulted in a 
weaker activation of the innate immune system upon in vivo administration2.  
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1.2.2 The incorporation of modified nucleotides results in increased antigen 
levels. 
Besides a reduced immune stimulatory capacity, the injection of modified mRNA obtained 
higher antigen levels compared to the injection of unmodified mRNA8,9. It is highly suggested 
that the increased antigen levels observed after transfection with modified mRNA are caused by 
enhanced stability rather than by improved translation efficacy. This hypothesis is supported by 
an in vitro study using a cell-free translation system revealing a decreased translation efficiency 
for all the tested mRNA modifications while the stability of the modified mRNA generally 
increased. Indeed, a higher resistance to hydrolysis and an increased base stacking was 
observed when uridine was replaced by pseudo-uridine10. This observation might explain the 
prolonged half-live of modified mRNA molecules2. Strikingly, at a cellular level, the translation 
efficiency appears to be influenced by the mRNA elicited anti-viral response. Thus, in contrast to 
the use of a cell-free systems, in vitro cell transfection data revealed increased translation levels 
for modified mRNA when compared to unmodified mRNA. This difference was caused by a 
reduced RIG-I and protein kinase R (PKR) activation by the modified mRNA8,11. Activation of PKR 
results in the phosphorylation of the eukaryotic translation initiation factor, eIF-2α, inhibiting 
translation initiation. In that way, making mRNA invisible for PKR might lead to an enhanced 
translation efficacy11.  
2. RESULTS 
Of note, earlier immunizations reported in this thesis were performed by subcutaneous 
injection. From this chapter on, the experiments will focus on intradermal injection as this 
immunization route showed stronger effector CD8+ T cell responses in a comparative study 
(data not shown). Furthermore, all experiments were performed using mRNA from a 
commercial source (TriLink Biotechnologies, USA) instead of homemade mRNA as used in 
chapter 4. This switch was made to guarantee mRNA purity and standard composition between 
all experiments. Preliminary data confirmed that the impact of type I IFNs on the CD8+ T cell 
responses to mRNA lipoplex vaccination was equal for subcutaneous and intradermal 
immunization. Furthermore, the negative impact of type I IFNs was shown to be fully 
independent of the source of mRNA (home-made or commercial).  
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2.1 TYPE I IFN INDUCTION BY MODIFIED MRNA LIPOPLEX VACCINE  
In order to verify the effect of mRNA modification (fully substitution of pseudo-UTP and  
5’methyl-CTP) on type I IFN responses, IFN-β+/Δβ-luc reporter mice were intradermally injected 
with 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) / 1,2-dioleoyl-sn-glycero-3-phospho-
ethanol amine (DOPE) lipoplexes comprising modified or unmodified mRNA. Three hours and six 
hours after injection, IFNβ induction was visualized via in vivo bioluminescence (Figure 2). A 
significant increase in IFNβ induction was observed in mice injected with unmodified mRNA 
lipoplexes. Unexpectedly, mice injected with modified mRNA lipoplexes also showed significant 
induction of type I IFNs, although visualy this induction is slightly weaker. However, no 
significance between modified and unmodified mRNA lipoplexes is quantified (p = 0,1574), 
although a visible decline is observed between both groups.  
 
Figure 2. Effects of unmodified and modified mRNA lipoplexes on type I IFN responses. IFN-β
+/Δβ-luc
 
reporter mice were i.d. injected with 7 µg of ovalbumine-mRNA lipoplexes or PBS in a total volume of 
20 µl. 3 hours (upper panel) and 6 hours (lower panel) after injection, type I IFN induction was imaged 
using in vivo bioluminescence. Data are shown as mean ± SEM of 3 mice. * p < 0,05;  ** p < 0,01; ns. 
3h p = 0,50; ns. 6h p = 0,1574 (One-way Anova test, post-hoc Fisher- LSD). Unmod., unmodified; 
mod.,  modified; p/s, photon/sec 
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Of note, as depicted in Figure 3, injection of free mRNA resulted in ten-fold IFNβ induction 
relative to equal amounts of mRNA complexed into mRNA lipoplexes. These data suggest that 
rather free mRNA is responsible for the induction of type I IFNs than the complexed part. 
 
 
Figure 3. Injection of uncomplexed mRNA induces ten-times strong IFNβ responses than lipoplex-
formulated RNA. IFN-β
+/Δβ-luc
 reporter mice were i.d. injected with 7 µg of unmodified and modified 
ovalbumine-mRNA lipoplexes or 7 µg naked (uncomplexed) mRNA in a total volume of 20 µl. 6 hours 
after injection, type I IFN induction was imaged using in vivo bioluminescence. Data are shown as 
mean ± SEM of 3 mice.  
2.2 ANTIGEN EXPRESSION LEVELS PRODUCED BY MODIFIED MRNA LIPOPLEX 
VACCINE  
To verify whether injection of modified mRNA (fully substitution of pseudo-UTP and  5’methyl-
CTP) lipoplexes results in improved antigen expression levels compared to their unmodified 
counterparts, luciferase-encoding mRNA lipoplexes were i.d. injected into the ear pinna. Eight 
hours later, the antigen levels were visualized via in vivo bioluminescence. As depicted in Figure 
4, injecting modified mRNA lipoplexes resulted in significantly higher antigen levels compared to 
the injection of unmodified mRNA. 
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Figure 4. Modifying the antigen-encoding mRNA improves antigen expression levels. Mice were i.d. 
injected with 7 µg of luciferase-encoding mRNA (modified or unmodified) complexed to DOTAP/DOPE 
or PBS (mock). 8 hours after injection, expression levels are measured using in vivo bioluminescence. 
Data are shown as mean ± SD of 3 mice. * < 0,05 (One-way Anova test). Unmod., unmodified; mod.,  
modified; p/s, photon/sec. 
 
2.3 CD8+ T CELL RESPONSE INDUCED BY MODIFIED MRNA LIPOPLEX VACCINE 
Considering the enhanced antigen expression levels generated by modified mRNA lipoplex 
formulations, we verified to what extent these properties would translate into an increased 
induction of CTL responses. In a first instance, we assayed the initial priming of antigen-specific 
CD8+ T cells via an OT-I proliferation assay. To this end, CFSE-labelled OT-I T cells were 
adoptively transferred to wild type recipient mice, which were subsequently immunized with 
unmodified or modified mRNA lipoplexes. Three days post immunization, the draining lymph 
nodes were dissected and OT-I T cell proliferation was analysed by flow cytometry (Figure 5a). 
As shown in Figure 5b, both formulations evoked strong CD8+ T cell proliferation. However, no 
significant differences were observed between the two immunized groups.  
In a next step, we addressed the functional properties of the induced CD8+ T cell response via an 
in vivo killing assay. To this end, two weeks after the booster immunization, mice were 
challenged with a 1:1 ratio of OVA peptide-pulsed CFSEhi splenocytes and non-pulsed CFSElow 
splenocytes. Two days later, the spleens were dissected and the ratio of target cells versus non-
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target cells was analysed by flow cytometry. As shown in Figure 5c, moderately weak CTL 
responses were observed with both formulations, so no improvement  for modified mRNA 
lipoplexes was measured.  
Based on the results of the reporter mice, showing strong – however, slightly reduced – IFNβ 
induction in response to the injection of modified mRNA lipoplexes, enhanced CTL responses in 
Ifnar-/- mice, relative to wild type mice might be expected. To further evaluate this hypothesis, 
an in vivo killing assay was performed, showing stronger killing capacities in Ifnar-/- mice, 
compared to wild type mice in response of  intradermal immunization of modified mRNA 
lipoplexes (Figure 5e). Of note, when compared to unmodified mRNA (Figure 5d), the difference 
between wild type mice and Ifnar-/- mice immunized with modified mRNA, tends to be smaller. 
However, a direct competitive experiment needs to be performed to draw any conclusion about 
this. Still, we can conclude that we did not achieve an improvement of the vaccine efficacy of 
mRNA lipoplexes by modifying the mRNA encoding device.  
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Figure 5. Modifying mRNA has no positive impact on CD8 T cell priming or effector function. a-b) Two 
days prior to immunization CFSE-labelled OT-I cells were adoptively transferred to wild type mice. 
Intradermal immunization was performed at the ear pinna with 7 µg of unmodified or modified 
ovalbumine (OVA) mRNA lipoplexes or free mRNA as a negative control. Three days after 
immunization, inguinal lymph nodes were isolated and CD8
+
 T cell proliferation was analysed by flow 
cytometry. Percentage CD8 T cells above the 4
th
 division is displayed. Data are shown as mean of 2-3 
mice (One-way Anova). c) Wild type (WT) mice were immunized with a two-week interval with 7 µg 
unmodified and modified OVA mRNA lipolexes. Two weeks after boost immunization, a mixture of 
CFSE-labelled cells pulsed with control (CFSE
low
) or OVA peptide (CFSE
high
) were adoptively 
transferred. Specific killing was measured 2 days later by flow cytometry. Data are presented as 
means of 100 -100x ((CFSE
high
/CFSE
low
)
immunized mice
/(CFSE
high
/CFSE
low
)
mock-mice
) of 4-5 mice per group. 
(One-way Anova) d) Wild type (WT) and Ifnar
-/-
 mice were immunized with a two-week interval with 
modified OVA mRNA lipolexes. Specific killing was measured as in (c). Data are shown of mean ± SD of 
5 mice per group.* p < 0,05 (One-way anova). e) Wild type (WT) and Ifnar
-/-
 mice were immunized 
  
156 | Results 
with a two-week interval with unmodified OVA mRNA lipolexes. Specific killing was measured as in (c). 
Data are shown of mean ± SD of 5 mice per group.* p < 0,05 (One-way anova). 
3. DISCUSSION 
We reported earlier that type I IFN induced by mRNA lipoplex vaccination hampers the efficacy 
of the mRNA vaccine1. In here, we analysed the impact of modifying the vaccine mRNA, by fully 
replacing UTP and CTP with the chemically modified pseudo-UTP and  5’methyl-CTP, on vaccine 
efficacy and type I IFN induction. Our results showed that quite unexpectedly the administration 
of modified mRNA lipoplexes did not significantly reduce the induction of type I IFNs, however a 
tendency could be observed. One possible explanation could be that the amount of free mRNA 
in the mRNA lipoplex formulation is too big to be masked by modification. Although we detected 
significantly enhanced antigen expression levels due to the modification of the mRNA, no impact 
on the capacity to elicit CD8+ T cell responses was measured. Our analysis of the induced CD8+ T 
cell response in wild type and Ifnar-/- mice confirmed that in spite of the modified mRNA format, 
the vaccination efficacy is still hampered by induced type I IFNs.  
4. MATERIALS AND METHODS 
Mice 
OT-I mice carrying a transgenic CD8+ T cell receptor specific for the MHC I-restricted ovalbumin 
(OVA) peptide SIINFEKL were donated by Dr. Bart Lambrecht from Ghent University (Ghent, 
Belgium). Ifnar1-/- mice, Ifnar1+/+ mice and balbc luciferase reporter mice (IFN-+/-luc) were bred 
at the breeding facility of the Vlaams Instituut voor Biotechnolgoy (VIB, Ghent, Belgium). All 
mice were 7-12 weeks old at the start of the experiment and maintained under specific 
pathogen-free conditions.  
mRNA lipoplexes 
mRNA was purchased from TriLink Biotechnologies (Sandiego, USA) : 5-MeC-ψU (modified) 
Firefly luciferase, L-6107; (unmodified) Firefly luciferase, L-6307; OVA (unmodified) L-6328; 5-
MeC-ψU (modified) OVA, L-3128. Both unmodified and modified RNA is ARCA capped. The UTP 
and CTP nuclotides in the modified mRNA molecules are fully substituted by pseudo-UTP and 5’-
 157 | Results 
methyl-cytidine. mRNA was complexed to 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) 
and 1,2-dioleoyl-sn-glycero-3-phosphoethanol-amine (DOPE) into lipoplexes at 
Nitrogen/Phosphate 1 (Avanti Polar Lipids, Alabaster, AL, USA). Lipoplexes were injected in 5% 
glucose water. 
In vivo imaging of IFNβ induction 
Heterozygous luciferase reporter mice (IFN-+/-luc) were injected intradermally, with PBS, 7 µg 
of OVA-mRNA (L-6328 en L-3128, TriLink) complexed with DOTAP/DOPE liposomes in a total 
volume of 20 μl 5% glucose water. IFNβ induction was measured at 0, 3 and 6 hours after 
injection via in vivo biolumenescence. For in vivo imaging, mice were injected intravenously with 
150 mg/kg of D-luciferin (PerkinElmer, Waktham, MA, USA) in PBS and monitored using an IVIS 
lumina II imaging system. Photon flux was quantified using the Living Image 4.4 software (all 
from Caliper life sciences, Hopkinton, MA, USA). 
In vivo expression  
Ifnar+/+ mice were intradermally injected with 7 µg of Luciferase encoded mRNA (6107 and L-
6307, TriLink) complexed with DOTAP/DOPE liposomes in a total volume of 20 μl 5% glucose 
water. Luciferase expression levels were measured 8 hours after injection via in vivo 
biolumenescence. For in vivo imaging, mice were injected intravenously with 150 mg/kg of D-
luciferin (PerkinElmer, Waktham, MA, USA) in PBS and monitored using an IVIS lumina II imaging 
system. Photon flux was quantified using the Living Image 4.4 software (all from Caliper life 
sciences, Hopkinton, MA, USA). 
In vivo CD8+ T cell proliferation  
Two days before immunization OT-I cells were labelled with 5 µM carboxyfluorescein diacetate 
succinimedyl ester (CFSE; Invitrogen, Merelbeke, Belgium). Two million CFSE-labelled OT-I cells 
were i.v. injected into Ifnar+/+ mice two days before i.d. immunization with 7 µg of OVA-mRNA 
(L-6328 en L-3128, TriLink) complexed with DOTAP/DOPE liposomes in a total volume of 20 μl 
5% glucose water. Three days after immunization draining lymph nodes were isolated and CD8+ 
T cell division was analysed by flow cytometry. Cells were stained with α-CD16/CD32 (BD 
Biosciences, San Diego, CA, USA), Live/Dead Fixable Aqua stain (Invitrogen), α-CD8 PerCP, α- CD3 
pacific blue, α-CD19 APC-Cy7 (all BD Biosciences, San Diego, CA, USA) and MHC dextramer H-2 
Kb/SIINFEKL-PE (Immudex, Copenhagen, Denmark). 
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In vivo killing assay 
Splenocytes from female wild type mice were pulsed with 1 µg/ml of MHC-I OVA peptide or HIV-
1 Gag peptide as a control before labeling with 5 µM or 0,5 µM CFSE (Invitrogen, Merelbeke, 
Belgium), respectively. Labelled cells were mixed at a 1:1 ratio, and a total of 1,5 x 107 cells 
mixed cells were adoptively transferred into immunized mice two weeks after boost. 
Immunization was performed by injection of 7 µg of OVA-mRNA (L-6328 en L-3128, TriLink) 
complexed with DOTAP/DOPE liposomes in a total volume of 20 μl 5% glucose water. 
Splenocytes from host mice were analyzed two days later by flow cytometry after staining with 
-F4/80 (BD Biosciences, San Diego, CA, USA) to exclude auto-fluorescent macrophages. 
Percentage antigen-specific killing was determined using the following formula: 100 – 100* ((% 
CFSEhi cells / % CFSElowcells)immunized mice /(% CFSEhi cells / % CFSElow cells)non-immunized mice. 
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CHAPTER 6.  
ARGININE-RICH PEPTIDE BASED MRNA 
NANOCOMPLEXES EFFICIENTLY INSTIGATE T 
CELL IMMUNITY  
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Abstract 
To-date, the mRNA delivery field has been heavily dominated by lipid-based systems. Reports on 
the use of non-lipid carriers for mRNA delivery in contrast are rare in the context of mRNA 
vaccination. In this paper, we have explored the potential of a CPP containing the amphipathic 
RALA motif, to deliver antigen- encoding mRNA to the immune system. RALA condensed mRNA 
into nanocomplexes that displayed acidic pH-dependent membrane disruptive properties. RALA 
mRNA nanocomplexes enabled mRNA escape from endosomes and thereby allowed expression 
of mRNA inside the DC cytosol. RALA mRNA nanocomplexes elicited potent cytolytic T cell 
responses against the antigenic mRNA cargo and showed superior efficacy compared to a 
standard lipid-based mRNA vaccine formulation.  
1. INTRODUCTION  
CD8+ cytolytic T cells have the unique potential to destroy virus infected cells and cancer cells. 
Cytolytic T cells are typically elicited against antigens present in the cytosol, which are processed 
by the proteasome and loaded onto nascent MHCI complexes for presentation to CD8+ T cells. 
Vaccines based on recombinant protein antigens fail to access this cytosolic route of antigen 
processing and thereby yield poor cytolytic T cell responses. Conversely, nucleic acid-based 
vaccines display a high potential to elicit cytolytic T cells provided they support the expression of 
adequate amounts of antigen in the cytosol of DCs, the most potent antigen presenting cells. 
Within the field of nucleic acid-based vaccination, mRNA has now outcompeted pDNA as the 
molecule of choice to deliver antigenic information due to its superior safety profile, its higher 
capacity to transfect non-dividing cells and its amenability to GMP production1-5. Over the past 
years, preclinical and clinical studies have highlighted the potential of antigen-encoding mRNA 
to elicit T cell immunity upon intradermal6 and intranodal immunization7,8. Nonetheless, these 
studies have also unmasked the limitations of naked mRNA vaccines and have emphasized the 
necessity to develop formulation strategies that can improve the potency of current mRNA 
vaccines. Packing the vaccine mRNA into nanoparticulate carriers constitutes an interesting 
avenue to achieve this goal as nanocarriers can protect the mRNA from fast degradation as well 
as selectively target DCs. To date, the mRNA delivery field has been heavily dominated by lipid-
based systems6,9-12. Reports on the use of non-lipid carriers for mRNA delivery in contrast are 
scarce. Moreover, virtually all polymeric carriers have been developed to deliver plasmid DNA 
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(pDNA) or small interfering RNA (siRNA) and perform very poor in the context of mRNA 
vaccination9,13. This failure of cationic polymers to deliver mRNA has been attributed to a too 
stringent binding of the mRNA to the cationic polymer along with an ineffective endosome-to-
cytosol translocation. In a pioneering paper, Bettinger et al. demonstrated that the use of low 
molecular weight cationic polymers diminishes the strength of interaction between carrier and 
mRNA to such an extent that efficient mRNA expression can be achieved provided an endosome 
disrupting agent is added14. Carriers suited for mRNA vaccination thereby should meet two 
major requirements. First, they need to bind mRNA with such strength that nanocomplexes are 
formed but ribosomal binding upon cytosolic delivery is not compromised. Second, they need to 
be endowed with endosome disrupting properties to translocate their mRNA cargo to the 
cytosol. Based on these premises, we speculated that cationic CPPs might constitute excellent 
vehicles for mRNA delivery as they combine lower charge densities with excellent membrane 
disruptive abilities. CPPs have been intensively exploited to deliver drugs, proteins, pDNA and 
siRNA to the cellular cytosol15-17 but have remained remarkably unexplored to deliver mRNA. 
Within the broad variety of CPPs, peptides containing the amphipathic RALA motif have 
emerged as particularly promising for systemic delivery of pDNA and siRNA because they 
selectively attack endosomal membranes and thereby display reduced toxicity18-20. 
In this study, we have explored the potential of RALA to deliver antigen-encoding mRNA to the 
immune system. RALA condensed mRNA into nanocomplexes that displayed pH-dependent 
membrane disruptive properties and efficiently translocated their mRNA cargo from endocytic 
vesicles to the cytosol. RALA mRNA nanocomplexes elicited potent cytolytic T cell responses in 
vivo against the antigenic mRNA cargo and showed superior efficacy in doing so compared to a 
standard lipid-based mRNA vaccine formulation.  
2. RESULTS  
2.1 CHARACTERIZATION OF RALA MRNA NANOCOMPLEXES  
The sequence and secondary structure of RALA are shown in Figure 1a. At acidic pH, RALA 
displays an amphipathic α-helical structure with all hydrophilic arginine residues facing one side 
and all hydrophobic leucine residues facing the other side. This amphipathic organization 
enables RALA to complex nucleic acids electrostatically and to intercalate into endosomal 
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membranes19. To address the capacity of RALA to condense mRNA into particles, we mixed 
increasing amounts of RALA with a fixed amount of mRNA and determined particle size by 
dynamic light scattering (DLS) and particle ζ-potential by electrophoretic mobility 
measurements, therefore we tested tree different N/P ratios. The N/P ratio represents the 
molar ratio of positively charged nitrogen atoms in the peptide to negatively charged 
phosphates in the mRNA backbone. At N/P 1, a mean hydrodynamic diameter of 144 nm was 
measured while at higher N/P ratios, the hydrodynamic diameter decreased to 89 nm (N/P 5) 
and 91 nm (N/P 10) (Figure 1b). The ζ-potential shifted from a negative value of – 6.6 at N/P 1 to 
respectively +14.6 and +26.3 at N/P 5 and at N/P 10, in line with an increasing amount of RALA 
incorporated into the complexes at higher N/P ratios (Figure 1c). Nanoparticle formation was 
confirmed by transmission electron microscopy (TEM) (Figure 1d). The amount of mRNA 
incorporated into the RALA-mRNA nanocomplexes increased with increasing N/P ratios, ranging 
from a mere 5 % at N/P 1, up to 88 % at N/P 10 (Figure 1e).   
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Figure 1. Characterization of RALA mRNA nanocomplexes. (a) RALA sequence and secondary structure. 
Arginine residues (R) are shown in blue, Leucine and Alanine residues in red. (b) Hydrodynamic 
diameter and (c) ζ-potential of RALA mRNA nanocomplexes at N/P 1, N/P 5 and N/P 10. (d) TEM 
images of RALA mRNA nanocomplexes at N/P 10. (e) Encapsulation efficiency of mRNA into RALA 
mRNA nanocomplexes as a function of the N/P ratio. Measurements are shown as mean (n=3) ± SD. 
2.2 PH DEPENDENT HEMOLYTIC ACTIVITY OF RALA MRNA NANOCOMPLEXES 
ENABLE MRNA EXPRESSION 
The most appealing property of RALA is its capacity to selectively disrupt membranes at acidic 
pH. This feature is illustrated in Figure 2a, showing RALA-induced hemolysis of chicken red blood 
cells (RBC) at neutral pH (pH 7,4) and at acidic pH (pH 5,6). To address whether this critical 
a 
b c 
d e 
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feature of RALA is retained upon mRNA binding, we performed an identical hemolysis assay, 
using mRNA complexed RALA. While little hemolysis was evident at N/P 1, RALA mRNA 
nanocomplexes did instigate significant hemolysis at N/P 5 and especially at N/P 10 (Figure 2b). 
Furthermore, levels of hemolysis were strongly elevated by lowering the pH, thereby 
demonstrating that RALA indeed retains its pH-dependent membrane disruptive properties even 
when complexed into mRNA nanocomplexes. To further verify to what extent this membrane 
disruptive feature of RALA mRNA complexes may enable mRNA expression inside DCs, we 
complexed mRNA encoding eGFP into RALA mRNA nanocomplexes. DC2.4 cells were incubated 
with free mRNA or with RALA mRNA nanocomplexes at respectively N/P 1, N/P 5 and N/P 10 for 
4 hours. The amount of mRNA delivered was kept constant in these experiments. Flow 
cytometric analysis revealed no eGFP expression upon incubation of DC2.4 cells with free mRNA 
or with RALA mRNA nanocomplexes at N/P 1 – at which we demonstrated most mRNA to be in a 
free, non-complexed status. Conversely, RALA mRNA nanocomplexes supported eGFP 
expression in approximately 35% of all cells at N/P 5 and at N/P 10 (Figure 2c). Promoting 
endosomal disruption by addition of chloroquine – an endosomal disrupting agent did not 
significantly augment the transfection efficiency of the RALA mRNA nanocomplexes (Figure 2d). 
This indicates that RALA by itself is fully competent to translocate its mRNA cargo to the cytosol. 
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Figure 2. pH dependent hemolytic activity of RALA mRNA nanocomplexes enable mRNA expression. 
Hemolytic activity on chicken RBCs at respectively pH 7.4 and pH 5.6 of (a) different amounts of RALA, 
according to amount applied for the three different ratios displayed in Fig.2 b. (b) 200 ng RNA 
complexed to 0,29 µg, 1,45 µg and 2,9 µg of RALA to form polyplexes of resp. N/P 1, N/P 5 and N/P 
10. Measurements are shown as mean (n=6) ± SD. (c) Transfection efficiencies as determined by the 
percentage of DC2.4 DCs expressing reporter eGFP mRNA after incubation with free mRNA or RALA-
mRNA nanocomplexes at N/P 1, 5 and 10. Measurements are shown as mean (n =3)  ± SD, ** p < 
0,01. (d) Transfection efficiencies as determined by the percentage of DC2.4 DCs expressing reporter 
eGFP mRNA after incubation with free mRNA or RALA-mRNA nanocomplexes at N/P 10 in absence or 
presence of chloroquine. Data are shown as mean (n=3) ± SD 
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2.3 IMMUNOGENICITY OF RALA MRNA NANOCOMPLEXES  
To determine the capacity of RALA mRNA nanocomplexes to prime CD8+ T cells, an OT-I 
proliferation assay was performed whereby C57BL6 mice were immunized with RALA complexed 
to mRNA encoding the model antigen ovalbumin (OVA). T cell priming was assessed by flow 
cytometric quantification of the proliferation of CD8+ OT-I T cells. An overview of the flow 
cytometry gating strategy is given in Figure S1. Figure 3a shows the flow cytometry plots and 
Figure 3b the percentages of OT-I T cells that have divided upon immunization with free mRNA 
or mRNA complexed with RALA at N/P 1, N/P 5 and N/P 10. Strong CD8+ T cell proliferative 
responses were observed only upon immunization with N/P 5 and N/P 10 mRNA RALA 
nanocomplexes.  
The incorporation of modified nucleosides, pseudo-uridine and 5-methylcytidine, into mRNA has 
been shown to improve mRNA expression in vivo and to diminish the strong innate immune 
activation evoked by unmodified mRNA21,22. To determine the optimal mRNA format in case of 
RALA-mediated mRNA vaccination, we compared the T cell response elicited by immunization 
with unmodified or pseudo-uridine/5-methyl-cytidine modified mRNA complexed to RALA. In 
these experiments, N/P 10 was selected as this N/P ratio allowed the best complexation of 
mRNA and enabled efficient CD8+ T cell priming. Priming of vaccine specific T cell responses was 
analysed by quantifying OT-I T cell proliferation. Representative flow cytometry plots are given 
in Figure 3c. Figure 3d shows the percentages and Figure 3e the total number of OT-I T cells 
having divided over 4 times. These data indicated that when complexed to RALA, modified OVA 
mRNA is far superior in eliciting OT-I T cell proliferation compared to unmodified mRNA.  
To determine whether the increased T cell proliferation following immunization also provoked 
cytolytic activity, an in vivo killing assay was performed. In such assay, immunized mice are 
challenged with 1/1 ratio of differentially CFSE-labelled target cells and non-target cells. Two 
days after challenge, the ratio of both populations represents a direct measure of the antigen-
specific cytolytic T cell activity. Vaccination with RALA-complexed modified OVA mRNA killed 
virtually all target cells, whereas no target cell killing was observed upon vaccination with RALA-
complexed unmodified OVA mRNA (Figure 3f,g). This higher immunogenicity of modified mRNA 
over unmodified mRNA is remarkable, as modified mRNAs have been developed by the gene 
therapy field exactly to avoid immune responses against the encoded protein21,22. These data 
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thus indicate that RALA has intrinsic immune activating properties on its own – a feature 
possibly related to RALA’s capacity to disturb endosomal membranes - thereby obviating the 
need for innate recognition of the mRNA to trigger immune activation.  
In order to validate the relative strength of RALA mRNA nanocomplexes in eliciting cytolytic T 
cell immunity, we performed a direct comparison with a more conventional lipoplex 
DOTAP/DOPE-based mRNA vaccine, the current benchmark for pre-clinical lipid-based mRNA 
vaccination. As shown in Figure 4, the combination of RALA with modified mRNA resulted in a far 
more pronounced antigen-specific killing of target cells, compared to mRNA lipoplexes 
formulated with modified or unmodified mRNA.  
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Figure 3. Immunogenicity of RALA mRNA nanocomplexes. (a,b) Flow cytometric analysis of OT-I T cell 
proliferation to immunizations with RALA mRNA nanocomplexes as a function of the N/P ratio 
applied. (a) Histograms showing the proliferation of CFSE labelled OVA-specific OT-I T cells in 
response to intradermal immunization with RALA OVA mRNA nanocomplexes. (b) Percentages of 
divided OT-I T cells in response to intradermal injection of PBS, non-complexed OVA mRNA and mRNA 
OVA nanocomplexes. Measurements are shown as mean (n =3) ± SD, *** p < 0.001). (c,e) Flow 
cytometric analysis of OT-I T cell proliferation in response to intradermal immunization with RALA 
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complexed unmodified OVA mRNA or pseudo-uridine and 5-methylcytidine modified OVA mRNA (N/P 
10, 7 µg of mRNA). (c) Histograms showing the proliferation of CFSE labelled OVA-specific OT-I T cells. 
Quantification of the percentage (d) and absolute numbers (e) of dividing OT-I T cells. Measurements 
are shown as mean (n =4) ± SD, *** p < 0.001. (f,g) Flow cytometric analysis of antigen-specific killing 
of target cells in response to prime and boost vaccination with RALA complexed unmodified OVA 
mRNA or pseudo-uridine and 5-methylcytidine modified OVA mRNA ( N/P 10,  7 µg of mRNA). (f) 
Histogram plots showing the presence of CFSE
hi
 target cells and CFSE
lo
 non-target cells in spleen of 
immunized mice. (g) Graph showing the percentage of antigen-specific killing of target cells. Data are 
reported as means (n = 4) ± SD, *** p < 0.001 
 
 
Figure 4. Cytolytic T cell responses following RALA-based versus lipid-based mRNA vaccination. 
Quantification of antigen specific killing induced by prime and boost vaccination with OVA mRNA 
complexed to RALA (N/P 10, 7 µg of mRNA) or to DOTAP/DOPE liposomes (N/P 1, 7 µg of mRNA). 
Measurements are shown as mean (n =4) ± SD, ** p < 0.01. 
2.4 NON-AMPHIPATHIC CATIONIC PEPTIDE VARIANTS: CHARACTERIZATION OF 
PEPTIDE MRNA NANOCOMPLEXES 
Having established the capacity of RALA to efficiently deliver an antigenic mRNA cargo to the 
immune system, we aimed to delineate to what extent the immunogenic properties of RALA 
mRNA nanocomplexes depend on RALA’s amphipathic α-helical nature. To this end, we designed 
two additional arginine-rich peptides that contain identical numbers of arginine residues as 
RALA on a molar basis but lack RALA’s hydrophobic residues. In the first peptide (named RGSG 
hereafter), the RALA motif was replaced by a hydrophilic RGSG motif. In the second peptide 
(named RRRR hereafter), the hydrophobic alanine and leucine residues of RALA were omitted, 
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resulting in a stretch of 7 arginine residues. Peptide sequences and predicted peptide secondary 
structures are depicted in Figure 5a. Both peptides lack RALA’s amphipathic α-helical structure 
as they do not contain hydrophobic residues. RGSG has a random-coil like structure, while RRRR 
forms a short α-helical structure to minimize electrostatic repulsion between the adjacent 
cationic arginine residues.  
First, we assessed the impact of these sequence modifications on the capacity of the respective 
peptides to disrupt membranes by performing a hemolysis assay. Disturbance of the 
amphipathic α-helical structure of RALA abrogated hemolytic activity, with RGSG and RRRR 
clearly failing to lyse RBCs regardless of pH (Figure 5b). Yet, due to their cationic arginine 
residues, RGSG and RRRR were still capable of condensing the mRNA into nanocomplexes. 
However, when compared to RALA, the dimensions of RGSG and RRRR mRNA nanocomplexes 
were strongly influenced by the N/P ratio applied (Figure 5c). Particle size for RGSG mRNA 
nanocomplexes peaked to around 600 nm at N/P 5 and subsequently declined to 150 nm at N/P 
10. In case of RRRR mRNA nanocomplexes, particle sizes ranged from 140 nm at N/P 1 over 200 
nm at N/P 5 up to 1050 nm at N/P 10. RGSG and RRRR mRNA nanocomplexes also showed a 
different surface charge evolution with increasing N/P ratios. Whereas RALA mRNA 
nanocomplexes robustly shifted their ζ-potential from negative to positive values at higher N/P 
ratios, the shift in ζ-potential was far less pronounced for RGSG and RRRR mRNA nanocomplexes 
(Figure 5d). Instead, RGSG mRNA nanocomplexes adopted a near neutral charge at N/P 5 and at 
N/P 10, whereas RRRR mRNA nanocomplexes remained negatively charged even at N/P 10. 
Finally, in order to compare the capacities of RALA, RGSG and RRRR to encapsulate mRNA into 
nanocomplexes, we measured the amount of non-encapsulated mRNA (Figure 5e). Also here, 
RALA was more efficient at encapsulating mRNA even at the low N/P 1 ratio. However, at N/P 
10, all peptides succeeded in encapsulating over 75% of the added mRNA. Consequently, N/P 10 
was selected for all subsequent experiments.  
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Figure 5. Characterization of RGSG and RRRR based mRNA nanocomplexes. (a) Sequences and 
secondary structures of RALA, RGSG and RRRR peptides, based on the de novo PEP-FOLD peptide 
prediction server. Arginine residues (R) are shown in blue, Leucine and Alanine residues in red, serine 
and glycine in green. (b) Graph depicting the hemolytic activity of equivalent amounts of RALA, RGSG 
and RRRR at pH 7.4 and at pH 5.6. (c) Hydrodynamic diameter (nm) of RALA, RGSG and RRRR peptide 
mRNA nanocomplexes at the indicated N/P ratios. (d) ζ-potential of RALA, RGSG and RRRR peptide 
mRNA nanocomplexes at the indicated N/P ratios. (e) Encapsulation efficiencies of mRNA into 
respectively RALA, RGSG and RRRR mRNA nanocomplexes as a function of the indicated N/P ratios. 
The percentage mRNA encapsulated was calculated as 100% - % free mRNA. Measurements are 
shown as mean (n =3) ± SD. 
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2.5 LACK OF T CELL PRIMING CAPACITY OF RGSG AND RRRR MRNA 
NANOCOMPLEXES 
To verify to what extent the loss of the amphipathic nature of RSGS and RRRR affect their 
capacity to prime CD8+ T cell responses against the mRNA encoded antigen, we complexed 
modified OVA-encoding mRNA with the respective peptides. All nanocomplexes were generated 
at a ratio of N/P 10 as this ratio was most efficient in mRNA complexation for RGSG and RRRR as 
well as for RALA. The priming activity of the mRNA nanocomplexes was assayed on the basis of 
the in vivo proliferation of adoptively transferred CD8+ OT-I T cells as before. RGSG and RRRR 
OVA mRNA nanocomplexes failed to prime substantial CD8+ T cell responses (Figure 6a), thereby 
indicating RALA has unique features that mediate its effectiveness as a carrier for mRNA 
vaccination. 
To address whether the failure of RGSG and RRRR mRNA nanocomplexes to elicit CD8+ T cell 
reactivity might be traced back to an insufficient antigen expression in DCs, we co-incubated 
DC2.4 DCs with eGFP-encoding mRNA complexed to either RALA, RGSG or RRRR. The results 
from flow cytometry (Figure 6b) as well as from confocal imaging (Figure 6c,d) confirm the 
efficacy of RALA-based transfection, as well as the failure of RGSG and RRRR mRNA 
nanocomplexes to enable eGFP expression in DC2.4 cells. 
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Figure 6. The lack of T cell priming capacity of RGSG and RRRR modified mRNA nanocomplexes (a) Flow 
cytometric analysis of OT-I T cell proliferation in response to intradermal immunization with 
respectively RALA, RGSG and RRRR OVA modified mRNA nanocomplexes. The graph shows the 
percentages of OT-I T cells having undergone over 4 divisions.  Measurements are shown as mean (n 
=4) ± SD, **** p < 0.0001. (b) Flow cytometric analysis of eGFP expression by DC2.4 DCs incubated 
with non-complexed eGFP modified mRNA and eGFP mRNA complexed to respectively RALA at N/P 
10. (n=5) (c) Confocal imaging analysis of eGFP expression in DC2.4 dendritic cells incubated with 
RALA eGFP modified mRNA nanocomplexes. (d) Quantification of eGFP expression upon transfection 
of DC2.4 DCs with RALA, RGSG and RRRR modified mRNA nanocomplexes. Measurements are shown 
as means ± SD, * p < 0.05. 
2.6 RALA, RGSG AND RRRR DIFFERENTIALLY FACILITATE THE UPTAKE AND 
ENDOSOMAL ESCAPE OF THE MRNA CARGO 
The differential capacities of RALA, RGSG and RRRR to transfect cells and to prime CD8+ T cell 
responses in vivo might reflect a differential uptake of the mRNA nanocomplexes and/or a 
differential capacity of the peptides to facilitate mRNA escape to the cytosol after endocytosis. 
In order to verify the uptake and intracellular fate of the mRNA cargo, mRNA was fluorescently 
labelled with Cy3b. Flow cytometric analysis showed significant differences in the percentages of 
DC2.4 DCs that had bound and/or internalized the respective peptide mRNA nanocomplexes 
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(Figure S2a). Whereas 72% of DC2.4 cells stained Cy3b positive after incubation with RALA Cy3b 
mRNA, this percentage dropped to a mere 7% for RGSG Cy3b mRNA and an intermediate 52% 
for RRRR Cy3b mRNA. Analysis of the mean fluorescence intensity revealed a similar trend with 
RALA enabling the strongest mRNA uptake, RGSG the lowest and RRRR an intermediate (Figure 
S2b). To further quantify to what extent the RALA, RGSG and RRRR peptides facilitated 
endosomal escape of their mRNA cargo, Mander’s colocalization coefficient was calculated for 
colocalization of macropinosomes (ARF6), clathrin coated vesicles (Clathrin Light Chain) or 
caveolae (Caveolin) and mRNA nanocomplexes (Figure 7). Only in the case of RALA-mediated 
mRNA delivery, we could detect mRNA inside DC2.4 cells that did not co-localize with any of 
these vesicular markers. Conversely, mRNA delivered by RRRR and RGSG always co-localized 
with at least one of the vesicular markers applied. These data indicate that RALA mRNA 
nanocomplexes enables endosomal escape of the antigen mRNA, in contrast to RGSG and RRRR-
delivered mRNA, which appears to remain trapped inside endocytic vesicles.  
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Figure 7. RGSG or RRRR delivered mRNA remains trapped in endocytic vesicles. (a) DC2.4 cells were 
transfected with the indicated peptide using Cy3b-labeled GFP mRNA (red). Cells were then stained 
for the indicated endosomal markers (green). Nuclei were stained with DAPI (blue). Cropped images 
are indicated by the white square. Line profiles are along the white arrow. Scale bar represents 10µm. 
(b) Bar graph summarizing the data from (a) that shows mean Mander’s colocalization coefficient per 
cell between mRNA and the indicated endosomal marker. Scale bars represent standard deviation. * 
p < 0.05.  
3. DISCUSSION 
CPPs have been widely explored in the context of siRNA and of pDNA delivery but have 
remained remarkably unexplored in the context of mRNA delivery. Here, we describe the use of 
the cationic, amphipathic CPP RALA to successfully deliver antigen-encoding mRNA to the 
immune system. We gained evidence that RALA-based mRNA delivery stimulated mRNA uptake 
by DCs and facilitated mRNA release from the endosomes to the cytosol, resulting in efficient 
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antigen expression inside the DC. Nanocomplexes of mRNA with arginine-rich peptide variants 
that lacked RALA’s amphipathic motif showed reduced DC uptake and remained entrapped in 
endosomal vesicles. Furthermore, these peptide variants failed to support the expression of the 
mRNA-encoded antigen that is required to prime T cell responses. Although we showed some 
strong indications to suggest that RALA lends his unique immunogenicity to its amphipathic 
character, one should keep in mind that RGSG and RRRR nanocomplexes differ from RALA 
nanocomplexes in size, surface charge and hydrophobicity. Therefore, at this stage, we cannot 
exclude that these differences are not affecting the uptake of the particles, the endosomal 
escape and as a consequence the immunogenicity of the nanocomplexes. 
In addition to a thorough assessment of the crucial features that determine the immunogenicity 
of RALA mRNA nanocomplexes at the peptide level, we also determined the impact of the mRNA 
format on the strength of the evoked T cell response at the mRNA level. In vitro transcribed 
mRNA is typically recognized by a set of immune receptors that trigger potent inflammatory 
cascades23-27. This innate immune recognition can be largely prevented through incorporation of 
modified nucleosides into the mRNA, which simultaneously ameliorates mRNA’s stability and 
enhances mRNA expression levels21,22. In combination with RALA, modified mRNA proved to be 
superior in eliciting cytolytic T cells to non-modified mRNA. This observation is striking, as 
modified mRNAs have been developed exactly to prevent innate immune activation in the 
context of gene therapy. As innate immune activation is required to prime T cell immunity, our 
data suggest RALA possesses intrinsic immune activating properties on its own.  
We have demonstrated the high potential of RALA in complexing antigen-encoding mRNA into 
immunogenic nanocomplexes. In terms of potency, RALA-mediated mRNA vaccination clearly 
outperformed a standard liposomal mRNA formulation composed of the cationic lipid DOTAP 
and the fusogenic lipid DOPE. Based on the combination of high immunogenicity and ease-of-
production, we believe that RALA – and by extension other CPPs – constitute highly promising 
delivery vehicles for mRNA vaccines that merit further study.   
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4.  RESULTS 
4.1 RALA-RNA VACCINES INDUCE LESS TYPE I IFNS COMPARED TO 
DOTAP/DOPE-RNA VACCINES. 
Earlier, we have shown that the activity of mRNA DOTAP/DOPE lipoplex vaccines was hampered 
by vaccine-evoked type I IFNs as immunizing Ifnar-/- mice resulted in increased vaccine-evoked 
CD8+ T cell responses. Further on, we demonstrated that RALA mRNA vaccines are more 
immunogenic when formulated to modified mRNA instead of unmodified mRNA, thus 
suggesting that also here type I IFNs induced by unmodified mRNA may exert an inhibitory 
effect on the vaccine immunogenicity. Finally, we showed in chapter 4 (Figure 4) that 
immunizing wild type mice with modified mRNA-RALA vaccines elicited significantly stronger 
immune responses compared to modified mRNA-DOTAP/DOPE vaccines. A logical question 
therefore is whether this difference in immunogenicity and sensitivity to RNA modification – 
mRNA-DOTAP/DOPE lipoplexes are insensitive to mRNA modification – reflects a different level 
of type I IFN induction by both vaccine delivery formats. To find out, IFNβ+/Δβ-luc reporter mice 
were injected i.d. with both RALA and DOTAP/DOPE formulations using either unmodified or 
modified ovalbumin-encoding mRNA. As shown in Figure 8, mice injected with RALA mRNA 
formulations showed hardly detectable IFNβ levels as opposed to mice injected with equivalent 
doses of DOTAP/DOPE mRNA lipoplexes. 
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Figure 8: RALA mRNA nanocomplexes induce less IFNβ compared to mRNA lipoplexes. (a) IFN-β
+/Δβ-luc
 
reporter mice were injected i.d. with 7 µg of ovalbumin-encoding mRNA DOTAP/DOPE lipoplexes of 
N/P 1, mRNA RALA nanocomplexes of N/P 10 or PBS (background in the graph) in a total volume of 20 
µl. Six hours after injection, IFNβ induction was measured via in vivo bioluminescence. (b) Graphical 
representation * p < 0,05; ** p < 0,01 (One-way ANOVA, post-hoc: Tukey’s). Data are shown as mean 
± SEM of 3 mice. Mod, modified mRNA; unmod, unmodified mRNA. 
4.2 THE EFFICACY OF MODIFIED MRNA RALA NANOCOMPLEXES IS NOT 
HAMPERED BY TYPE I IFNS. 
In view of the remarkable low IFNβ levels of RALA mRNA nanocomplexes, we assessed whether 
the strength of the immune response elicited upon RALA mRNA nanocomplex vaccination is still 
hampered by type I IFNs. To this end, Ifnar-/- and wild type mice were immunized with RALA 
mRNA nanocomplexes, followed by an in vivo killing assay in order to quantify vaccine-elicited 
CD8+ T cell effector functions. Strikingly, no difference was seen between Ifnar-/- and wild type 
mice immunized with modified mRNA RALA nanocomplexes, whereas unmodified mRNA RALA 
nanocomplexes did perform significantly better in Ifnar-/- mice compared to wild type mice. 
(Figure 9). 
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Figure 9: The efficacy of modified mRNA RALA nanocomplexes is not hampered by type I IFNs. Wild 
type and Ifnar
-/-
 mice were immunized twice with 7 µg of unmodified and modified mRNA RALA 
nanocomplexes at N/P 10 in a total volume of 20 µl. Two weeks after boost, CFSE-labelled OVA-
pulsed and irrelevant peptide-pulsed cells were adoptively transferred in an 1:1 ratio. Two days later, 
spleens were dissected and splenocytes were analysed by flow cytometry to measure the specific 
killing capacities of the vaccine elicited CD8
+
 T cell responses. Data are shown as mean ± 5 mice per 
group. *** p < 0,001 one-way ANOVA (post hoc: Tukey’s test). 
4.3 IN VIVO DETECTABLE ANTIGEN EXPRESSION LEVELS ARE CAUSED BY FREE 
MRNA 
We next assessed whether the mRNA vaccine carrier affect the expression levels of the mRNA-
encoded antigen. Wild type mice were injected with modified mRNA formulated into RALA- or 
DOTAP/DOPE-based particles. To our surprise, no signal could be detected when RALA-mRNA 
nanoparticles at N/P 10 – the most optimal N/P ratio for immunizations – were administered, 
opposed to free mRNA or DOTAP/DOPE mRNA complexes (Figure 10a,b). However, when the 
N/P ratio of RALA was lowered to N/P 1 – meaning only 10 % of the mRNA remains encapsulated 
- weak expression levels were seen. As we identified RALA mRNA nanocomplexes of N/P 10 as 
being more immunogenic than RALA nanocomplexes at N/P 1 (Figure 10c), we can conclude that 
the quantified antigen expression levels cannot be directly related with the immunogenicity of 
the particles. 
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Figure 10. Quantified antigen expression levels do not reflect immunogenicity. (a-b) Wild type mice 
were shaved and injected with a total volume of 50 µl PBS or 20 µg luciferase- encoding modified 
mRNA free or complexed to RALA of DOTAP at the indicated N/P ratios. 8 hours after injection, in vivo 
bioluminescence was measured by injecting D-luciferine substrate. Data are shown as mean of 3 
mice. (c) Graphical representation of OT-I proliferation after immunization. Two days prior to 
immunization CFSE-labelled OT-I cells were adoptively transferred to wild type mice. Intradermal 
immunization was performed at the ear pinna with 5 µg of modified ovalbumin mRNA lipoplexes of 
nanocomplexes at the indicated N/P ratio. Free mRNA and PBS were injected as a negative control. 
Three days after immunization inguinal lymph nodes were isolated and CD8
+
 T cell proliferation was 
analysed by flow cytometry.  
4.4 THE INNATE IMMUNE ACTIVATION MECHANISM OF PEPTIDE- AND LIPID-
BASED MRNA VACCINES DIFFERS 
The low to undetectable levels of IFNβ observed upon injection of RALA mRNA nanocomplexes 
indicated that RALA-delivery does not trigger a pronounced type I IFN-dependent innate 
immune activation. In order to elucidate the molecular pathway(s) underlying innate immune 
activation, we performed an in vivo killing assay to compare vaccine-elicited CTL responses in 
MyD88-/- and Trif-/- mice. MyD88 plays a central role in the innate immune responses as an 
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adaptor molecule for signal transduction of all Toll-like receptors except TLR328,29. This pathway 
involves the early phase of NF-ƘB activation, resulting in the production of inflammatory 
cytokines29. TLR3 is the only TLR receptor that is not dependent on MyD88 but signals via TRIF. 
The TRIF-dependent signalling pathway will result mainly in the induction of type I IFNs via the 
activation of the transcription factors IRF3 and IRF7. In here, we showed that modified mRNA 
RALA nanocomplexes completely lost their capacity to evoke functional CTL responses in Trif-/- 
mice compared to wild type, whereas MyD88 deficiency seems to slightly strengthen - although 
not significant - CD8+ T cell immunity (Figure 11a). On the contrary, immunization of MyD88-/- 
and Trif-/- mice with modified mRNA DOTAP/DOPE lipoplexes did not result in significant 
stronger or weaker CTL responses relative to wild type mice (Figure 11b). 
 
 
Figure 11. Different mechanisms of innate immune activation by RALA- and DOTAP-mRNA vaccines. 
Wild type, MyD88
-/-
 and Trif
-/-
 mice were immunized twice with 7 µg of modified mRNA complexed to 
(a) RALA at N/P 10 and (b) DOTAP at N/P 1 in a total volume of 30 µl. Two weeks after boost, CFSE 
labelled OVA-pulsed and irrelevant peptide-pulsed cells were adoptively transferred at a 1:1 ratio. 
Two days later, spleens were dissected and splenocytes were dissected to analyse the effector 
function of the vaccine-elicited CTL responses. Means of 4-5 mice ± SD per group are shown. * p < 
0,05; ** p < 0,001; *** p < 0,0001; One-way Anova. 
5. DISCUSSION 
In this study, we demonstrated that modified mRNA RALA nanocomplexes showed improved 
vaccine efficacy to unmodified mRNA RALA nanocomplexes. This result is in sharp contrast to 
lipid-based delivery of mRNA, showing no strengthened CD8+ T cell immunity in response to 
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modified antigen-encoding RNA delivery. Further, we have analysed whether RALA mRNA 
nanocomplex injection resulted in IFNβ induction, like mRNA DOTAP lipoplex vaccines do. Using 
an IFN-β+/Δβ-luc reporter mice we revealed that RALA mRNA nanocomplexes induced significant 
lower IFNβ levels compared to DOTAP-based delivery. Although the injection of both 
unmodified and modified mRNA RALA nanocomplexes showed no detectable IFNβ induction in 
the reporter mice, only modified mRNA RALA nanocomplexes  showed equal CTL responses in 
wild type and Ifnar-/- mice. To our surprise, unmodified mRNA RALA nanocomplexes still showed 
stronger CTL responses in Ifnar-/- mice. When interpreting these results, two main conclusions 
can be drawn. First, these data clearly demonstrate that RALA outcompetes DOTAP/DOPE to 
function as a carrier for modified mRNA-based CTL-inducing vaccines. In addition, we have 
provided clear evidence that modified mRNA RALA nanocomplexes are not hampered by type I 
IFNs, a phenomenon we earlier observed in the context of DOTAP/DOPE-based delivery. 
At last, to gain some insights in how both nanoparticle formats trigger innate immunity, we 
performed an in vivo killing study using wild type, MyD88-/- and Trif-/- mice. As immunization of 
Trif-/- mice with RALA mRNA nanocoplexes showed complete lack of cytotoxic CD8+ T cell 
responses, it is highly suggested that the immunogenicity of mRNA RALA nanocomplexes might 
be dependent on TLR3 triggering. The immunization of Trif-/- and MyD88-/- mice with mRNA 
DOTAP lipoplexes showed no significant differences to wild type mice. These data may indicate 
that lipoplex-based delivery of mRNA results in the activation of multiple cytosolic receptors 
and/or TLRs, resulting in a redundant effect in a specific knock-out model. As this is a 
preliminary experiment, further research is needed to reveal the underlying mechanisms of the 
immunogenicity of RALA- and DOTAP/DOPE – based vaccines.  
6. MATERIALS AND METHODS 
Animals 
Female C57BL/6 mice and OT-I mice (7 weeks old) were purchased from Janvier (Le Genest Saint 
Isle, France). All mice were maintained under specific pathogen-free conditions and treated 
according to the European guidelines for animal experimentation. All experiments were 
approved by the local ethical committee of Ghent University (Ghent, Belgium). 
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Nanoparticle preparation 
RALA was produced by solid-state synthesis and supplied as an acetate salt lyophilized powder 
(Biomatik, USA). EGFP mRNA (L-6301) and Ovalbumin mRNA (unmod: L-6326; mod: L-6128) 
were purchased from TriLink BioTechnologies (San Diego, USA). RALA/mRNA complexes were 
prepared at N/P ratios 1, 5 and 10 by adding appropriate volumes of RALA peptide solution to a 
specific amount of mRNA. The N/P ratio represents the molar ratio of positively charged 
nitrogen atoms in the peptide to negatively charged phosphates in the mRNA backbone. For 
lipid-based complexation of mRNA cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were added to the mRNA 
at N/P ratio 1 (both Avanti Polar Lipids, Alabaster, AL, USA). 
Nanoparticle characterization 
For size and zeta potential measurements, particles were analyzed using a Nano ZS Zetasizer 
(Malvern Instruments, UK). The shape and surface morphology were observed using Jeol 
JEM1400plus transmission electron microscope at 30 kV. 
Encapsulation assay 
Quant-iT™ RNA assay kit (Life Technologies, UK) was diluted 1:200 in TAE buffer and added to an 
equal volume of nanoparticle prepared solution. Sample fluorescence was analyzed using a 
Synergy 2 Multi-Mode Microplate Reader (BioTek Instruments Inc, UK).  
Hemolysis assay 
Chicken red blood cells (RBCs) (Veterinary department, UGent) were resuspended in pH 5.6 and 
pH 7.4 buffer solutions separately. The cell suspensions were treated with the indicated 
formulations. 20% Triton was used as a positive control representing 100% hemolysis. After 1 
hour incubation (37°C), samples were centrifuged to pellet intact RBCs. Supernatants were 
collected and absorbance was measured at 450nm using iMark Microplate Reader (Biorad, USA) 
In vitro DC transfection 
DC2.4 cells (1.2 x 105 cells/well) were incubated for 2 hours in Opti-MEM serum free media 
(Gibco, UK) prior to addition of 50 µl RALA-mRNA complexes (2.5µg mRNA). Four hours later, 
eGFP expression as analyzed on a LSRII flow cytometer (BD Biosciences). 
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In vivo T cell proliferation assay 
OT-I T cells were labelled with 5 µM carboxyfluorescein diacetate succinimedyl ester (CFSE) 
(Invitrogen, Belgium) and 1 million CFSE labelled cells were i.v. injected two days prior to 
immunization. Mice were intradermally immunized with 7 µg of unmodified or modified mRNA 
nanocomplexes in a total volume of 20 µl. Three days later, lymph nodes were isolated and OT-I 
T cell division was analysed by flow cytometry. Cells were stained with α-CD16/CD32 (BD 
Biosciences, USA), Live/Dead Fixable Aqua stain (Invitrogen), α-CD8 PerCP, α- CD3 pacific blue, 
α-CD19 APC-Cy7 (all BD Biosciences, USA) and MHC dextramer H-2 Kb/SIINFEKL-PE (Immudex, 
Denmark). 
In vivo cytotoxicity assay 
Mice were intradermally immunized with 7 µg of unmodified or modified mRNA nanocomplexes 
in a total volume of 20 µl. Two weeks after prime and boost vaccination with a two week 
interval, splenocytes from C57BL/6 mice were pulsed with MHC-I OVA peptide (target cells) (30 
µg/ml) or left unpulsed (non-target cells) for 60 minutes at 37°C, and subsequently labelled with 
respectively 5 µM or 0.5 µM CFSE (Invitrogen, Belgium) accordingly to the manufactur’s 
protocol. Labelled cells were injected into immunized mice at a 1/1 ratio. Spleen suspensions 
were analysed 48 hours later by flow cytometry. The percentage antigen-specific killing was 
determined using the following formula: 1 - ((%CFSEhi cells / %CFSElow cells)
immunized mice /(%CFSEhi 
cells / %CFSElow cells)
non-immunized mice). 
mRNA labelling 
Multiply labeled tetravalent RNA imaging probes (MTRIPs) were constructed as described in  
reference21. We designed four different 2’O-methyl RNA-DNA chimeric oligos containing 17-18 
nucleotide regions with a short 5-7 poly(T) linker. Oligos were antisense to 4 adjacent sequences 
spanning the mRNA 3’ UTR and contained three to four amino-modified thymidines each and 
containing a biotin modification (Biosearch). MTRIPs were assembled by conjugating Cy3B-NHS 
ester (GE Healthcare) to oligo amine groups using manufacturer protocols. Complete MTRIPs 
were assembled by incubation with Neutravidin (Pierce) for 1 hour at RT followed by filtration 
using 30 kD MWCO centrifugal filters (Millipore). mRNA was buffer exchanged into 1x PBS and 
heated to 70°C for ten minutes and immediately placed on ice, combined with MTRIPs in a 1:1 
mRNA:MTRIP ratio for each MTRIP, then incubated overnight at 37°C. The next day, the mixture 
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was filtered using a 200 kD MWCO ultrafiltration unit (Advantec MFS Inc) and concentrated by 
50 kD MWCO centrifugal filters (Millipore).  
Co-localization studies 
DC 2.4 cells were plated on glass coverslips 24 hours prior to transfection with RALA, RGSG, or 
RRRR along with 250 ng of eGFP mRNA labeled with cy3b MTRIPs per well. 5 hours post 
transfection, cells were fixed in 4% PFA and staining was performed for Caveolin (Santa Cruz 
Biotechnology - SCBT), Clathrin Light Chain (SCBT), ARF6 (SCBT), or a combination of CD63 
(Developmental Studies Hybridoma Bank - DSHB), EEA1 (BD Biosciences), and LAMP1 (DSHB). 
Images were taken using a Flash 4.0 v2 sCMOS camera (Hamamatsu) with a 60x NA 1.4 Plan-
Apochromat objective on an Ultraview spinning disk confocal microscope (Perkin Elmer). 
Imaging and analysis was performed in Volocity (Perkin Elmer). Statistical analysis and plots 
were performed in Prism 7 (Graphpad). 
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7. SUPPLEMENTARY DATA 
 
Figure S1. Gating strategy used for OVA- specific CD8
+
 T cell proliferation. Cells are gated based on FSC 
and SCC, before single cells are gated based on SSC-area and height. Living cells are selected and 
gated for CD3
+
CD19
- 
T cells. Within CD8
+
 T cells, OVA-specificity is gated by labelling with MHC-I 
SIINFEKL – PE dextramer. Proliferation of CFSE positive OVA-specific CD8
+
 T cells is shown by counting 
% OT-I cells above 4
th
 division 
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Figure S2. Effects of peptide composition on uptake of the mRNA cargo. (a,b) Flow cytometric analysis 
of cargo mRNA uptake after incubation of DC2.4 dendritic cells with Cy3b-labeled mRNA complexed 
to respectively RALA, RGSG and RRRR at N/P 10. The percentage of Cy3b positive DC2.4 cells is shown 
in (a) whereas the mean fluorescence intensity (MFI) of Cy3b-positive DC2.4 is depicted in (b). 
Measurements are reported as means (n = 4) ± SD, *** p < 0.001, ** p < 0.01.  
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Abstract 
Non-coding single stranded RNA (ssRNA) is being intensively evaluated as vaccine adjuvants due 
to their capacity to promote cytolytic CD8+ T cell responses against co-delivered protein 
antigens. This intrinsic potential of ssRNA to promote cellular immunity is conveyed by their 
capacity to trigger TLRs 7/8 in the endosomal compartments of dendritic cells, leading to an 
inflammatory signalling cascade that culminates in the release of IL-12 and type I IFNs. 
Nonetheless, unformulated ssRNAs succumb to rapid degradation and largely fail to reach their 
TLR target in the endosomal compartment of DCs. In this study, we describe a pHPDA-based 
polymeric nanoparticulate system that combines efficient protection of the ssRNA with a highly 
effective targeting of DCs in the vaccine draining lymph node. When compared to unformulated 
ssRNA, pHPDA-formulated RNA drastically promoted the priming of antigen-specific CD8+ T cells 
with cytolytic effector function against a co-administrated protein antigens. 
1. INTRODUCTION 
The generation of potent cytolytic CD8+ T cell responses is considered to be crucial for the 
development of vaccines both capable of fighting insidious intracellular pathogens or cancer 
cells1,2. Unfortunately, the classical aluminium-based adjuvants fail to elicit this arm of T cell 
immunity3,4, which urges the need for novel adjuvant formulations that do possess the ability to 
instigate cellular immunity against co-administrated antigens. Activation of T cell immunity 
critically depends on the prior activation of innate immune cells, which is mediated through the 
triggering of host PRRs by Pathogen Associated Molecular Patterns (PAMPs). Depending on the 
set of PRRs triggered, innate immune cells will release a distinct inflammatory cytokine profile, 
which will ultimately determine the characteristics of the ensuing T cell response. Viral nucleic 
acids are amongst the most prominent inducers of type I IFNs and IL-12, the key cytokines that 
govern the differentiation of antigen experienced CD8+ T cells into cytolytic effector cells5–7. Viral 
ssRNA could activate TLR7 and TLR8 in specialized endosomal compartments and strongly 
promote cytolytic T cell responses. As a consequence, agonists of TLR7/8 have emerged as 
highly promising vaccine adjuvants. Imidazoquinolines were the first class of TLR7/8 agonists 
developed for human use8. The development of imidazoquinolines as antivirals for topical 
treatment of genital warts preceded their actual identification as TLR7/8 agonists9. Subsequent 
murine studies demonstrated that imidazoquinolines act as adjuvants that stimulate cytolytic T 
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cell responses against co-administrated antigens. Imidazoquinolines however rapidly diffuse 
from the injection site and trigger systemic inflammatory responses resulting in temporal 
leukocyte depletion and altered lymphoid architecture. On top, imidazoquinolines have been 
reported to amplify inflammation through TLR7/8 independent pathways10.  
Guanidine and uridine rich ssRNA constitute the natural agonists of TLR7/8 in the endosomes of 
DCs and represent less pro-inflammatory, safer alternatives to imidazoquinolines11. 
Nonetheless, to develop ssRNAs as successful adjuvants, several hurdles need to be taken. 
Natural ssRNAs are notoriously instable and prone to rapid degradation upon injection, a feature 
that interferes with their capacity to reach their endosomal TLR7/8 target. To prevent 
premature degradation and to increase DC uptake, ssRNAs have been complexed to cationic 
lipids such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)12,13 or to cationic polymers 
such as polyethyleneimine (PEI)11 and protamine14. Whereas such approach indeed strongly 
increased the adjuvanticity of the ssRNA, the amount of complexed ssRNA that actually reached 
the draining lymph node upon intradermal/subcutaneous injection remained highly limited15. As 
a high dose of adjuvant in the vaccine draining lymph node – the sites of antigen presentation 
and T cell priming – have been associated to the induction of superior T cell immunity, we aimed 
to develop a nanoparticulate formulation that not only protects from degradation, but also 
efficiently delivers the ssRNA to lymph node DCs. 
To achieve these goals, we formulated ssRNA into PEGylated (PEG, poly(ethylene)glycol)- pHPDA 
polymeric nanocomplexes. PEGylation constitutes a well described strategy to enhance the 
colloidal stability of nanocomplexes by shielding their cationic charges. PEGylation has been 
mainly applied to increase the circulation time and half-life of nanoparticles upon intravenous 
administration, but PEGylation also increases lymphatic drainage of nanoparticles upon 
intradermal or subcutaneous injection16. The incorporation of PEG into polyplexes is commonly 
achieved by using a block copolymer consisting of cationic and PEG-domains, that 
simultaneously acts as a condensing agent (e.g. PEG-polylysine17,18, PEG-poly(aspartamide)19,20, 
PEG-poly(amido amines)21,22 and PEG-PEI23,24). However, it has been argued that such PEG-block-
polymer particles are less stable than polyplexes based on cationic polymers since the PEG-
chains of block- or graft-copolymers may hinder or prevent the interaction between the cationic 
polymer and the nucleic acids25,26. An alternative method to overcome this problem is to 
PEGylate the surface of preformed nucleic acid-polymer complexes, called post-PEGylation. 
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Several papers have indicated that, compared to polyplexes formed by PEG-cationic block or 
graft polymers, post-PEGylated polyplexes hardly showed interactions with blood components 
and revealed prolonged circulation time in mice after intravenous administration27–29. 
In this paper, we have utilized copper-free click chemistry to post-modify mRNA polyplexes with 
PEG-Bicyclo[6.1.0]nonyne (PEG-BCN). We further show that these PEGylated polymeric 
formulation efficiently encapsulate the RNA cargo and moreover protect it against degradation. 
Moreover, the formulation of ssRNA into PEGylated polymers enhanced ssRNA targeting to 
lymph node DCs when compared to unformulated ssRNA or ssRNA complexed to cationic 
liposomes. Most importantly, we present PEG-pHDPA RNA polyplexes as potent novel adjuvant 
for the eliciting of potent cytolytic CD8+ T cells responses against co-delivered protein antigens. 
2. RESULTS 
2.1 PEG-PHDPA  RNA POLYPLEXES; PRODUCTION PROCESS AND 
CHARACTERIZATION 
In this study, pHDPA polymer composed of p(HPMA-DMAE-co-PDTEMA-co-AzEMAm) was used 
to complex ssRNA into RNA polyplexes followed by PEGylation, hereafter named as PEG-pHDPA 
RNA polyplexes. A detailed description about the production process of the pHDPA polymer can 
be found in the material and methods section. A schematic presentation of the production 
process of the PEG-pHDPA RNA polyplexes is provided in Figure 1a. In brief, PEG-pHDPA RNA 
polyplexes were formed through a three-step process. The first step consists electrostatic 
formation of the cationic polymer pHDPA with ssRNA to form nanosized polyplexes (Figure 1a). 
To limit the amount of free polymer in the ssRNA polyplex solution a Nitrogen/Phosphate (N/P) 
ratio of 4 was selected. Second, the ssRNA polyplexes were post-PEGylated by adding PEG-BCN 
to the polyplex solution. This PEGylation step was followed by a third step in which Dithiothreitol 
(DTT) was added to cross-link the polyplexes via thiol-disulfide bonds exchange30,31, yielding 
PEGylated, stable and nearly neutral-charged RNA polyplexes. 
At N/P ratio 4, PEG-pHDPA RNA polyplexes are slightly positive to near neutral and display a 
diameter around 150 nm for both ssRNA formats tested; luciferase encoded mRNA and polyU 
(Figure 1b). The stability of the PEG-pHDPA RNA polyplexes was evaluated after incubation at 37 
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oC in the presence of 10 % serum in order to mimic in vivo conditions. The size distribution of 
the PEG-pHDPA RNA polyplexes in presence of serum was determined by fluorescent single 
particle tracking (fSPT)32 and compared to polyplexes diluted in PBS. As depicted in Figure 1c, the 
particles size remained stable after 1 hour of incubation, and only slightly increased after 2 
hours. Importantly, the PEG-pHDPA RNA polyplex size was similar before and after lyophilisation 
(Figure 1d), suggesting that the PEG-pHDPA RNA polyplexes can be stored in dry powder form, a 
great advantage since the shelf-life of RNA-based particles is rather short. 
 
Figure 1. Schematic presentation of PEG-pHDPA RNA polyplex procedure and characterization. a) 
Schematic presentation of polyplex preparation: p(HPMA-DMAE-co-PDTEMA-co-AzEMAm) was 
synthesized by radical polymerization under a nitrogen atmosphere to form pHDPA polymer. (a) 
pHDPA polymer was mixed with ssRNA to form pHDPA RNA polyplexes (b) Next, Cyclooctynes (PEG-
BCN) was added via the copper free click method using the polymer-azide binding. (c) followed by 
crosslinking of the polymer using Dithiothreitol (DTT), for 2 hours at pH 7.4. b) Size and Zeta-potential 
of PEG-pHDPA RNA polyplexes using ssRNA (mRNA and polyU RNA) c) Size distribution of PEG-pHDPA 
Cy5-RNA polyplexes after incubated with 10 % of serum at 37 
o
C for 2 hours and d) after lyophilisation 
measured by Nanosight. 
2.2 PEG-PHDPA  RNA POLYPLEX FORMULATION PROTECTS SSRNA AGAINST 
DEGRADATION 
ssRNA is a very fragile molecule due to its sensitivity to RNAses, resulting in a high risk for 
degradation after in vivo injection. First, to quantify the RNA release, a fluorescence correlation 
spectroscopy (FCS) study was performed using Cy5-labeled RNA. PEG-pHDPA RNA polyplexes 
f f 
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were dissolved in 10 % serum and a slow but gradual release of RNA up to 60 % after 2 hours 
incubation was detected (Figure 2a). To further address the stability of the PEG-pHDPA RNA 
polyplexes and the degradation resistance of RNA polyplexes to serum, a gel retardation study 
was performed (Figure 2b). After incubation of uncomplexed RNA with 10 % serum at 37oC for 
30 minutes, hardly any free RNA can be detected suggesting that the RNA has been totally 
degraded by present nuclease enzymes (Figure 2b, lane 9). On the contrary, PEG-pHDPA RNA 
polyplexes showed partial protection of the RNA in the presence of serum (Figure 2b, lane 5). As 
a control DTT and pGA were added to destabilise the PEG-pHDPA RNA polyplexes by disturbing 
the cross-linking of the polymer and by expelling the RNA respectively. Remarkably, as depicted 
in Figure 2b, lane 3 and 4, most of the RNA remained attached to the polymer, indicating that 
the destabilization of the polyplexes was not completed. In order to check the destabilization 
effects of the DTT and pGA treatment, one could extend the incubation period. 
To further evaluate the integrity of ssRNA upon formulation into PEG-pHDPA RNA polyplexes, 
translation efficacy of luciferase-encoding RNA was tested using an in vitro cell-free translation 
system. As only translation of full length RNA sequences will result in detectable signal, 
measuring the luciferase intensity will display the amount of qualitative, non-degraded RNA 
present in PEG-pHDPA RNA polyplex solution. As depicted in Figure 2c, in presence of serum, 
uncomplexed RNA showed no detectable antigen amounts, in contrast to free RNA in PBS. 
Whereas PEG-pHDPA RNA polyplexes resulted in clear antigen expression levels after 90 
minutes of incubation in serum, indicating that the PEG-pHDPA polyplexes have the capacity to 
prevent breakdown of the RNA by serum proteins, leading to the maintenance of full length 
mRNA. The fact that the PEG-pHDPA RNA polyplexes showed lower translation levels compared 
to uncomplexed RNA, might attribute to RNA remained inside the polyplexes.  
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Figure 2. PEG-pHDPA RNA polyplex formulation protects ssRNA against degradation. a) The percentage 
of Cy5-labeled luciferase RNA released out of PEG-pHDPA RNA polyplexes in 10 % serum is analysed 
by fluoresence correlation spectroscopy (FCS) at 0 hour, 1 hour and 2 hours upon incubation at 37
o
C. 
b) Agarose gel retardation assay of PEG-pHDPA RNA polyplexes which were  incubated with 10 mM 
DTT, polyGlutamicAcid (pGA) or 10 % serum for 0.5 hour at 37
o
C. c) Free luciferase-encoded RNA or 
PEG-pHDPA luciferase-RNA polyplexes were incubated in PBS or with 10 % serum (FBS) for 0.5 hour at 
37 
o
C before in vitro translation was measured with a Rabbit Reticulocyte Lysate Translation Systems. 
2.3 COMPLEXATION OF SSRNA INTO PEG-PHDPA RNA POLYPLEXES IMPROVES 
SSRNA UPTAKE BY DCS  
To fulfil their role as an adjuvant, ssRNA needs to reach the endosomal compartment of DCs in 
order to trigger TLRs. The impact of RNA formulation into PEG-HDPA RNA polyplexes on DC 
uptake was analysed by incubating DC2.4 DCs with either uncomplexed or PEG-HDPA polyplexed 
Cy5-labeled RNA. Flow cytometry data are presented in Figure 3a,b. Whereas virtually no DCs 
internalized unformulated Cy5-labeled RNA, the vast majority of DCs became positive for Cy5-
labeled RNA after incubation with PEG-pHDPA Cy5-labeled RNA polyplexes. As a control, 
lipofectamine-based transfection was performed resulting in similar levels of uptake compared 
to polymer-based transfection.  
PBS 
FBS 
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Figure 3. RNA polyplexes improve DC transfection. a) 10
5
 DC2.4 dendritic cells were incubated with 0,5 
µg Cy5-labeled RNA, PEG-pHDPA Cy5-labeled RNA polyplexes for 4 hours, followed by flow cytometer 
analysis. As a control 0,5 µg of RNA was transfected using lipofectamin (= lipofec). The means of the 
percentage of DCs positive for Cy5-labeled RNA are presented ± SD (n=3). b) Corresponding confocal 
microscopy images of DC2.4 cells transfected with PEG-pHDPA Cy5-labeled RNA polyplexes. Hoechst, 
DNA stain; CTB = cholera toxin subunit B- AF 488 ; ssRNA = Cy5-labeled RNA. 
2.4 PHDPA SSRNA POLYPLEXES EFFICIENTLY TARGET SSRNA TO LYMPH NODE 
DENDRITIC CELLS IN VIVO 
The induction of effector CD8+ T cell responses relies on the presentation of antigens by 
activated DCs to T cells in the draining lymph nodes. As a consequence, vaccine potency is 
considered to benefit from strategies that augment adjuvant uptake by DCs in the draining 
lymph nodes. Cationic lipids or polymers have been explored to protect ssRNA from degradation 
and increase ssRNA uptake by DCs in vivo. Nonetheless, these cationic ssRNA lipoplexes and 
polyplexes display limited mobility in vivo, resulting in low ssRNA presence in draining lymph 
node DCs. To address whether ssRNA delivery through PEG-pHDPA RNA polyplexes would 
augment ssRNA uptake by lymph node DCs, we complexed Cy5-labeled RNA into our polyplex-
based formula and injected them s.c in the footpad. As a control, Cy5-labeled ssRNA was 
formulated into DOTAP/DOPE lipoplexes, the current bench-mark delivery system for ssRNA. 24 
hours after injection, the popliteal lymph nodes were isolated and analysed by flow cytometry. 
DCs were identified based on their expression of CD11c and further subdivided into MHCIIint DCs 
and MHCIIhigh DCs. As can be appreciated from Figure 4a, s.c. injection of PEG-pHDPA RNA 
polyplexes strongly increased the percentages of ssRNA-positive MHCIIhi DCs when compared to 
non-complexed ssRNA or to lipoplex-based injection of ssRNA (Figure 4a, b). Such MHCIIhi DCs 
might correspond to lymph node DCs that have become activated in the lymph node after 
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uptake of the ssRNA or might correspond to skin DCs that migrated to the lymph node after 
PEG-pHDPA RNA polyplexes uptake at the injection site. Incorporation of ssRNA in the PEG-
pHDPA RNA polyplexes not only enhanced the number of Cy5-labeled ssRNA positive DCs in the 
vaccine draining lymph node (Figure 4c), but also strongly increased the amount of Cy5-labeled 
ssRNA on a cell-per-cell basis as measured by the mean fluorescence intensity in the Cy5 
channel (Figure 4d). Taken together, these data showed that formulating the RNA into PEG-
pHDPA RNA polyplexes dramatically increased the amount of ssRNA in the target cell population 
– DCs, in the vaccine draining lymph node. 
 
Figure 4. RNA polyplexes are present in lymph node CD11c+ MHCII
high
 DCs after 24 hours upon 
injection. Mice were s.c. injected in the footpad with PBS, 10 µg of uncomplexed ssRNA or the 
equivalent amount of ssRNA complexed in PEG-pHDPA polyplexes or DOTAP/DOPE lipoplexes. 24 
hours after injection, popliteal lymph nodes were isolated and prepared for flow cytometric analysis. 
DCs (CD11c+) were subdivided into MHCII
high
 DCs (red population) and into MHCII
int
 DCs (blue 
population) and analysed for Cy5-labeled ssRNA uptake. a) Representative flow cytometry 
scatterplots. b) Percentage of Cy5-positive MHCII
high
 CD11c+ DCs and MHCII
int  
CD11c+ DCs. Data are 
presented as means ± SD of 5 mice/group. c) Total cell count of MHCII
hi
 CD11c+
 
Cy5-positive DCs. 
Data are presented as means ± SD of 5 mice/group. d) Mean fluorescence intensity (MFI) of the Cy5-
signal of all MHCII
high
 CD11c+
 
Cy5-positive DCs. Data are presented as means ± SD of 5 mice/group. 
mRNA polyplex = PEG-pHDPA RNA polyplexes; mRNA lipoplex = mRNA DOTAP/DOPE lipoplexes. 
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2.5 PEG-PHDPA RNA POLYPLEXES ELICIT POTENT CD8+ T CELL RESPONSES 
AGAINST CO-DELIVERED ANTIGENS 
In view of the high percentage mRNA-positive DCs in the draining lymph nodes, we assumed 
that the RNA polyplexes have great potential to elicit CD8+ T cell responses against co-delivered 
antigens. To address the impact of polyplex formulation of RNA on the magnitude and 
functional properties of vaccine-evoked CD8+ T cell responses, an in vivo immunization study 
was performed. First, mice were s.c. immunized with PEG-pHDPA RNA polyplexes co-delivered 
with soluble ovalbumin (OVA) protein. A prime and boost immunization schedule was 
performed as presented in Figure 5a. As a control, soluble OVA was injected in absence and 
presence of the polymers or uncomplexed RNA. Six days after the booster immunization, blood 
was collected and the percentages OVA-specific CD8+ T cells were determined via flow 
cytometry. As shown in Figure 5b, only mice injected with OVA in combination of PEG-pHDPA 
RNA polyplexes showed detectable vaccine-evoked CD8+ T cells in the blood (Figure 5b). Next, 
we analysed the impact of PEG-pHDPA RNA polyplexes on the effector functions of these 
vaccine-elicited CD8+ T cell responses. Therefore, mice were challenged with a 1:1 ratio of OVA 
peptide-pulsed CFSEhi splenocytes (target cells) and non-pulsed CFSElow splenocytes (non-target 
cells), two weeks after the second boost (Figure 5a). Two days later, spleens were isolated and 
the ratio of target cells versus non-target cells was analysed by flow cytometry to determine the 
killing capacity of the different vaccine formulations. Mice who received OVA co-delivered with 
the pHPDA polymer showed no significant improvement of killing functions compared to mice 
injected with soluble OVA (Figure 5c). Mice receiving OVA co-delivered with uncomplexed RNA 
displayed a broader range of killing efficacies, resulting in a slight but significant increase 
compared to mice immunized with soluble OVA. Whereas immunizing mice with OVA co-
delivered with PEG-pHDPA RNA polyplexes resulted in almost 100 % killing of target cells, a 
significant difference compared to all other control formulations (Figure 5c). Taken together, 
these findings demonstrate that formulating RNA into PEG-pHDPA RNA polyplexes positively 
impact the strength of the evoked cytotoxic CD8+ T cell responses against co-delivered antigens. 
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Figure 5. The co-delivery of PEG-pHDPA RNA polyplexes evoke CD8
+
 T cell responses against ovalbumin- 
protein. a) Experimental set up of tetramer staining and in vivo killing assay. Mice were immunized 
three times with a two week interval. 6 days after last boost, blood was collected to determine the 
percentages of CD8
+
 T cells in the blood via tetramer staining. Two weeks after boost, in vivo killing 
assay was performed. b) Mice were immunized with OVA co-delivered with PEG-pHDPA RNA 
polyplexes. As a control, mice were immunized with PBS, soluble OVA in absence or presence of 
polymers or uncomplexed RNA. 6 days after last boost immunization, blood was taken to determine 
the percentages of OVA-specific CD8
+
 T cells via tetramer staining followed by flow cytometry. Data 
are shown as mean of 4-5 mice per group. ** p < 0,01 (One-way Anova). c) Two weeks after he 
second boost immunization, a mixture of CFSE-labeled  cells pulsed with control or OVA peptide were 
adoptively transferred to the same mice. Specific killing was measured 2 days later by flow cytometry. 
Data are presented as means of 100 - 100x ((CFSE
high
/CFSE
low
)
immunized mice
/ (CFSE
high
/CFSE
low
)
mock-mice
) of 
4-5 mice per group. * p < 0,05 ** p < 0,01 ; **** p < 0,0001 (One-way Anova). 
3. DISCUSSION 
ssRNAs have gained great interest as molecular adjuvants to evoke Th1 and cytolytic immune 
responses against co-delivered antigens due to their TLR7/8 activating capacities. One major 
drawback of ssRNA is its sensitivity to RNAses and its low efficacy in targeting DCs in the vaccine 
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draining lymph node upon in vivo administration. Complexation of ssRNA to cationic lipids or 
polymers can improve ssRNA stability and DC uptake. Yet, the vast majority of cationic ssRNA 
lipid/polymer nanocomplexes are retained at the vaccination site and show little drainage to the 
vaccine draining lymph nodes, resulting in suboptimal efficacy of ssRNA as adjuvants. To 
improve the draining capacity of RNA adjuvants, we designed a polymer-based complex which 
shows low cationic density in combination with a PEGylation shield. These two factors are 
suggested to positively impact the drainage capacity of PEG-pHDPA RNA polyplexes and thereby 
enhance the RNA adjuvant efficacy. 
First, the PEG-pHDPA polymers were shown to protect the RNA in the presence of serum and 
enabled transfection of dendritic cells. Second, the formulation of RNA into PEG-pHDPA RNA 
polyplexes increased the amount of ssRNA in CD11c+ MHCIIhigh dendritic cells in the vaccine 
draining lymph nodes 24 hours after injection. These data might indicate that the PEG-pHDPA 
RNA polyplexes have been taken up by dendritic cells followed by active migration to the lymph 
nodes. However, one could not exclude that these cells are representing resident DCs which 
have taken up the PEG-pHDPA polymers after passive drainage. Efficient drainage to the lymph 
nodes is considered as a vital feature of adjuvants since it has been reported that restricting the 
inflammatory responses locally at the injection site and draining lymph nodes positively 
influenced the strength of the CTL responses33–36. PEGylation is a well-studied strategy to shield 
surface charges by creating a neutral hydrophilic shell around the polyplex and is reported for 
their positive impact on particle drainage16,37. However, to determine the need of the PEGylation 
in this formulation, a comparison drainage study needs to be performed using pHDPA RNA 
polyplexes without a PEG-shield. Furthermore, although PEGylation is beneficial for the drainage 
capacity of the particle, when the PEG density is too high, it might have a negative influence on 
the interaction between TLR7/8 and the RNA cargo and thereby interfering with the adjuvant 
capacity of the RNA polyplexes. For this reason, it would be interesting to perform an in vitro 
maturation study to further evaluate the optimal PEGylation density for DC activation and 
maturation. Besides the need to adjust the PEGylation density in order to improve TLR7/8 
triggering, the strength of the polymer cross-linking should be evaluated. As the polymer 
seemed to be partially insensitive to DTT treatment, it might be possible that the particles are 
cross-linked to such a strong extent that the interaction between RNA and TLR7/8 is inhibited. 
Thus, as a future perspective, it would be of great value to further optimize both physical 
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parameters in order to improve TLR7/8 triggering and as a consequence to improve the 
adjuvant capacity. 
4. MATERIALS AND METHODS 
Mice 
Female wild type C57BL/6 mice were purchased from Janvier (Le Genest Saint Isle, France). OT-I 
mice carrying a transgenic CD8+ T cell receptor specific for the MHC I-restricted ovalbumin (OVA) 
peptide SIINFEKL were donated by Dr. Bart Lambrecht from Ghent University (Ghent, Belgium). 
All mice were 7-12 weeks old at the start of the experiment and maintained under specific 
pathogen-free conditions. Animals were treated according to the European guidelines for animal 
experimentation. All experiments were approved by the local ethical committee for animal 
experiments of Ghent University (Ghent, Belgium).  
Synthesis  and characterization of pHDPA 
p(HPMA-DMAE-co-PDTEMA-co-AzEMAm) was synthesized by radical polymerization under a 
nitrogen atmosphere.  The polymers were synthesized using a monomer to initiator ratio (M/I) 
of 50. Different molar feed ratios of HPMA-DMAE, PDTEMA and AzEMAm were used; 70/20/10. 
In a typical experiment of p(HPMA-DMAE70-co-PDTEMA20-co-AzEMAm10), 200 mg (0.77 
mmol) HPMA-DMAE, 56.7mg (0.22 mmol) PDTEMA (HPMA-DMAE/PDTEMA 95/5), 17 mg (0.11 
mmol) AzEMAm and  3.6mg (0.022 mmmol) AIBN (M/I 50/1 ) were dissolved in dry DMSO 
(1mM) in flasks sealed with rubber septa and subjected to vacuum-N2 cycles. The polymerization 
was carried at 70 °C for 48h. Next, the DMSO solutions were precipitated in cold diethyl ether, 
dissolved in  DMF repeated 3 times. After extensive dialysis (8 kDa) against an NH4OAc buffer of 
pH 5.0 (10 mM, last step 5 mM) at 4°C, the polymer was collected after freeze drying.  
The molecular weights and polydisperisity (Mw /Mn) of pHDPA were determined by GPC 
analysis using a Viscotek-GPCmax (Viscotek, Oss, The Netherlands) light scattering (λ = 670 nm, 
right (90°) and low (7°) angle)/viscosimetric detection system, using a ultrahydrogel 2000 7.8 × 
300 mm columns in series with a ultrahydrogel 6.0 × 40 mm guard column and 0.3 M NaAc pH 
4.4,30% Acetonitrile as eluent. The flow rate was 0.8 mL/min and the run time was 40 min.  PEG 
standards (Viscotek Benelux (Oss, the Netherlands)) was used for calibration. The copolymer 
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composition of the different pHDPA was determined by 1H NMR analysis performed with a 
Gemini 400 MHz spectrometer (Varian Associates Inc., NMR Instruments, Palo Alto, CA) in D2O. 
The ratio HPMA-DMAE/PDTEMA/AzEMAm was determined by comparison of the integrals at δ 
4.3 ppm (bs, OCH2CH2,HPMA-DMAE), δ7.69ppm (bs, pyridyl group proton, PDTEMA) and 
δ4.08ppm(m, CH2N3 , AzEMAm)(δ4.3/δ7.69/δ4.08).  
Synthesis of  PEG-BCN: To a solution of DMSO (1.3 mL), NH2-PEG-OH (100 mg, 0.02 mmol, 1 
equiv), and cyclooctyne-NHS (BCN-NHS; 9 mg,  0.024  mmol,  1.2 equiv) and trimethylamine (8.5 
µL, 0.06  mmol, 3 equiv) was  added, the  reaction  was  stirred  at  RT  overnight. The TEA and 
NHS byproduct was removed by precipitated into cold ether twice, then dissolved in water for 
dialysis 2 days, after filtration then freeze-drying get white powder. Yield 90 mg ,85.7%. 1H NMR 
(400 MHz, DMSO): δ = 7.05(s, 1H;OC(=O)NH), 7.05(s, 1H;C=ONH), 4.52 (t, 2H; PEG-OH),4.00 (d, 
2H; BCN-CH2-O(=O)), 3.66 (t, 2H; PEG-CH2), 3.48 (br s, 440H; PEG), 3.04 (s, 2H; OCONHCH2), 
2.90 (s, 2H; C=ONHCH2), 2.0-2.21(m, 4H; CH2C(=O)NH2, alkane),1.99(m,2H; NHCH2CH2),1.69-
1.41 (m, 6H; alkane), 1.54-1.13 (m, 1H; alkane), 0.80-0.71 (m, 2H; alkane). 
Reactivity of Cyclooctynes (PEG-BCN) toward Polymer-azide (pHDPA); Polymer pHDPA2 and 
PEG-BCN ((1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-yl)were separately dissolved in 10 mM HEPES 
buffer (pH 7.4) at  a  concentration  of  10.0  mg/mL  (4.88  mM)  and  20  mg/mL  (3.7 mM),  
respectively.  Polymer solution  (13.2  µL)  and  PEG-BCN  solution  (17.3  µL ,molar ratio 1:1 or 
8.65 µL molar ratio 2:1) were  mixed  and  diluted  with  10  mM HEPES buffer (pH 7.3) (69.5 µL 
or 78.2 µL). The reaction mixture was incubated at room temperature and collected at 
incubation times of 0, 1, 2, 3, 4, 8, 12 and 24 h. The mixture can be diluted with 10 mM HEPES 
buffer in different reaction concentration for reaction or been freeze-dried. The collected 
reaction mixtures were immediately analysed by size exclusion chromatography (SEC). The SEC 
analyses were conducted using an Alliance HPLC System (Waters) [column: Ultrahydrogel 1000 
(Waters); eluent 0.3M NaAc, pH 4.4 with 30% Acetonitrile ; flow rate: 0.8  mL /min; 
temperature: 30 oC]. The conjugation ratios were calculated from the peak intensity ratio of 
unreacted PEG-BCN by concentration calibration curve in the SEC chart at RI detection. 
Preparation of  RNA polyplexes 
To prepare RNA polyplexes four volumes of polymer and one volume of ssRNA were mixed. 
Dependent on the experiment, three different ssRNA molecules were used: Luciferase, L-6307, 
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TriLink Biotechnologies, USA; polyU, InVivoGen; Cy5- luc, TriLink Biotechnologies, USA) were 
mixed for complexation in 10 mM HEPES buffer, pH 7.4, at desired N/P ratio. Polyplexes were 
crosslinked by addition of Dithiothreitol (DTT) corresponding with a half molar equivalent to PDS 
groups of polymer for 2 hours at pH 7.4. Except mentioned otherwise, the polyplexes were 
prepared at N/P ratio 4, at RNA concentration of 100 µg/mL. 
mRNA lipoplexes 
Dependent on the experiment, three different ssRNA molecules were used: Luciferase, L-6307, 
TriLink Biotechnologies, USA; polyU, InVivoGen; Cy5- luc, TriLink Biotechnologies, USA). mRNA 
was complexed to 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-
glycero-3-phosphoethanol-amine (DOPE) into lipoplexes at Nitrogen/Phosphate 1 (Avanti Polar 
Lipids, Alabaster, AL, USA). Lipoplexes were injected in 5% glucose water. 
Particle size and zeta-potential measurements 
The size of the polyplexes was measured with DLS on an ALV CGS-3 system (Malvern 
Instruments, Malvern, UK) equipped with a JDS Uniphase 22 mW He–Ne laser operating at 632.8 
nm, an optical fiber-based detector, a digital LV/LSE-5003 correlator with temperature 
controller set at 25 °C or 37 °C. The zeta-potential (ζ) of the polyplexes was measured using a 
Malvern Zetasizer Nano-Z (Malvern, UK) with universal ZEN 1002 ‘dip’ cells and DTS (Nano) 
software (version 4.20) at 25 °C or 37 °C. Polyplex measurements were performed in 10 mM 
HEPES pH 7.4 at a mRNA/polyU concentration of 15 μg/mL. 
Fuorescence single particle tracking (fSPT) 
fSPT was performed to measure the size - over two time periods - of the cationic Cy5-mRNA 
polyplexes in 10 % serum. fSPT is a fluorescence microscopy technique that uses a fast and 
sensitive CCD camera to record movies of diffusion particles in fluids. These movies are analysed 
using in-house developed software, to obtain size distributions32.  
Gel retardation study 
Polyplex (in)stability was studied by addition of dithiothreitol (DTT) (as reducing agent) and/or 
pGA (polyGlutamic acid) (as counter polyanion) and /or  serum. Two microliters of DTT (100 
mM) and/or different amount of pGA (50 mg/mL) and/ or  2.5 μL FBS were added to 25 μL of 
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polyplex dispersion in HBS (40 μg/mL of RNA) yielding a final concentration, 10 mM DTT and 240 
μg/mL pGA, 10% serum. After 0.5 h incubation time at 37 °C, for serum protection study, the 
reaction was terminated with 4 μL of 0.5M EDTA (pH 8.0) and then placed on ice for 10 min. 20 
μL of the sample was mixed with 3 μL 6× Loading Dye, loaded into 1% agarose gel in Tris–
acetate–EDTA (TAE) buffer containing GelGreen (Biotium) at 120 V for 30 min. RNA was 
detected using a Gel Doc™ XR + system (BioRad Laboratories Inc., Hercules, CA) with Image Lab 
software. 
Fluorescence Correlation Spectroscopy (FCS)  
Cy5-mRNA release from PEG-pHDPA RNA polyplexes after incubation with 10% serum during 2 
hours at 37°C was followed using FCS. Fluorescence correlation spectroscopy (FCS) is applied as 
mentioned in38. 
In vitro translation of RNA polyplexes  
In vitro translation was conducted using a nuclease-treated rabbit reticulocyte lysate translation 
system, according to the manufacture’s recommendations (Promega, USA). Briefly,  12.5 μL of 
0.5 μg luciferase free mRNA or polyplexed luciferase mRNA was pre-treated with 10 % serum 
and added to 17.5 μl Rabbit Reticulocyte Lysate. Luciferase activity was measured after 90 min 
incubation (37 °C) by luciferase reporter gene assay (Promega, USA), equipped with a 
luminescence light guide (BMG LabTech, Germany). 
DC2.4 transfection 
DC2.4 cells were seeded on 96-well plate (105 cells/ well) and incubated for 24 hours in cRMPI. 
Cy5-labeled luciferase-encoding mRNA was complexed to the polymers as described above. The 
cells were treated with polyplexes (0.5 µg Cy5 ssRNA) N/P 4 for 4 hours without serum. To 
quench the fluorescence of polyplexes adsorbed, the cells were incubated with 0.4 % trypan 
blue-containing PBS buffer for 5 min and washed with PBS. Cells were stained with Hoechst to 
stain DNA and CTB (cholera toxin subunit B- AF 488) to label membranes. Cellular uptake of RNA 
polyplexes was examined by flow cytometry (Canto II, BD).  
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Drainage of Cy5-labeled ssRNA polyplexes  
C57BL/6 mice were s.c. injected with Cy5-labeled ssRNA (TRiLink biotechnologies) polyplexes 
and lipoplexes in the footpad. 10 µg of ssRNA was applied in all groups. Popliteal lymph nodes 
were isolated 24 hours post injection and analysed by flow cytometry. Cells were stained with α-
CD16/CD32 (BD Biosciences, San Diego, CA, USA) to block non-specific FcR binding, and with 
Live/Dead Fixable Aqua stain (Invitrogen) to eliminate dead cells from analysis. Antibodies used 
were MHC-II-FITC, α-CD11c PerCP-Cy5.5, α-F4/80 PerCP (all BD Biosciences, San Diego, CA, USA). 
Analysis was performed on a triple-laser (B-V-R) LSR-II (Becton Dickinson, San Jose, CA, USA) 
followed by FlowJo (Treestar, OR) data processing. 
CD8+ T cell dextramer staining 
3 subcutaneous immunizations were performed in C57BL/6 mice at tail base in a 2 week 
interval. 10 µg of OVA-encoding mRNA was complexed to polyplexes as described above or to 
lipoplexes using DOTAP/DOPE at N/P ratio of 1 (Avanti Polar Lipids, Alabaster, AL, USA) in a total 
volume of 40 μl of 5% glucose water (Ambion, Life technologies, USA). Six days after last boost, 
blood samples were taken and red blood cells were removed using ACK lysis buffer 
(BioWhittaker, Wakersville, MD, USA). Cells were stained with α-CD16/CD32 (BD Biosciences, 
San Diego, CA, USA), Live/Dead Fixable Aqua stain (Invitrogen), α-CD8 PerCP, α- CD3 pacific blue, 
α-CD19 APC-Cy7 (all BD Biosciences, San Diego, CA, USA) and MHC dextramer H-2 Kb/SIINFEKL-
PE (Immudex, Copenhagen, Denmark). 
In vivo killing assay 
3 subcutaneous immunizations were performed in C57BL/6 mice at tail base in a 2 week 
interval. 10 µg of OVA-encoding mRNA was complexed to polyplexes as described above. 
Splenocytes were pulsed with 1 µg/ml of MHC-I OVA peptide or HIV-1 Gag peptide as a control 
before labeling with 5 µM or 0,5 µM CFSE (Invitrogen, Merelbeke, Belgium), respectively. 
Labelled cells were mixed at a 1:1 ratio, and a total of 1,5 x 107 cells mixed cells were adoptively 
transferred into immunized mice two weeks after last boost. Splenocytes from host mice were 
analysed two days later by flow cytometry after staining with -F4/80 (BD Biosciences, San 
Diego, CA, USA) to exclude auto-fluorescent macrophages. Percentage antigen-specific killing 
was determined using the following formula: 100 – 100* ((% CFSEhi cells / % CFSElowcells)immunized 
mice /(% CFSEhi cells / % CFSElow cells)non-immunized mice. 
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1. ANTIGEN-ENCODING MRNA VACCINES TO ELICIT CD8+ T CELL IMMUNITY  
RNA vaccines are designed to mimic infectious challenges to stimulate antigen-specific humoral 
and cellular immunity. Thereby, they changed the vaccine paradigm that only live – or 
inactivated pathogens induce diverse CD8+ T cell immunity. The immunogenicity of RNA vaccines 
is based on their intrinsic adjuvant character as RNA is a natural ligand of cellular pattern 
recognition receptors (PRRs). PRRs signalling results in the induction of pro-inflammatory 
cytokines, which are vital for the activation and skewing of Th1 immunity. Furthermore, mRNA 
vaccines have conceptual advantages in relation to pDNA vaccines. They cannot integrate into 
the genome and therefore are considered to be safer, and there is no need for mRNA vaccines 
to cross the nuclear core in order to be translated and processed into peptides. However, the 
major drawbacks of RNA vaccines are their low stability and weak capacity to be efficiently taken 
up by dendritic cells. Two strategies have been elaborated in the past to tackle these major 
limitations to make direct in vivo administration of mRNA an attractive alternative for ex vivo DC 
manipulation. A first achievement was the chemical and structural modification of in vitro 
transcribed (IVT) RNA, resulting in improved RNA stability and half-life and as a consequence, 
enhanced in vivo expression levels. A second strategy that improved the in vivo performance of 
RNA vaccines included the design of nanoparticle delivery vehicles, which both protected and 
targeted the RNA to the dendritic cells. The combination of the tremendous progress of mRNA 
vaccines and their attractive safety profile has propelled the RNA format to clinical trials.  
Vaccine-evoked Type I IFNs. What is going on? 
Earlier, it was described by Pollard et al. that the induction of type I Interferons (IFNs) upon 
mRNA lipoplex vaccination appeared to be a double edged sword1. They observed superior gag-
specific T cell responses upon mRNA lipoplex treatment of Ifnar-/- DCs compared to wild type 
DCs. In addition, they reported that IFNAR signalling was not required for DC activation and in 
vivo induction of IFNɣ-secreting CD4+ and CD8+ T cells upon subcutaneous mRNA lipoplex 
immunization. In this thesis, we have extended this observation to intradermal and intranodal 
delivery of mRNA lipoplexes and evaluated the effects of type I IFNs on the vaccine-evoked CD8+ 
T cell response in a tumor model (Chapter 4).  
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First, using IFNβ reporter mice, we demonstrated that mRNA lipoplexes induced strong IFNβ 
levels upon intradermal, subcutaneous and intranodal injection. Furthermore, these vaccine-
evoked type I IFN responses exerted a negative impact on the priming and effector functions of 
the elicited CD8+ T cell responses upon immunization. These findings were confirmed in a 
prophylactic B16.OVA tumor experiment, showing that Ifnar-/- mice benefited more from 
vaccination than WT mice, resulting in increased survival rates. This result is highly striking as 
Ifnar-/- mice completely lack spontaneous type I IFN-mediated anti-tumor responses1,2. However, 
therapeutically vaccinated Ifnar-/- mice succumbed earlier to B16 challenges compared with wild 
type mice; which is a complete reverse outcome compared with the prophylactic experimental 
setup. Apparently, in the therapeutic setting, the endogenous type I IFNs are vital and even 
overrule their negative impact on vaccine-evoked anti-tumor immunity. As it was impracticable 
to distinguish the endogenous type I IFN effects from vaccine-evoked type I IFN effects, the 
results of the therapeutic tumor experiment were hardly interpretable. In an attempt to 
specifically inhibit IFNAR signalling at the site of immunization instead of using completely IFNAR 
deficient mice, we immunized wild type mice with mRNA lipoplexes, co-delivered with IFNAR 
blocking antibodies. These data revealed that the co-delivery of an IFNAR blocking antibody 
prolonged survival rate of immunized wild type mice in both  a prophylactic as well as a 
therapeutic setting. 
Still, the mechanism behind the negative impact of type I IFNs on locally administered lipoplex 
vaccines remains unresolved. In view of the natural anti-viral functions of type I IFNs – such as 
the stimulation of RNAses and translation arrest through phosphorylation of eIFN2α2,3 - it is 
tempting to speculate that type I IFNs might interfere with generating T cell responses by 
downregulating antigen expression levels. In addition, earlier research in our lab revealed that in 
vitro transfected Ifnar-/- DCs expressed enhanced antigen levels. Taken together, it was strongly 
indicated that type I IFNs hampered lipid-based mRNA vaccination by inhibiting or lowering in 
vivo antigen expression levels. Nevertheless, we were not able to measure significant 
differences between the antigen expression levels of wild type and ifnar-/- mice upon 
intradermal injection of mRNA lipoplexes. These results are in contrast to other reports that 
have showed increased antigen levels upon intravenous injection of mRNA lipoplexes in ifnar-/- 
mice compared to wild type mice4. However, in these studies the increased antigen expression 
levels came along with a decreased T cell response4,5. Thus, these findings seem to contradict 
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the hypothesis that type I IFNs regulate T cell immunity upon mRNA lipoplex vaccination by 
tuning down antigen expression levels. 
Another possible mechanism explaining the inhibiting effects of type I IFNs might be based on 
the relative timing between IFNAR and T cell receptor (TCR) activation. A recent report by Crouse 
and colleagues, analysing the direct and indirect effects of type I IFNs on T cells, has suggested 
that IFNAR signalling can positively or negatively influence antiviral T cell responses, depending 
on the timing between IFNAR signalling and TCR activation6. In general, when TCR stimulation 
shortly precedes IFNAR signalling, the role of type I IFNs as signal 3 cytokines predominates. 
Conversely, when IFNAR signalling precedes TCR stimulation, the anti-proliferative and pro-
apoptotic character of type I IFNs predominate6. The molecular mechanism supporting this 
hypothesis is based on the variety of pathways that could be activated upon IFNAR signalling. 
Indeed, IFNAR signalling can lead to the activation of 7 STATs which all initiate a different set of 
transcription factors and as a consequence they all might induce a totally different immune 
outcome. For example, it has been shown that type I IFNs act as signal 3 cytokines in mouse 
CD8+ T survival and cytolytic function by activating STAT47 when a low STAT1/STAT2 state is 
present8,9. Whereas signalling through STAT1/STAT2 heterodimers in a low STAT4 environment 
resulted in the initiation of anti-proliferative and even apoptotic programmes10–12. How a CD8+ T 
cell decides to activate STAT4 or STAT1/STAT2 and how this process is regulated appeared to be 
dependent on the timing of the IFNAR signalling relative to the T cell receptor (TCR) activation 
(Figure 1)6. An activated TCR prior to type I IFN signalling results in the phosphorylation of STAT4 
instead of STAT1 and stimulates a pro-survival CD8+ T cell state. Reversely, when IFNAR 
signalling precedes TCR activation, STAT1 is activated resulting in anti-proliferative and apoptotic 
situations13–15.  
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Figure 1. Illustration of how the relative timing of IFNAR and TCR activation may affect vaccine-evoked 
CD8
+
 T cell responses. 
 
In view of this theory – The impact of type I IFNs on anti-viral responses depends on the timing 
between IFNAR signalling and TCR activation - we believe that the inhibiting effects of type I IFNs 
on mRNA vaccine-evoked CTL responses might be caused by type I IFN induction prior to IFNAR 
signalling. After subcutaneous or intradermal administration of mRNA lipoplexes, we typically 
observed a rapid type I IFN induction, peaking between 3 and 6 hours after injection. Antigen 
expression takes longer to unfold, and peaks between 8 post injection. In addition, DCs that take 
up mRNA lipoplexes in the skin still need to migrate to the draining lymph node in order to 
present the antigen, creating an extra delay in TCR activation. Likely, due this process the bulk of 
antigen presentation occurs after T cell exposure to type I IFNs. Supporting this hypothesis, two 
recently published manuscripts have demonstrated that type I IFNs actually promote CD8+ T cell 
immunity upon systemic delivery of similar (RNAiMAX™ and DOTMA/DOPE) mRNA lipoplexes 
and have identified type I IFNs as crucial signal 3 cytokines4,5. Here, antigen expression was 
reported to peak between one and four hours post injection. IFNα titres showed peak levels in 
circulation at six hours post immunization. As antigen expression by DCs occurs in the spleen, 
this means antigen presentation to splenic T cells can occur very rapidly. TCR triggering of T cells 
will thereby precedes or co-incides with IFNAR triggering and type I IFNs can act as true signal 3 
cytokines that promote T cell differentiation.  In line with the hypothesis, we could speculate 
that in a systemic setting, the kinetics of antigen expression and IFNAR signalling might be 
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reverse to a local setting. For this reason, type I IFNs support T cell immunity upon intravenous 
mRNA lipoplex injection rather than hampering the elicited CTL responses.  
Vaccine-evoked type I IFNs. How to deal with them? 
OPTIMIZING THE ANTIGEN-ENCODING DEVICE; MODIFIED NUCLEOTIDES 
In view of the negative effects of type I IFNs on the efficacy of mRNA lipoplex vaccines, we 
decided to evaluate a new strategy that should dampen type I IFN induction upon immunization. 
Based on the non-immunogenic character of chemically modified mRNA16–19, we evaluated 
whether modified mRNA lipoplexes might have an impact on the induction of type I IFNs upon 
subcutaneous and intradermal injection (Chapter 5). First, we showed that the injection of 
modified mRNA lipoplexes induced slightly lower IFNβ levels – although not significant - 
compared to unmodified mRNA lipoplexes. Despite the rather small impact on IFNβ induction, 
we quantified significantly higher antigen accumulation levels upon injection of modified mRNA 
lipoplexes relative to unmodified mRNA lipoplexes (Table 4). Still, to our surprise, no 
improvement on the capacity to elicit CD8+ T cell responses was observed using modified mRNA 
lipoplexes. 
These data indicated that we have not succeeded to improve the efficacy of mRNA lipoplexes via 
chemical modification of the antigen-encoding mRNA. A possible explanation for this failure 
might rely on the fact that a lot of free mRNA is present after formulating the RNA into 
lipoplexes of N/P 1,  the ratio applied for immunizations. We obtained evidence that the IFNβ 
induction appeared to be mainly induced by free mRNA, rather than complexed mRNA. To our 
believes, the high amount of free mRNA makes it impossible to significantly dampen the IFN 
induction by modifying the mRNA. Or in other words, the quantity of free mRNA might be too 
high to be neutralized by modification in order to evade innate immunity. This hypothesis is 
supported by our data showing no significant difference in IFNβ induction between unmodified 
and modified mRNA, although a visible trend can be detected. In line with these results, 
immunizing Ifnar-/- mice with modified mRNA lipoplexes still resulted in strengthened T cell 
responses. Although, dependent on the experiment, the differences between WT and Ifnar-/- 
seems to be smaller upon modified mRNA lipoplex immunization. However, a direct comparison 
study should produce evidence to confirm this. 
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It might be possible to eliminate this inhibiting effects of type I IFNs by enhancing the N/P ratio 
of the lipoplexes in order to limit the amounts of free mRNA. Unfortunately, immunizing mice 
with mRNA lipoplexes with an increased N/P ratio of 10, revealed no antigen expression and no 
IFNɣ-secreting CD4+ or CD8+ T cells. 
OPTIMIZING THE DELIVERY FORMAT; RALA MRNA NANOCOMPLEXES 
Besides the modification of the mRNA, we validated in Chapter 6 a RALA-based delivery format 
as an alternative to the mRNA lipoplex vaccine approach. RALA is a cell penetrating peptide, 
composed of 32 amino acids containing 7 arginine residues separated by hydrophobic regions. 
First, we investigated the capacity of the amphipathic cell penetrating peptide (CPP) RALA to 
efficiently formulate and to deliver mRNA in vivo. At N/P 1, only 5 % of the RNA was 
encapsulated into RALA nanocomplexes. When the N/P ratio was increased up to 10, almost all 
the RNA was complexed. Further, these near-saturated mRNA nanocomplexes of N/P 10 
instigated superior eGFP expression levels upon DC transfection. We further obtained evidence 
to associate the high antigen expression levels with the pH-specific membrane disruptive 
feature of RALA. Moreover, mice immunized with RALA modified mRNA nanocomplexes of N/P 
10 evoked strong CTL responses (will be discussed later). 
To further address to what extent the pH-dependent amphipathic nature of RALA was crucial for 
the efficient generation of antigen-specific CD8+ T cell responses upon mRNA vaccination, we 
designed two additional peptides - named RGSG and RRRR, which did not have an amphipathic 
α-helical structure. Though, RALA, RGSG and RRRR contain equal amounts of arginine to ensure 
that the binding capacity to mRNA is not effected. We demonstrated that in contrast to RALA, 
both RGSG and RRRR failed to prime CD8+ T cell responses in vivo. Although we showed some 
strong indications to suggest that RALA lends his unique immunogenicity to its amphipathic 
character, crucial for its endosomal disruptive activities, one should keep in mind that RGSG and 
RRRR nanocomplexes differ from RALA nanocomplexes in size, surface charge and 
hydrophobicity. Therefore, at this stage, we cannot exclude that these differences are not 
affecting the uptake of the particles, the endosomal escape and as a consequence the 
immunogenicity of the nanocomplexes. 
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The combination of RALA-based delivery and modified nucleotides; A    
golden marriage? 
In regard to the low amounts of free mRNA when complexed to RALA nanocomplexes at N/P 10, 
we tested to what extent type I IFNs were induced upon injection. As we expected, IFNβ 
reporter mice showed remarkably lower IFNβ induction upon RALA mRNA nanocomplexes 
injection compared with DOTAP lipoplexes (Table 4).  
Earlier, we suggested that the modification of mRNA failed to improve the capacity of mRNA 
lipoplex vaccines due to a high percentage of free mRNA. Given the fact that RALA mRNA 
nanocomplexes are fully functional in an almost complete saturated state (N/P 10), it might be 
interesting to test if the small remaining amounts of free mRNA can be masked for innate 
immunity by chemical modification. To reveal the impact of the mRNA modification on the 
vaccine efficiency of RALA nanocomplexes, wild type mice were intradermally immunized with 
RALA nanocomplexes. Here we showed that RALA modified mRNA nanocomplexes elicited 
superior CTL responses compared to unmodified mRNA nanocomplexes, an observation we 
could not make in the context of lipid-based mRNA vaccination (Table 4). We further 
demonstrated that RALA mRNA nanocomplexes reached similar efficacy in wild type mice 
compared to Ifnar-/- mice, a goal we initially tried to reach by optimizing the lipid-based 
formulation. By accomplishing this, we present a new format of mRNA vaccines, based on CPP-
delivery of modified mRNA - which evades the inhibiting effects of induced type I IFNs, without 
losing the immunogenicity of the mRNA vaccine.  
The reason why immunizing mice with RALA modified mRNA vaccine reached far stronger 
immunity compared to the lipid-based modified mRNA vaccine might rely on the limited 
amounts of free mRNA (Table 4). Although, further research is needed to confirm this 
hypothesis. Either the question remains which factor is causing innate immunity when RALA 
modified mRNA nanocompexes are administered. One could speculate that RALA itself shows 
intrinsic innate immune activating properties, likely independent of the binding of RNA to TLRs. 
Indeed, it is highly suggested that the capacity of RALA to disrupt the endosomes is responsible 
for the immunogenicity of the modified mRNA RALA nanocomplexes. Although, amphipathic 
CPPs are described in the literature as non-immunogenic20. Therefore, a better understanding 
about the immunological mechanisms of RALA-based delivery for mRNA vaccines is required. 
Preliminary data revealed a total loss of RALA mRNA vaccine functionality in Trif-/- mice, whether 
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MyD88-/- mice revealed even slightly better outcome than wild type mice. These data might 
suggest that RALA modified mRNA nanocomplexes might trigger innate immunity via TLR3 
signalling (Table 4).  
 
DOTAP  
lipoplexes 
RALA  
nanocomplexes 
Type  I IFN induction High Low/No 
Negative Impact of type I IFNs 
- If complexed to unmodified mRNA 
- If complexed to modified mRNA  
 
Yes 
Yes 
 
Yes 
No 
Importance of free mRNA Yes No 
Impact of modified mRNA No impact Benefits from modified mRNA 
In vivo Antigen expression 
Detectable  
antigen levels 
No functional 
expression detected 
Immunogenicity Multiple PRRs? TRIF dependent? 
Table 4. Differences between RALA and DOTAP working mechanisms. 
FUTURE PERSPECTIVES 
For many years, the transfer of ex vivo mRNA-modified DCs has dominated the area of mRNA-
based vaccination. To date, successful studies led to the generally acceptance that direct in vivo 
administration of mRNA is more simplified and cost-effective alternative. In this doctoral study, 
we aimed to further improve the in vivo administration of mRNA-based vaccines and tackle the 
inhibitory impact of locally evoked type I IFNs on elicited CTL responses. Interestingly, we 
revealed that for both lipid- as well as for peptide-based delivery, the efficacy of unmodified 
mRNA vaccines is inhibited by type I IFNs upon local administration.  
Recently we gained access to conditional Ifnar-/- mice, showing specific IFNAR deficiency in the 
dendritic cell line or in the T cell line, which might be very useful to gain some insights into the 
mechanism behind the inhibitory effects of type I IFNs after topical application. More 
specifically, they can learn us whether the inhibitory effects are mediated by direct IFNAR 
signalling in T cells or through modulation of DC functions. In case of the first option, one could 
have a further look into the our hypothesis regarding the relative timing between IFNAR and 
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TCR activation. In view of this hypothesis, a direct comparison between a local versus systemic 
delivery of RNA vaccines in Ifnar-/- and wild type mice would be of great value. 
In a second part of this thesis, we present a new vaccine format based on the amphipathic 
peptide RALA which showed superior CD8+ T cell responses, completely independent of type I 
IFN induction. It would be of great interest to further validate this novel format in a prophylactic 
and therapeutic disease model. During many years, researchers focussed mainly on the 
development of mRNA-based vaccines for cancer treatment (melanoma, small cell lung cancer, 
prostate cancer).  As more recently mRNA-based vaccines have been validated for preventing 
infectious disease21,22, it would be interesting to address the capacity of RALA mRNA 
nanocomplexes as a cytotoxic T cell-inducing vaccine against infectious diseases caused by 
human deficiency virus (HIV), cytomegalovirus (CMV) and influenza virus. 
To further assess a thorough preclinical evaluation of RALA mRNA nanocomplexes as a CTL-
eliciting vaccine, the underlying mechanism and characteristics of RALA mRNA nanocomplexes 
at the level of safety and immunogenicity must be addressed. Safety is one of the major 
concerns of clinical applications. To achieve a safe vaccine format, the induction of pro-
inflammatory cytokines should be transient and local, avoiding a systemic cytokine release. We 
did not detect a systemic IFNβ induction upon intradermal injection of RALA mRNA 
nanocomplexes, which might indicate a low risk for systemic cytokine release. Nevertheless, 
further research should be performed to confirm this. As RALA is designed to obtain membrane 
disruptive features specifically in low pH environments, like inside the endosomes, the toxicity 
risks of RALA mRNA nanoparticles are expected to be limited upon in vivo administration. 
Furthermore, earlier research revealed that RALA-DNA immunization did not evoke RALA-
specific antibody responses (personal communication), indicating that repeated injections of 
RALA  nanocomplexes can be applied. In addition, the RALA peptide is completely 
biodegradable. Taken together, we have strong indications that  the local administration of 
RALA mRNA nanoparticles should be a safe and robust vaccine approach to initiate anti-tumor 
responses in a human situation. Furthermore, besides the eliciting of CD8+ T cells, mRNA 
vaccines further competence to instigate a broad Th1 immunity, including CD4+ T cell responses 
and antibody production1,23,24. The competences of RALA RNA nanocomplexes to induce CD4+ T 
cell responses and humoral immunity  should be addressed. 
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In a pre-clinical phase, a head-to-head comparison with the protamine-delivery format 
(RNActive®, Curevac, Germany)25–27 would provide clear information about the competence of 
RALA-based mRNA vaccination as a clinical therapeutic. Protamine is a small Arginine-rich 
nuclear protein which stabilizes DNA during spermatogenesis. Although the structural similarity 
between protamine and RALA - both form an α-helix - it is tempting to speculate that RALA-
mediated delivery of mRNA antigens might be preferable to protamine-based delivery due to 
weaker binding interaction between the RALA-peptide and RNA. The protamine-mRNA 
interaction is very tight, in such extent that the adjuvant effect comes at the cost of weak 
antigen expression levels26. To solve that problem, a two-component format was developed 
(RNActive®), whereby mRNA was only partially complexed to protamine in order to provide an 
adjuvant component along with free RNA responsible for high antigen expression levels. At this 
point no information is obtained regarding the strength of interaction between RALA and RNA 
but a better balance between tight interaction and intracellular release might contribute to a 
simplified composition of the vaccine and  improved efficacy. 
mRNA VACCINES, TO BE CONTINUED… 
In this thesis I focussed on the application of RNA vaccination as a cancer immunotherapy but 
the applicability of mRNA vaccines is far broader. Their strong Th1 immunostimulatory capacity 
was initially validated in a tumor model, followed by validation against infectious disease28. 
Recently, mRNA vaccines encoding hypoallergenic molecules have been presented as an 
attractive prophylactic vaccination strategy to prevent type I allergy based on Th1 polarization29. 
Such a hypoallergen is a modified allergen with a reduced binding capacity for pre-existing 
allergen-specific IgE. Roesler and colleagues showed subtle Th1 priming by RNA vaccines were 
sufficient for the recruitment of protective Th1 cells in a mouse model of allergy29,30. A prime 
immunization revealed to be adequate for long-term prevention due to the natural boosting 
procedure by allergen exposure during the pollen season. Besides the modulation of T cell 
responses, another reason for the success of RNA vaccines to provide protection against 
allergens is the induction of IgG antibodies that compete with IgE isoform for their binding sites 
on allergens. In summary, the concept of mRNA vaccination to combat allergies relies on the 
immune deviation toward a Th1 immunity, rather than the induction of regulatory T cells or 
tolerance31. 
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Self-amplifying mRNA. Initially this strategy was designed to induce protective immunity 
against flavivirus infection and succeeded herein by injecting less than 1 ng of IVT genomic 
mRNA32. Self-amplifying mRNA vector systems are ideally suited for vaccine development 
because they provide high transient antigen expression and inherent adjuvant effects due to the 
intracellular replication which triggers PRRs and causes inflammatory responses. Novartis 
started a platform which focuses on self-amplifying mRNA (SAM®) vectors expressing the highly 
conserved nucleoprotein (NP) and the matrix protein 1 (M1) of the influenza virus33. In vivo lipid-
based immunization of SAM® resulted in robust CD4+ and CD8+ T cells induction in mice. In 
addition, an enhanced recruitment of NP-specific CTLs was observed in the lungs of immunized 
mice after influenza infection, which might be associated with the reduced lung viral titters and 
increased survival after homologous and heterosubtypic influenza challenges33. These preclinical 
results are very promising as current hemagglutinin-based seasonal influenza vaccines induce 
vaccine strain-specific neutralizing antibodies which usually fail to protect against other 
circulating strains.  
2. RNA-MEDIATED ADJUVANTS TO ELICIT CD8+ T CELL IMMUNITY  
Non-coding RNA is intensively evaluated as adjuvant components for protein vaccines due to 
their TLR activating capacities34,35. Likewise the application of antigen-encoding RNA, RNA 
adjuvants also benefit from being encapsulated into nanoparticles34,36. Complexation of RNA to 
or polymers can improve ssRNA stability and DC uptake. Yet, the vast majority of cationic ssRNA 
polymers are retained at the vaccination site and show little drainage to the vaccine draining 
lymph nodes, resulting in suboptimal efficacy of ssRNA as adjuvants. In this thesis, we 
investigated to what extent the formulation of ssRNA into PEGylated-pHDPA RNA polymer-
based complexes had an impact on the adjuvant capacities of ssRNA to protein vaccines 
(Chapter 7). We showed that immunizing mice with PEG-pHDPA ssRNA polyplexes, elicited 
strong cytotoxic CD8+ T cell responses against co-delivered ovalbumin. We further suggested 
that the capacity of PEG-pHDPA polyplexes to induce CTL responses is associated with an 
improved uptake by dendritic cells in the draining lymph nodes, the site of antigen presentation 
and T cell priming.  
As conventionally protein vaccination is known to evoke mainly Th2 oriented humoral immune 
responses, due to MHC-II driven peptide presentation to CD4+ T cells, PEG-pHDPA RNA 
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polyplexes might succeeded to promote cross-presentation, resulting in strong effector CD8+ T 
cell responses against the co-delivered antigen, fully capable of killing antigen-specific target 
cells. Cross-presentation occurs mainly in professional APCs and specifically in CD8α+ dendritic 
cells and is promoted by IL-12 and type I IFNs37–40. For this reason it would be of great interest to 
analyse in vitro and in vivo to what extent PEG-pHDPA RNA polyplexes enable the induction of 
IL-12 and/or type I IFNs.  
Earlier, we showed that coupling of the TLR7 agonist imiquimod to nanogels limited type I IFN 
responses to the intradermal injection site and its draining lymph node, whereas soluble 
imiquimod provoked systemic type I IFN responses. We further reported that a local rather than 
a systemic induction elicited superior Th1 immunity against co-delivered proteins36. In view of 
this, it would be interesting to get some insights in the mechanism behind the improved efficacy 
of formulated RNA by analyzing to what extent polyplex-based delivery of RNA results in a local 
or systemic type I IFN induction.  
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Het dankwoord… zo raar, ik heb de laatste jaren echt uitgekeken naar het moment waarop ik 
iedereen mag bedanken die me tijdens dit ongelooflijke avontuur heeft geholpen en gesteund. 
En nu het moment eindelijk aangebroken is, kan ik best moeilijk starten. Waar moet je ook 
beginnen wannneer je zoveel lieve collega’s en leuke herinneringen hebt. 
In de eerste plaats wil ik graag mijn promoter bedanken. Johan, bedankt dat je me de kans hebt 
gegeven om dit onderzoek uit te voeren onder jouw toezicht én met jouw ondersteuning. Toen 
ik kwam aankloppen bij het Lab Moleculaire Immunologie als kandidaat voor dat ‘cool RNA-
project’, voelde ik me meteen erg welkom. Er stond een enthousiast team klaar met gedreven 
wetenschappers die me motiveerden om dit avontuur binnen ‘den LMI’ te beginnen. Al zagen 
we die collega’s allemaal vertrekken de laatste jaren, ik wil je bedanken voor je steeds positieve 
ingesteldheid en de steun die je me hebt gegeven tot het einde. 
Een speciaal woordje van dank voor mijn co-promoter. Stefaan, ik heb ongelooflijk veel van jou 
geleerd! Telkens kwam je met een nieuw interessant idee dat zéker nog getest moesten 
worden. Met alles wat er nu nog steeds op mijn ‘hier-moet-ik-zeker-tijd-voor-maken-lijstje’ 
staat, kan ik nog een tweede doctoraat vullen. Naast jouw uitgebreide wetenschappelijke 
bijdrage, wil ik je ook graag bedanken voor de mentale steun die ik bij jou vond. Ook toen je 
voor een carrière buiten de LMI koos, stond je steeds klaar met raad en daad. Dat was voor mij 
echt een enorme steun om dit doctoraat af te maken en die thesis te schrijven. Ik wens je super 
veel succes toe in je verdere carrière!   
Going further, I’d like to thank Vimal, for being such an attentive and nice colleague. When I had 
a panic attack, you were always there to listen and calm me with chocolate. I wish you all the 
best writing your dissertation! Lientje, je bent in ons lab begonnen als thesisstudent en het werd 
snel duidelijk…we hadden met jou een grote vis gevangen.  Ik kan je niet genoeg bedanken voor 
alle hulp tijdens het uitvoeren van de talrijke iv’s en uitlezingen wanneer ik handen tekort 
kwam! Ik ben zeer blij dat jij met al je talenten en enthousiasme het ‘RNA project’ mag verder 
zetten. Heerlijk om op zo’n goede college te kunnen rekenen. Ik wens je een topdoctoraat toe 
als start van een bloeiende academische carrière, you go girl! Muriel, de lab-goeroe, 
mausoleum-goeroe, inventaris-goeroe, organisatie-goeroe,...ben ik dan nog iets vergeten? Je 
bent de enige die wat structuur en orde wist te brengen in ons zootje ongeregeld, daar kon ik - 
en eerlijk gezegd de rest van ons lab - alleen maar van leren. Ik vrees dat ik er niet in geslaagd 
ben jouw taak zo succesvol verder te zetten na je vertrek. Ik wil je ook graag bedanken voor de 
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talloze babbeltjes tijdens het practisch werk maar ook na de werkuren waar onze PhD-
frustraties, reisverhalen, nieuwe adresjes in Gent en uiteraard ook de nodige gossip, uitgebreid 
aan bod kwamen. Bovendien wil ik graag Charlotte bedanken voor haar hulp en de begeleideing 
bij het opstarten van mijn project. Maar naast de kennis die je me bijbracht, heb ik ook erg 
genoten van onze labo-weekendjes en avonturen op Aalst carnaval. Thomas, zo grappig. Ik ga 
ook nooit vergeten hoe je tijdens Charlottes doctoraatsfeest iedereen entertainede met jouw 
MC-talenten en hoe zot je altijd verkleed was tijdens Aalst Carnaval! Charlotte, Thomas (en 
ondertussen ook de kleine Oscar), het was echt leuk samenwerken met jullie en ik wens jullie al 
het beste toe in jullie nieuwe leventje in Göteborg! Eline, Sarah en Ilke, ook jullie wil ik bedanken 
voor de leuke tijden die we samen hadden als collega’s.  
Further, I want to thank my colleagues from abroad. Gaëlle and Laure, it was really pleasant to 
work together with you. Unfortunately, the in vivo electroporation did not work out for my RNA 
project. But nevertheless, it was a pleasant experience to work together on the pDNA 
electroporation project. Laure, I wish you all the best with finishing your thesis and maybe we 
will meet in the industry, that would be great! Gaëlle, thank you very much for he nice 
cooperation. I wish you all the best with your further academic career. Joanne, the most 
enthusiastic and energetic scientist I ever met. Thank you for being such a nice colleague and 
thank you for the warm welcome and nice time I had when I visited your lab in Belfast. 
Whenever you plan to visit Ghent again, you may let me know! Bo, I think it is a pity we only 
started our cooperation last year because your great competences as a chemist and our 
expertise in mice studies, could have led to many promising projects. Though, I hope we will be 
able to finish our manuscript and get it published before the end of your PhD! I wish you all the 
best in your future career.  
Maar ook buiten de LMI verdienen vele collega’s een welgemeend woordje van dank. Eerst en 
vooral Charlotje, my best friend, plus-collega en vaste feestpartner. We hebben elkaar leren 
kennen tijdens onze studie en toen was het meteen duidelijk hoe een straffe madam jij bent. 
Het grootste feestbeest van de bende en tegelijk de primus van de klas. Gelukkig was je ook 
tijdens onze tijd in het VIB nooit ver weg! Ik moest enkel de gang oversteken vooraleer ik me op 
de stoel naast jou kon laten ploffen om mijn onaangekondigd bezoekje te beginnen met ‘moet 
je nu wat weten!!’. Je stond altijd paraat voor een oploskoffietje - totdat jullie zo’n zot machine 
kregen – en een babbeltje aan de blokken.  Het is fantastisch om zo’n goede vriendin zo dicht bij 
te hebben. Ons tripje naar het congres in Wenen is één van de hoogtepunten van mijn 
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doctoraat. Bedankt voor alles. Ik ga je missen..echt! Maar al zijn we dan nu niet langer collega’s, 
beste maatjes zullen we altijd blijven.  
Jinke en Natalie, mijn foster-collegaatjes. Jinke, de vrolijkheid zelve! Hoe jij zo enthousiast aan 
zo’n snel tempo kunt babbelen om toch maar helemaal bijgepraat te zijn na de lunchpauze, zalig 
gewoon! Ik hoop dat we elkaar nog gaan blijven zien, maar daar zal ik wel persoonlijk voor 
zorgen! En dan kwam je schoonzusje uit de hemel vallen, recht op de bureaustoel naast mij! Yes, 
een leuke, coole nieuwe buurvrouw! Natalietje, zo leuk dat je tijdens het laatste jaar van mijn 
doctoraat een plaatsje naast mij toegewezen kreeg. Je was zeer aangenaam gezelschap en 
ondertussen ben je mijn vaste sportpartner geworden. Bedankt om mijn dagen op het VIB te 
kleuren, schoonzusjes! 
Daarnaast wil ik de collega’s van de verschillende cores binnen het IRC bedanken. Ann 
S. en Christiane, bedankt voor jullie harde werk en dagelijkse vrolijke ‘goeiemorgens’! Daar start 
je je dag door met een glimlach. Katrien, Patricia, Carine en alle proefdierverzorgers, dankjewel 
voor de goede zorgen! Daisy, dankjewel voor de logistieke regelingen en vaak chaotische 
bestelling van buitenaf of last minute exports. Ann M., Wilma, Natalie en Isabelle, dankjewel voor 
het harde werk dat jullie verrichten in TC om de contaminaties in te dijken en ons werk mogelijk 
te maken. Bedankt Chantal en Marita voor de bestellingen en financiële regelingen voor de 
evenementen die we organiseerden! Bedankt Kim en Gert voor de hulp bij de FACS 
experimenten. Gert, na mijn plantenstage onder jouw hoede ben ik toch overgelopen naar ‘the 
dark side’. Dat heb ik mogen horen van jou, maar nog geen jaar later stond je daar ook!:) Ook 
een speciaal bedankje voor de vaste party-crew van de toch wel legendarische IRC-feestjes, Eef, 
Evelien en Amanda, Marie, Elien, Lien en Charlot. Stuk voor stuk toppertjes! Ik vond het telkens 
super leuk om met jullie het IRC-feest te organiseren en natuurlijk ook af te sluiten. Stiekem ga 
ik deze feestjes toch wel missen. Veel succes met de volgende edities, kom ik wel party crashen 
in juni.;)Verder wil ik ook de Berxkes en de Van Roy unit bedanken voor de goede organisatie van 
het lab en hun vrolijke aanwezigheid! En dan een woordje van dank aan de Nico’s en de collega’s 
van de Saelens groep voor de babbeltjes in de gangen, op de recepties en feestjes, de stukjes 
taart,… Maar vooral Kenny wil ik apart bedanken voor de vele uren die hij gestoken heeft in mijn 
iv’s en de vaak hilarische babbels die daarmee gepaard gingen. Bedankt Kenny! Silvie, Laura and 
Alice, my writing buddies, thank you for your support during our infernal hours at the library. We 
all made it, who had thought this five months ago? Yasmine, ons verblijf in Utrecht tijdens de 
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Flow-cursus ga ik niet gauw vergeten, topgriet jij! Bedankt voor jouw oppervrolijke babbeltjes in 
de gangen, dju, hadden wij elkaar maar eerder leren kennen hé? 
Het begint al een erg lang dankwoord te worden maar er verdienen nog een heleboel 
belangrijke mensen een woordje van dank!  
Om te beginnen, mijn allerliefste homies ‘the girlz’! Sanne, Ine, Inne, Karolien en Kaat. Jullie 
waren geweldig! Al die jaren mijn verhalen moeten aanhoren, waarschijnlijk hebben jullie de 
wildste ideeën van ‘een flow’ en beeldde je me in naast een oud telefoontoestel als ik zei dat ik 
weer eens uren aan de facs had gezeten. Toch bleven jullie tot de laatste maanden paraat voor 
peptalks of ontspannende momenten! Ik heb enorm genoten van onze hilarische etentjes, 
lachbuien, weekendjes uitwaaien aan zee, een gin tonicske inclusief vlekken, verwenpakketjes 
en bloomon bloemen! Ik wil jullie dan ook enorm bedanken voor alle steun die jullie me gegeven 
hebben de voorbije maanden. Ik ben enorm blij met zulke vriendinnen als jullie! Dan de 
fantastische ‘Gentenaressen’, Sarah, Charlotte, Charlot en Kaat! Wat is het fantastisch om zo’n 
lieve, hippe, vrolijke meisjes rondom mij te hebben! Voor mij is het steeds opnieuw genieten 
van de avonden wanneeer we samen koken, of van onze shopdagjes of koffietjes (lees met een 
bordje ‘ervaring’ erbij) in het stad! Of gewoon een goeie film met een dekentje met jullie, meer 
moet dat niet zijn! Ik ben jullie heeeel veel dank verschuldigd voor jullie steun de voorbije 
maanden. Ik kijk al uit naar ons kersttripje! Bij de ‘Gentenaressen’ horen natuurlijk ook de 
‘Genteneirs’, Tomas, Gert, Tim, Bonti, Damske, Thomas en Cupi. Culinaire verwend worden door 
de gerechtjes van Gertje en Bonti en de daarop volgende legendarische ‘den dansvloer is 
geopend’ feestjes… Jullie zijn de max! Verder wil ik ook mijn vriendinnetjes van het STK 
bedanken Karen, Elien, Freya, Lisbet en Hanne. Bedankt voor jullie overvloedige steun de laatste 
maanden. Jullie berichtjes en schattige gezinsuitbreiding-gerelateerde foto’s deden echt wel 
deugd tijdens mijn isolatie bij het schrijven. Maar ook de BCBT’ers, Jonas, Daphne, Erwin, 
Sammy, Pieter, Bonti, Charlot, Jarne, Marie-Laureke, Julie, Charles, Annelynn, Karen, Celine en 
Lientje wil ik graag bedanken. Wat een vijf zalige jaren hebben wij niet beleefd tijdens onze 
studies. De uit-de-hand-gelopen feestjes bij Charles en Julie, de talloze practicum namiddagen, 
de chemica-feestjes, onze skireis, ons avonturen in Spanje en de Ardennen! Haha, met onze 
excellekes en bcbt-bankkaart zijn jullie veruit de best georganiseerde vriendengroep die ik heb. 
Zo leuk dat we na die vijf jaar studeren bijna met zen allen aan de slag konden in het VIB als 
doctoraatstudenten. Ik kijk er dan ook echt naar uit om te komen luisteren naar al jullie PhD-
verdedigingen….natuurlijk gevolg door een goed feestje!  
 247 | Dankwoord 
 
Een speciaal woordje van dank voor mijn mama, papa, broer en zus. Ik prijs me enorm gelukkig 
dat ik ben opgegroeid in dit warme gezinnetje en zonder jullie had ik niet eens dit dankwoord 
kunnen schrijven. Mama en papa, jullie hebben me altijd gesteund en aangemoedigd in de 
dingen die ik deed en voor jullie onvoorwaardelijke liefde kan ik jullie niet genoeg bedanken. 
Doordat jullie zo in mij geloofden, geloofde ik ook in mezelf. Ik wil jullie uit de grond van mijn 
hart bedanken om er altijd te zijn voor mij en om me alle kansen te geven die ik nodig had om te 
bereiken wat ik tot hiertoe bereikt heb. Ik weet dat jullie stilletjes mee afzien als ik aan het 
stressen ben, daarom ben ik ook echt blij dat de laatste loodjes voorbij zijn. Lieve Wout, zo’n 
attente broer zou ik iedereen willen toewensen. Ik wil je super hard bedanken voor je lieve 
berichtjes en steun de voorbije maanden. We zijn nu zo goed als tegelijk afgestudeerd en 
kunnen samen op zoek naar een job, wie had dat gedacht! Ik hoop dat je na je studies toch in 
het Gentse blijft wonen, kan je nog vaak op bezoek komen met Lisa! Liefste Kaat, je bent hier al 
een paar keer gepasseerd omdat je ook opduikt in mijn andere vriendengroepjes, maar toch 
verdien je het nog eens apart bedankt te worden. Buiten het feit dat je gewoon de beste bakster 
van Gent bent, ben je ook echt gewoon de meest perfecte zus voor mij! We hebben een hechte 
band, altijd al gehad maar die wordt precies alleen maar sterker. Je bent er altijd voor mij. Ik 
hoop dat ik ook voor jou zo’n steun en toeverlaat kan betekenen. Dat jij en Damske op zoek zijn 
naar een huisje in Gent is echt wel fantastisch want ik kan jullie niet dicht genoeg in de buurt 
hebben. Michiel, dankjewel om zo’n goed lief voor mijn zusje te zijn en zo’n goeie vriend - of 
eigenlijk toch wel al schoonbroertje na al die tijd - voor mij! Jullie twee zijn fantastisch, bedankt 
daarvoor! Ook moeke en vake wil ik bedanken om zo met me mee te leven. Ik denk dat ik jullie 
vandaag toch wel een beetje fier maak en dat doet me erg plezier! Ook mijn 
schoonfamilie, Hilde, Michel, Ine, Dries en Simon, dankjewel voor jullie steun! 
Tijd om de belangrijkste persoon in mijn leven te bedanken voor zijn onvoorwaardelijke steun en 
liefde. Allerliefste Thomas, het is moeilijk om te omschrijven hoe gelukkig ik me voel, jou als lief 
te hebben gehad deze voorbije jaren. Zonder jou had ik hier vandaag niet gestaan met een 
thesis in mijn handen. Ongelooflijk hoe je samen met mij blij kon zijn met succesvolle, 
belangrijke experimenten. En bij de zoveelste tegenslag hielp jij me alles relativeren. Je bent 
steeds in mij blijven geloven, ook wanneer ik het extra moeilijk had tijdens deze laatste 
maanden. Bij jou thuis komen is tot rust komen, ontstressen en eventjes alle zorgen van dat 
doctoraat vergeten. Dankjewel voor alles, ik zie je ongelooflijk graag! 
 
